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ABSTRACT

Acute limb compartment syndrome (CS), a devastating complication of
musculoskeletal trauma, develops in response to elevation of the pressure within
a closed osseofascial compartment, producing muscle- and limb-threatening
ischemia. Full decompression of all involved compartments by fasciotomy is the
current gold-standard therapy, but it must be performed within a surgical window
of 6-8 hours, before tissue damage becomes permanent.
Carbon monoxide (CO), a byproduct of heme metabolism, has been
shown protective in ischemia. While inhalation of CO leads to elevation of
carboxyhemoglobin (COHb), recent development of transitional metal carbonyls,
CO-releasing molecules (CO-RMs), particularly the water-soluble CORM-3,
delivers CO in a controlled manner without COHb formation, making it well suited
to clinical applications.
The purpose of this thesis was to examine the effects of CORM-3-derived
CO on microvascular dysfunction due to elevated compartment pressure within
skeletal muscle, using clinically relevant models of CS. The efficacy of both CO
and CORM-3 was tested in the rat, demonstrating that CORM-3, just like inhaled
CO, was able to prevent the CS-associated microvascular perfusion deficits,
tissue injury and inflammation, all without the CO-generated elevation of COHb.
The effects of CORM-3 were then tested in a preclinical large animal
model of CS (pig), demonstrating the abolition of CS-induced systemic leukocyte
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activation correlated with the inhibition of systemic TNF-α release, improved
tissue microvascular perfusion, diminished tissue injury and apoptosis.
To lay the foundation for translation of animal CS research to humans, CS
was modelled in vitro, employing tissue culture of human vascular endothelial
cells and serum of CS patients. CORM-3 was able to prevent free-radical
formation, breakdown of endothelial barrier, apoptosis, leukocyte activation and
transendothelial migration in response to CS stimulus.
Thus, CORM-3 appears to have an enormous clinical potential; it might be
capable of at least prolonging the surgical window, if not significantly reducing
the need for fasciotomy.
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fasciotomy, tissue injury, inflammation, leukocyte activation,
cytokines, carbon monoxide, CORM-3, oxidative stress.
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CHAPTER 1

INTRODUCTION AND HISTORICAL REVIEW

2
CHAPTER 1: INTRODUCTION AND HISTORICAL REVIEW

1.1

COMPARTMENT SYNDROME
Compartment syndrome (CS) is a devastating limb- and life-threatening

condition

caused

by

elevated

pressure

within

a

closed

osseofascial

compartment, resulting in microvascular compromise, cellular anoxia and cell
death (Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978, Matsen, Winquist
et al. 1980, Hartsock, O'Farrell et al. 1998). If left untreated, it produces
significant tissue ischemia, which usually leads to severe functional impairment
of the affected limb. CS can develop in response to a multitude of traumatic
injuries and medical co-morbities: fractures, burns, exercise, crush injuries, and
ischemia-reperfusion injury (McQueen, Gaston et al. 2000); less common causes
may include bleeding disorders (Hope and McQueen 2004), diabetes,
administration of statins (Chautems, Irmay et al. 1997, Jose, Viswanathan et al.
2004), infection (Schnall, Holtom et al. 1994), hypothyroidism (Hsu, Thadhani et
al. 1995), lithotomy position (Mathews, Perry et al. 2001), snake bites (Vigasio,
Battiston et al. 1991), arterial rupture (Brumback 1990) and blast injuries (Born
2005).
Case reports of extremity contracture after trauma have been reported as
early as 1840; most were, at that time, believed to be a result of direct neurologic
injury. CS was first described in depth by Richard von Volkmann in 1881.
Volkmann, a German surgeon, noted deformities of the hand and wrist following
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supracondylar fractures of the distal humerus; he believed that these
contractures were related to (and always preceded by) the application of tight
bandages to the injured limb, producing an “inflammatory myositis”. Eventually,
Volkmann suggested that resulting limb paralysis and ischemic contracture were
due to the interruption in arterial blood supply, leading to tissue ischemia;
however, the precise cause of CS remained open for debate for decades to
come (von Volkmann 1881).

1.2

DIAGNOSIS OF CS

1.2.1 Clinical Diagnosis
Diagnosis of acute CS is challenging, as there is no ‘true’ diagnostic or
imaging test; instead, the surgeon must rely on the clinical examination and
observation of certain signs and symptoms. The first description of clinical criteria
for the diagnosis of CS was provided by Griffiths in 1940. Griffiths established the
original “four Ps”: pain out of proportion and pain on passive stretch,
paraesthesia, paralysis and ‘puffiness’ (Griffiths 1940). Eventually, pallor and
pulselessness were added to the signs of CS (Cascio, Wilckens et al. 2005).
Today, those six criteria represent the basis of CS diagnostics.

1.2.1.1

Pain

The first symptoms of acute CS appear to be the disproportionate pain
relative to the injury and pain on passive muscle stretch (PPS) (Whitesides and
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Heckman 1996). Thus, a progressive increase in analgesia requirements (or total
unresponsiveness to narcotics) may be an indication of impeding CS (Bae,
Kadiyala et al. 2001).
Both pain out of proportion to what is expected of the injury (based on the
physical examination) and PPS are the most sensitive clinical findings (19%) and
are often the only observation that precede ischemic dysfunction in the nerves
and muscles of the affected compartment (Whitesides and Heckman 1996,
Ulmer 2002). While the specificity of both pain measures is high (97%), the
sensitivity is very poor (19%); thus, pain as a diagnostic criterion fails to identify a
high percentage of individuals with acute CS (Ulmer 2002). Rather, the absence
of pain is a more useful measure in ruling out acute CS, given the low false
positive rate. However, an adequate level of suspicion must be maintained by the
attending surgeon, as the absence of pain may indicate individual variation,
altered states of pain perception, compartment syndrome of the deep posterior
compartment, or missed acute compartment syndrome that has resulted in
altered sensation (Whitesides and Heckman 1996).

1.2.1.2

Paraesthesia, Paralysis

Approximately 1 hour after the onset of ischemia, the patient may
experience the first sensory changes (Whitesides and Heckman 1996). The first
neurological signs of acute CS are usually hypoesthesia and paraesthesia in the
dermatomal distribution of the nerve(s) of the involved compartment (Hargens,
Akeson et al. 1978, Mubarak, Owen et al. 1978, Matsen, Winquist et al. 1980).
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For example, altered sensation in the first web space of the foot is indicative of
the involvement of the deep peroneal nerve and anterior compartment syndrome,
while numbness of the dorsum of the foot may indicate lateral compartment
syndrome with compression of the superficial peroneal nerve. Yet, these signs
may also be caused by direct trauma to the nerve (Mubarak, Owen et al. 1978).
As a clinical measure of acute CS, paraesthesia has a sensitivity of 13%
and a specificity of 98% (Ulmer 2002). Unfortunately, paresis and/or paralysis of
the muscles of the involved compartment are considered to be signs of a late
acute CS; at this stage, the patient is less likely to respond to fasciotomy (Matsen
and Clawson 1975, Ulmer 2002).

1.2.1.3

Pallor, ‘Puffiness’, Pulselessness

A pale, tense, swollen compartment resulting from increased intracompartmental pressure, sometimes with bruising of the skin, is recognized as
an early physical sign of acute CS (Mubarak, Owen et al. 1978), although the
measure may not be evident with isolated involvement of a deep compartment.
Dressings and casts should be immediately removed to accurately assess
swelling.
The lack of a pulse rarely occurs in CS patients, as pressure that causes
CS is often well below arterial pressure, and thus is not a feature of acute CS;
additionally, the relevant artery may not be contained within the affected
compartment (Shears and Porter 2006). Alternatively, the presence of a pulse
does not exclude CS.
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While congestion of the digits and prolonged capillary refill time may also
indicate acute CS, these measures should not be relied upon, as they may be
affected by many different external factors (e.g. shock, dehydration, decreased
peripheral perfusion (Shears and Porter 2006).
In addition to the observation and monitoring of the above-mentioned
clinical signs, it has been suggested that intra-muscular (IM) pH monitoring may
also be of benefit, as IM pH of less than 6.38 was found in 80% of CS cases
(Elliot 2014).

1.2.2 Compartment Pressure Monitoring
Once a surgeon suspects a development of acute limb CS, diagnosis
requires confirmation by the actual measurement of intra-compartmental
pressure (ICP) (Hargens and Ballard 1995). Thus, measurement of ICP is a
valuable tool for providing objective criteria for the diagnosis of acute CS,
provided the proper technique is used. In order to capture the peak ICP value,
measurements should be taken at the level of the fracture, as well as at sites up
to 5 cm proximal and distal to injury (Heckman, Whitesides et al. 1994). In
addition, pressures should also be measured in the other compartments of the
affected limb, to ensure that a compartment syndrome is not missed.
The indications for ICP measurement include unconscious patients
(Gelberman, Garfin et al. 1981, Hargens, Akeson et al. 1989, Schwartz,
Brumback et al. 1989); difficult-to-assess patients (e.g. young children, patients
with psychiatric problems, or those under the influence of narcotics) (Whitesides,

7
Haney et al. 1975); patients with equivocal signs and symptoms (Gelberman,
Garfin et al. 1981), especially when accompanied by nerve injury (Whitesides,
Haney et al. 1975, Wright, Bogoch et al. 1989); and patients with multiple injuries
(Schwartz, Brumback et al. 1989). Additionally, all tibial diaphyseal fractures
(especially those in young men), high energy distal radial and forearm diaphyseal
fractures in young patients, high energy fractures of the tibial metaphysis, and
soft tissue injury or bleeding diathesis should also be monitored (McQueen,
Gaston et al. 2000).

1.2.2.1

Devices for ICP Measurement

Current routine clinical compartment pressure monitoring uses one of the
three main types of invasive devices: needle manometer, wick catheter (an
adaptation of needle manometer), slit catheter (a modification of needle
manometer), or electronic transducer-tipped catheter (Hargens and Ballard
1995). Non-invasive ICP measurements, using near-infrared spectroscopy (NIR)
to measure tissue oxygenation (Arbabi, Brundage et al. 1999), have also been
proposed as an additional diagnostic tool, but require further research prior to
their clinical use (Arbabi, Brundage et al. 1999, Gentilello, Sanzone et al. 2001,
Katz, Nauriyal et al. 2008). Additionally, it has been demonstrated that
temperature differences between the thigh and the foot show a unique pattern in
individuals with acute CS (Katz, Nauriyal et al. 2008).
The needle manometer consists of a 20cc syringe full of air, attached to a
column that contains both air and saline. The ICP is the pressure required to
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flatten the meniscus between the saline and the air (Whitesides, Haney et al.
1975). The technique had been modified by Matsen et al (Matsen, Winquist et al.
1980) to measure ICP as the amount of pressure required to overcome the
pressure in the circuit and infuse a small amount of saline into the compartment.
While this method is simple and low-cost, it is the least reliable, as the needle
can easily be occluded (Moed and Thorderson 1993).
The wick catheter is an adaptation of the needle manometer in which
fibers project from the end of the catheter (Hargens and Ballard 1995). The fibers
prevent tissue plugging, thus maintaining patency of the catheter to improve
accuracy (Hargens and Ballard 1995). Disadvantages of this device include
possible occlusion of the catheter tip by a blood clot and air in the fluid column,
yielding falsely low measures.
The slit catheter, described by Rorabeck et al (Rorabeck, Castle et al.
1981) is another modification of the needle manometer technique that relies on
the principle of increased surface area and increased patency (Hargens and
Ballard 1995). The tip of the catheter is cut longitudinally, forming plastic petals.
A fluid column, connected to a transducer, measures pressure.
Transducer-tipped catheters designed with the transducer housed in the
catheter tip have improved the accuracy of compartment measurements
(Hargens and Ballard 1995). An early variant of this was the solid-state
transducer intra-compartmental catheter (STIC), which offered increased
accuracy compared to the slit and wick catheters; the disadvantage is that it still
relies on an infusion for pressure measurement (McDermott, Marble et al. 1984).
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This is not the case with the newer electronic transducer-tipped systems:
electronic devices are independent of limb position and the height of the pressure
transducer and do not require calibration (Mubarak, Hargens et al. 1976,
Mubarak, Owen et al. 1978, McDermott, Marble et al. 1984, Moed and
Thorderson 1993, Willy, Gerngross et al. 1999). Disadvantages of these devices
are their high cost and difficulty with re-sterilization.

1.2.2.2

ICP Measurement Threshold

Although controversial, the role of ICP measurement in acute CS remains
valuable. While the comparative benefit of ICP measurements relative to clinical
assessment and the definition of an ICP measurement determining the need for
fasciotomy are unclear, appropriately utilized ICP monitoring is a valuable
diagnostic tool. Continuous compartment pressure monitoring decreases the
delay to fasciotomy and may, therefore, decrease the long-term complications of
the disorder (McQueen, Christie et al. 1996). In addition, ICP monitoring confirms
clinical findings in difficult cases.
While ICP monitoring is utilized in the diagnosis of acute CS, there is no
clear protocol for a specific pressure threshold at which fasciotomy should be
carried out. The threshold ICP for decompression has been listed as 30mmHg
(Mubarak, Owen et al. 1978), 40mmHg (Schwartz, Brumback et al. 1989) and
45mmHg (Matsen, Winquist et al. 1980). Whitesides et al (Whitesides, Haney et
al. 1975) proposed the idea that the differential pressure (ΔP) is indicative of
tissue ischemia. They suggested that tissue ischemia began when the difference
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between ICP and diastolic pressure was 20mmHg (Whitesides and Heckman
1996). McQueen et al (McQueen and Court-Brown 1996) recommended that the
threshold ΔP be 30mmHg, based on the retrospective observation that this value
lead to no apparent missed cases of acute compartment syndrome. As of this
day, many trauma surgeons prefer ΔP to the use of an absolute ICP threshold.
The advantages of a differential pressure threshold include better utility in
hypotensive trauma patients and a lower overall fasciotomy rate, compared to an
absolute pressure threshold (Matsen, Winquist et al. 1980, McQueen and CourtBrown 1996).

1.2.3 Consequences of Missed Diagnosis of CS
Early diagnosis of acute CS is absolutely critical to its successful
management and subsequent clinical outcome. The failure of timely diagnosis
appears to be the single most important cause of adverse outcomes (Matsen and
Clawson 1975, Rorabeck 1984, McQueen, Christie et al. 1996, Mars and Hadley
1998). Early diagnosis of CS is facilitated by the recognition of patient risk
factors, understanding of the early clinical symptoms of CS, and the judicious use
of compartment pressure monitoring (Matsen, Winquist et al. 1980, McQueen,
Gaston et al. 2000). Risk factors for the development of acute compartment
syndrome include gender (males are more prone to CS than females), young age
group (below 30 years of age), tibial fracture, high-energy forearm fracture, highenergy femoral diaphyseal fracture and bleeding diathesis or anticoagulation
(McQueen, Gaston et al. 2000).
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Missed or late diagnosis of acute CS can result in serious complications:
muscle infarction, muscle contracture, secondary deformity, weakness, and
neurologic dysfunction (Whitesides and Heckman 1996). Less common sequelae
include infection, gram-negative sepsis, amputation and end-organ involvement
(Whitesides and Heckman 1996). Time from onset to necrosis is variable, with an
accepted upper limit of 6 hours (Elliott and Johnstone 2003). Determination of
the exact time of onset of acute compartment syndrome is often difficult, as it
may not parallel the onset of injury.
Once irreversible myoneural ischemia occurs, some degree of permanent
neurological deficit and muscle dysfunction will always be present. Depending on
the proportion of tissue involvement, the severity can range from mild weakness
to ischemic contractures. If there is a sufficient amount of muscle tissue involved,
CS can lead to crush syndrome: rhabdomyolysis, renal failure (secondary to
myoglobinuria) and shock (Sanghavi, Aneman et al. 2006, West 2007). Limb
amputation will not be life saving at this point.
Missed or late diagnosis is often a result of clinical inexperience, lack of
suspicion, or a confusing clinical presentation (McQueen, Christie et al. 1996).
Altered pain perception, as seen with changes in level of consciousness, regional
anesthesia, patient-controlled analgesia and nerve injury are risk factors for late
diagnosis (Mubarak and Wilton 1997, Harrington, Bunola et al. 2000).
Maintaining an appropriate index of suspicion is important in preventing the
negative sequelae of late-diagnosed acute compartment syndrome, as well as
malpractice litigation (Bhattacharyya and Vrahas 2004).
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1.3

THERAPEUTIC APPROACH TO CS
The management goals of acute CS are to minimize permanent injury of

the affected limb by restoring microcirculation to the muscle and nerve, and
therefore avoiding the sequelae of ischemic contracture. While non-operative
techniques may be employed initially in impending CS, surgical decompression
of all involved compartments through fasciotomy remains the only gold standard
therapy for acute established CS to this day, provided the diagnosis of CS is
made within the recommended surgical window of 6-8 hours (Matsen, Winquist
et al. 1980, McQueen and Court-Brown 1996, Lawendy and Sanders 2010).
Given the fact that the consequences of delaying the fasciotomy are severe, nonoperative measures have been shown to have a very limited role; rather, medical
management is restricted to an adjunctive role supplemental to fasciotomy.
Although leg is most frequently involved (80% of all cases), followed by
the forearm, CS has been reported in every muscle compartment of the upper
extremity, lower extremity and trunk (McQueen, Gaston et al. 2000).

1.3.1 Limb Anatomy
1.3.1.1

Leg

The leg consists of tibia and fibula, and is divided into four compartments:
anterior, lateral, superficial posterior and deep posterior (Figure 1.1) (Gray 2000)
Muscles of the anterior compartment, innervated by deep peroneal nerve and
vascularized through anterior tibial artery, are responsible for the dorsiflexion of
the foot and ankle. The compartment is comprised of tibialis anterior, extensor
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Figure 1.1.

Compartments of the leg. Leg (shown in cross-section) consists
of two bones, tibia and fibula, and several muscles that are
separated into four different osseofascial compartments: anterior,
lateral, superficial posterior and deep posterior.
Reproduced with permission from Lawendy and Sanders (2010).
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digitorum longus, extensor hallucis longus and peroneus tertius muscles (Gray
2000). The compartment boundary is delineated medially by the extensor surface
of the tibia, laterally by the intermuscular septum, and posteriorly by the extensor
surface of the fibula and the interosseous membrane. The anterior compartment
is completely enclosed by the deep fascia of the leg.
Muscles of the lateral compartment, innervated by superficial peroneal
nerve and vascularized by anterior tibial and fibular arteries, are responsible for
plantarflexion and eversion of the foot. The compartment is comprised of
peroneus longus and peroneus brevis muscles. The compartment boundary is
delineated medially by the fibula, while the intermuscular septum surrounds it
both anteriorly and posteriorly (Gray 2000).
Muscles of the posterior compartments, innervated by the tibial nerve and
vascularized through posterior tibial, fibular and popliteal arteries, are responsible
for plantarflexion of the foot and ankle. The deep posterior compartment consists
of popliteus, flexor hallucis longus, flexor digitorum longus and tibialis posterior
muscles. The anterior boundary is delineated by the fibula, interosseous
membrane, posterior intermuscular septum and the posterior surface of the tibia,
while the posterior boundary is delineated by the transverse intermuscular
septum (Gray 2000).
The superficial posterior compartment consists of gastrocnemius, plantaris
and soleus muscles, and its boundary is delineated anteriorly by the posterior
intermuscular septum and posteriorly by the deep fascia of the leg (Gray 2000).
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1.3.1.2

Forearm

Forearm is made up of the antebrachium and hand. The antebrachium
consists of the radius and ulna, and is divided into three interconnected
compartments: “mobile wad”, anterior (volar) and posterior (dorsal) (Gray 2000)
(Figure 1.2). The compartments are separated by antebrachial interosseous
membrane between the radius and ulna; fascial extensions from the antebrachial
fascia anatomically sequester the mobile wad into its own compartment.
Muscles of the “mobile wad” (sometimes referred to as the lateral
compartment) are innervated by the radial nerve and the posterior interosseous
nerve; the blood supply comes primarily from the radial artery and the profunda
brachii. The muscles of this compartment act collectively as elbow flexors (Gray
2000).
Muscles of the volar compartment, innervated primarily by the median
nerve and vascularized by the ulnar and radial arteries, are divided into
superficial, intermediate and deep groups; these are primarily involved with
flexion and pronation (Gray 2000).
Muscles of the dorsal compartment, innervated by the posterior
interosseous nerve and supplied by the branches of ulnar and radial arteries, are
further subdivided into superficial and deep groups; they are primarily involved
with the extension of the wrist and digits, as well as supination of the forearm
(Gray 2000).
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Figure 1.2.

Compartments of the forearm. Forearm (shown in cross-section)
consists of two bones, radius and ulna, and several muscles that
are separated into three different osseofascial compartments:
dorsal, volar and mobile wad.
Reproduced with permission from Lawendy and Sanders (2010).
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1.3.2 Fasciotomy
Fasciotomy is a surgical procedure where the fascia is cut to relieve the
elevated ICP within the affected compartments (Schmidt 2007, Lawendy and
Sanders 2010). Wounds are usually left open for 48-72 hours prior to skin
closure, with possible skin grafting necessary (Lawendy and Sanders 2010).
Fasciotomy, as a therapeutic option in patients with impeding Volkmann’s
contracture, was first described in 1911 by Bardenheuer (Bardenheuer 1911); he
termed it an ‘aponeurectomy’. Eventually, Murphy (Murphy 1914) suggested
early fasciotomy as a means of preventing paralysis and contracture when the
pressure within fascial-enclosed space was increased due to hemorrhage and
edema, stressing urgency in terms of preservation of function and patient
outcomes. Murphy’s treatment is the mainstay of surgical practice today.
In 1926, Jepson was able to demonstrate that surgical exploration and
drainage of affected limb could avoid myonecrosis, and a relatively normal limb
function could be resumed (Jepson 1926). Other authors (Jorge 1925,
Moulonquet and Seneque 1928, Massart 1935) also stressed the need for
fasciotomy in selected patients.
The first detailed record of the actual operative technique for fasciotomy
was provided by Benjamin (Benjamin 1957), who described the surgical
approach to the forearm. This was followed by Eichler and Lipscomb (Eichler and
Lipscomb 1967), Matsen and Clawson (Matsen and Clawson 1975), Eaton and
Green (Eaton and Green 1972), Gelberman (Gelberman, Zakaib et al. 1978) and
Henry (Henry 1973).
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While initial fasciotomy technique descriptions came from the studies of
the forearm, Reneman undertook the discussion of the proper surgical exposures
during fasciotomy in the lower limb (Reneman 1975). Almost concurrently,
Mubarak (Mubarak and Owen 1977) and Matsen (Sheridan and Matsen 1976)
also released detailed descriptions of their techniques for leg fasciotomy; all of
these are still in use today.

1.3.2.1

Surgical Techniques for Fasciotomy

In the leg, three surgical techniques for complete fascial release are most
commonly described: two-incision fasciotomy (Mubarak and Owen 1977), single
incision perifibular fasciotomy (Matsen 1979), and fibulectomy (Ernst and Kaufer
1971) (Appendix I). In the forearm, most CS cases can be adequately treated by
the release of superficial volar compartment (Matsen, Winquist et al. 1980,
Ronel, Mtui et al. 2004); however, to avoid the possibility of missed CS, most
surgeons prefer the technique where both volar and dorsal compartments are
released at the same time (Jones, Santamarina et al. 2010) (Appendix I).

1.3.3 Complications of Fasciotomy
Fasciotomy, although being a gold standard therapy for CS (independent
of its etiology), is not without complications – it is a procedure that carries
significant risks, affecting patient morbidity and mortality. Possible complications
include skin sloughing, infection, nerve, blood vessel and muscle damage, as
well as scarring (Schmidt 2007). Some patients have been found to develop
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deep chronic venous insufficiency (Bermudez, Knudson et al. 1998); 15-40% of
patients reported wound healing complications (Johnson, Weaver et al. 1992,
Heemskerk and Kitslaar 2003), neurological and vascular injury; 35% of patients
suffered excessive bleeding, infection, scarring.
In their retrospective study of trauma patients undergoing fasciotomy,
Dover et al found that 20% of patients developed early post-operative
complications; of these, severe symptoms were found in 80% of patients. After
recovery, 70% of patients suffered persistent symptoms, which severely limited
them either occupationally or socially (Dover, Marafi et al. 2011, Dover, Memon
et al. 2012)
Fitzgerald et al retrospectively assessed complications of fasciotomy in
both upper and lower extremities over an 8-year period (Fitzgerald, Gaston et al.
2000). They found that 77% had neurologic symptoms, such as altered sensation
of wounds, and one in every ten patients had chronic pain associated with their
fasciotomy wounds. Other frequent complications included dry skin, pruritus, and
discolouration of wounds. Chronic swelling, tethering of tendons and scars,
recurrent ulceration, and muscle herniation were also reported. The effect on
patient’s life was also detrimental, as 28% changed hobbies and 12% changed
occupation secondary to the complications of their fasciotomy. More than 20% of
patients covered their scars due to the aesthetic appearance of the wound
(Fitzgerald, Gaston et al. 2000).
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CS may recur in as many as 3 to 20% of cases after fasciotomy (Barr
2008). Causes include excessive formation of scar tissue and inadequate initial
release of the fascia (Schmidt 2007).
Timing of fasciotomy is absolutely critical in acute CS, as delay to
treatment is associated with increased complications and negative outcomes
(Finkelstein, Hunter et al. 1996). Delay to fasciotomy of greater than 12 hours
was found to increase the rate of infection to 28% versus 7.3% in patients treated
early (Williams, Luchette et al. 1997). In one of the largest series in the literature,
Ritenour et al (Ritenour, Dorlac et al. 2008) found significant complications
secondary to fasciotomy revision surgery in military combat casualties. In their
retrospective study of 336 patients who underwent 643 fasciotomies, they found
an association between fasciotomy revision and increased rates of muscle
excision, as well as a three-fold increase in mortality. Furthermore, delayed
fasciotomies doubled the rate of amputation and increased the mortality rate
fourfold, as compared with patients who underwent early fasciotomies (Ritenour,
Dorlac et al. 2008).
Thus, despite being the most effective treatment for CS, fasciotomy is not
trivial to patient outcomes, and techniques, timing, and alternate therapies need
to be further investigated.

1.3.4 Non-Operative Treatment of CS
Before 1911, CS treatments had placed emphasis on managing the
sequelae of ischemic contracture. Thus, non-operative methods consisted mainly
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of limb mobilization and muscle stretching. Today, in a patient who presents with
a tight-fitting cast or occlusive dressing with increased neuritic and vascular
symptoms, the removal of a cast or occlusive splints is the initial treatment of
impending CS; if symptoms persist, fasciotomy is indicated.
Non-operative management of CS is used only in the cases where
fasciotomy is absolutely contraindicated: in cases where the affected limb is nonviable due to multiple injuries or severe ischemia, which would almost certainly
lead to multiple organ dysfunction (i.e. reperfusion syndrome) (Schmidt 2007).
Thus, fasciotomy is the only gold standard therapy for CS. Given the fact that the
consequences of delaying the fasciotomy are severe, non-operative measures
are restricted to an adjunctive role supplemental to fasciotomy, and may be
employed to attempt the prolongation of the window between the onset of CS
and the time when irreversible changes occur.
Lately, several non-operative options have been researched in various
animal models of CS: mannitol (Daniels, Reichman et al. 1998), vitamin C
(Kearns, Daly et al. 2004), N-acetyl cysteine (NAC) (Kearns, O'Briain et al. 2010),
non-steroidal anti-inflammatory drugs (Manjoo, Sanders et al. 2010), tissue
ultrafiltration (Odland, Schmidt et al. 2005), and hyperbaric oxygen therapy
(Strauss, Hargens et al. 1983, Strauss, Hargens et al. 1986).
Thus, while clinical trials are needed to assess their efficacy, these
additional medical techniques may prove to be effective in patients presenting
with an impending CS.
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1.3.4.1

Mannitol

Mannitol is a sugar alcohol that is clinically used as an osmotherapeutic
agent, to reduce intracranial pressure after head trauma (Cruz, Minoja et al.
2001), and in oliguric renal failure (Alvarez, Chatwin et al. 2000), among other
things. Mannitol has been shown to increase water and sodium excretion,
thereby decreasing extracellular fluid volume.
Mannitol has been administered in canine and rabbit models of CS, where
it appeared to act, presumably, by reducing the edema (Ricci, Corbisiero et al.
1990, Better, Zinman et al. 1991, Oredsson, Plate et al. 1994, Daniels, Reichman
et al. 1998). Case studies have been reported where fasciotomy was
successfully averted following the use of mannitol in the context of clinically
diagnosed CS (Daniels, Reichman et al. 1998, Gold, Barish et al. 2003).

1.3.4.2

L-Ascorbic Acid

L-ascorbic acid (vitamin C) is an essential nutrient produced by many
animals and plants. Although a requirement of normal nutrition, humans and
some other vertebrates lack the ability to produce it, and thus must obtain it from
their diet (Sorice, Guerriero et al. 2014).
Vitamin C is necessary for the formation of collagen within tissues; its
deficiency causes scurvy (Sorice, Guerriero et al. 2014). In addition, it is a potent
anti-oxidant that appears to play an important role in immune function (Jacob and
Sotoudeh 2002).
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It has been demonstrated that the administration of vitamin C in a rat
cremaster muscle model of CS was capable of preserving muscle function,
decreasing myeloperoxidase (MPO) activity and tissue edema (Kearns, Daly et
al. 2004).

1.3.4.3

N-Acetyl Cysteine

N-acetyl cysteine (NAC) is a precursor to glutathione, a potent antioxidant. NAC has been shown to have many clinical uses: protection of
hepatocytes in acetaminophen overdose (Williamson, Wahl et al. 2013),
nephroprotective agent in radiocontrast-induced nephropathy (Anderson, Park et
al. 2011), as a mucolytic agent (emphysema, bronchitis, bronchiectasis,
pneumonia, chronic obstructive pulmonary disease, pulmonary fibrosis) (Santus,
Corsico et al. 2014), alleviation of cyclophosphamide-induced hemorrhagic
cystitis (Palma, Villaca Junior et al. 1986), and interstitial lung disease (Santus,
Corsico et al. 2014).
Administration of NAC in a rat cremaster muscle model of CS has been
shown to preserve muscle contractility (Kearns, O'Briain et al. 2010).

1.3.4.4

NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that
interfere with arachidonic acid metabolism, via inhibition of cyclooxygenase
(COX) enzyme. Two isoforms have been identified: the constitutively expressed
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COX-1, and inducible COX-2. COX-2 expression can be upregulated in response
to inflammatory stimuli and pro-inflammatory cytokines (Jan and Lowry 2009).
Activation of leukocytes appears to play a significant role in the generation
of tissue injury seen in CS (Lawendy, Bihari et al. 2015). As such, antiinflammatory medications may prove to be of benefit. It has been demonstrated
that administration of indomethacin, a COX-2 inhibitor, in a rat model of CS led to
an improvement in tissue perfusion and viability (Manjoo, Sanders et al. 2010).

1.3.4.5

Tissue Ultrafiltration

Tissue ultrafiltration has been used to reduce ICP by reducing fluid
volume, thus decreasing the magnitude of tissue swelling (Odland, Schmidt et al.
2005). Odland, Schmidt et al (Odland, Schmidt et al. 2005) have found that
application of tissue ultrafiltration resulted in significant decrease in tissue injury
in a porcine model of limb CS, presumably by lowering the actual fluid volume,
hence tissue pressure, within the affected compartment.

1.3.4.6

Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy involves medical use of oxygen at levels
higher than atmospheric pressure. The equipment consists of a hyperbaric
pressure chamber and a means of delivering 100% oxygen (normal atmospheric
oxygen content is approximately 21%). In the context of CS, the mechanism of
action is thought to reduce edema within the affected compartment by inducing
vasoconstriction in response to high oxygen, while maintaining oxygen perfusion
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at lower perfusion pressure (Nylander, Nordstrom et al. 1987). Some case
studies reported success in averting fasciotomy in patients with CS (Strauss,
Hargens et al. 1983, Wattel, Mathieu et al. 1998, Gold, Barish et al. 2003).
Unfortunately, this method has limited availability, due to the need for very
specialized equipment.
Hyperbaric oxygen has also been shown to improve wound healing,
thereby reducing the need for amputation and unnecessary surgical procedures
(Roeckl-Wiedmann, Bennett et al. 2005).

1.3.5 Outcomes
It is very difficult to determine the consequences of CS, since the injury
itself might contribute to adverse outcomes. Very little published materials are
available that specifically address the influence of fasciotomy on patient
outcome. Mortality rates of 11-15% and amputation rates of 11-21% have been
previously reported (Heemskerk and Kitslaar 2003). The outcome of patients with
tibial fractures appeared to depend on the timing of fasciotomy: delayed
fasciotomy resulted in muscle weakness and contractures, and higher risk of
fracture healing complications (McQueen, Christie et al. 1996), as well as
increased chance of death and amputations (Finkelstein, Hunter et al. 1996).
In their review of lower limb fasciotomy, Heemskerk and Kitslaar (2003)
found that 45% of patients had good limb function, 28% had successfully
salvaged limbs with diminished function, 12% had to have a limb amputation and
15% died. While all of the patients had serious overall morbidity, the only factor
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predictive of poor outcome was patient age greater than 50 years; the underlying
diagnosis did not contribute to the results after fasciotomy (Heemskerk and
Kitslaar 2003).
While they might be considered non-life threatening, the scars caused by
fasciotomies are not negligible to patients’ functional outcomes: the study by
Giannoudis et al (2000) found that patients who find their wounds aesthetically
unappealing reported significantly poorer health-related quality of life as
compared to patients who had no problem with the appearance of the wound.
Rate of wound closure and need for skin graft were also associated with
increased pain and discomfort (Giannoudis, Nicolopoulos et al. 2002).

1.4

PATHOPHYSIOLOGY OF CS
In order to improve diagnosis and treatment of CS, a much better

understanding of its pathophysiology is needed; this would allow for the
development of methods that would lessen (or prevent) tissue damage by
targeting the specific mechanisms that contribute to the development and
consequences of this condition. One common ‘prerequisite’ for the formation of
CS is the rigidity of fascia; its unyielding nature (Gratz 1931) prevents expansion
of tissue volume to compensate for an increase in fluid within the tissue. While
multiple explanations for the complex pathophysiology of CS exist, the final
commonality to all appears to be cellular anoxia and its consequences.
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1.4.1 Historical Progression of Understanding CS Pathophysiology
Historically, it was Volkmann, in 1881, who first suggested that limb
paralysis due to CS was secondary to the interruption in arterial blood supply,
producing ischemia (von Volkmann 1881). Following Volkmann, Leser in 1884
designed animal models to test the idea; his experiments were crucial in
confirmation of the muscle necrosis as a part of the condition (Leser 1884).
Building on these studies, Hildebrand in 1890 demonstrated nerve involvement in
addition to necrosis. Hildebrand was one of the first to coin the term “Volkmann’s
contracture” (Hildebrand 1906). In 1909, based on his extensive retrospective
review, Thomas also felt that neural tissue involvement was paramount to the
understanding of the clinical presentation of CS; his findings were supported by
the fact the deformity in Volkmann’s ischemic contracture was a claw hand, often
caused by nerve damage to the upper extremity, although the observed
deformity in Volkmann’s contracture was seen far more rapidly than what was
observed with nerve compromise (Thomas 1909). In 1900, Bernays provided
detailed description of the pathology of ischemic muscle and associated
contracture, also making a reference to potential litigation and physician liability
in these cases (Bernays 1900).
In contrast to the previous ideas of arterial and nerve involvement, Murphy
drew attention to the venous obstruction as a possible factor in contracture
formation (Murphy 1914). His idea was then followed by Brooks, with the concept
of increased pressure (as initially described by Volkmann) remaining as the early
consistent feature and the cause of muscle damage in CS (Brooks 1922). In
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1926, Jepson demonstrated that the occlusion of an extremity by the means of a
tourniquet was always followed by an edema (Jepson 1926). Both Brooks and
Jepson believed that the re-establishment of circulation to compromised tissue
could inevitably contribute to the CS pathology; this is in full agreement with
today’s understanding of ischemia-reperfusion injury.
Subsequently, Leriche (Leriche 1928), Griffiths (Griffiths 1940) and Foisie
(Foisie 1942) all noticed the correlation between the ‘arterial spasm’ and tissue
injury, and thus tried to restore the notion of Volkmann that it was the arterial
injury that caused ischemic paralysis. Although erroneously interpreting the
cause of CS, Griffiths advocated that the treatment should be aimed at exploring
the artery in an impending Volkmann’s contracture, inadvertently leading to
secondary application of fasciotomy as a necessity of the surgical dissection
(Griffiths 1940).
The

biggest

shift

in

the

paradigm

of

understanding

the

CS

pathophysiology came during the World War II: in 1941, Bywaters and Beall
noticed that the revascularization of injured limbs in otherwise stable patients led
to decreased urine output, systemic deterioration, multi-organ failure and
eventual death, even when the injured limbs had been amputated (Bywaters and
Beall 1941). This led to the discovery of ‘crush syndrome’, defining the clinical
findings associated with what is known today as a severe ‘reperfusion syndrome’.
Up to this point, few case reports regarding lower extremity involvement
had been documented. Hughes (Hughes 1948), and later Mavor (Mavor 1956)
were among the first to present clinical cases of atraumatic onset of ischemic
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necrosis in the lower extremity secondary to strenuous exercise. The link
between elevation of ICP and surrounding fascia, and its effects on vascularity
was an important milestone and observation in defining the pathophysiology of
Volkmann’s ischemia. Mavor also independently demonstrated that with
decompression of the fascial compartments, clinical resolution of symptoms was
obtained (Mavor 1956). Both Hughes and Mavor brought forward the
understanding that Volkmann’s ischemia is not isolated to the upper extremity;
they stressed that it was equally as important that fascial release, independent of
the underlying mechanism, may be a critical part of treating this disorder.
Benjamin first correlated increased tissue pressure with the extent of injury
seen in CS (Benjamin 1957). His idea was then later reinforced by Reneman,
who also emphasized the importance of fasciotomy and discussed the proper
surgical exposures during fasciotomy (Reneman 1975). Thus, by the mid-1970s,
increased tissue pressure became accepted as the common basis of the CS
disease process.
Matsen, in his paper on the unified concept of CS, synthesized the state of
knowledge of CS up to that point (Matsen 1975). He confirmed that not only was
CS not isolated to the upper extremity, but also that an increase in tissue
pressure was a critical feature in the pathophysiology of the condition –
fasciotomy provided an effective treatment. Once the increased pressure
became accepted as the cause, research could then focus on the pressure
measurement and definition of the threshold for the treatment.
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Whitesides et al (Whitesides, Haney et al. 1975) developed the
methodology for measuring intra-compartmental tissue pressure, and suggested
thresholds for fasciotomy. The methodology of ICP measurement was further
improved upon by Mubarak et al (Mubarak, Hargens et al. 1976), Matsen et al
(Matsen, Mayo et al. 1977) and Rorabeck (Rorabeck and Clarke 1978,
Rorabeck, Castle et al. 1981). Rorabeck then confirmed that the absolute tissue
pressures in CS might be quite variable, producing clinical symptoms in a range
of pressures as low as 28mmHg to as high as 47mmHg; he suggested that the
post-operative outcomes would most likely be dependent on the magnitude of
tissue pressure the time of CS onset (Rorabeck 1984).

1.4.2 Current Understanding
While all previous research had focused on defining compartment
pressure thresholds and diagnostics of CS, microscopic changes to the tissue
and microvasculature were also being studied. Increased pressure within the
closed compartment had been shown to create tissue ischemia, restricting the
oxygen and nutrient delivery, thus failing to meet the metabolic demands of the
affected tissue. Ischemia-generated anoxia was then shown to lead to
microvascular perfusion derangements and severe inflammation (Lawendy,
Sanders et al. 2011, Lawendy, Bihari et al. 2015).
Thus, while the current understanding of CS pathophysiology is still not
complete, microcirculatory dysfunction due to ongoing ischemia-reperfusion
injury, early leukocyte activation and the ensuing inflammation appear to be the
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driving forces behind generation of the CS, and the detrimental outcomes of CS
injury.

1.5

MICROCIRCULATION IN CS
Normal skeletal muscle microcirculation is comprised of arterioles,

capillaries and venules (Fig 1.3). Terminal vascular beds bring flowing blood into
close proximity with parenchymal cells, where adequate exchange of materials
between blood and tissues is met by large numbers of closely spaced capillaries.
A single layer of vascular endothelial cells lines all vessels, sitting upon a
condensed layer of extracellular matrix (basement membrane); the outer portions
of the vessels are largely comprised of ordered layers of contractile
mesenchymal cells (i.e. smooth muscle). While arterioles are comprised of
smooth muscle cell-containing wall and have a divergent branching pattern, the
post-capillary venules have no smooth muscle, and are instead lined by
pericytes. Venules collect the blood from the capillaries, and have a larger cross
sectional area than the corresponding arterioles, resulting in a lower flow velocity
and wall shear stress. Thus, leukocyte adhesion (and inflammation) is normally
restricted to venules; this is also augmented by the selective expression of
adhesion molecules on venular (but not arteriolar or capillary) endothelium (Ley
2008).
As the ICP rises, generating CS, there is a disruption in microvascular
perfusion, reducing oxygen and nutrient delivery to the tissue to a point where
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Arteriole

Figure 1.3.

Capillary Bed

Venule

Microcirculation of the skeletal muscle. Normal microvascular
unit is made up of an arteriole that branches into capillaries.
Oxygenated blood flows from arterioles (red) into capillary beds;
deoxygenated blood from the capillary beds is then collected in the
post-capillary venules (blue).
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the remaining perfusion can no longer meet the tissue demand (Lawendy,
Sanders et al. 2011). This creates an ischemic insult, resulting in the production
of reactive oxygen metabolites, oxidation of iron and membrane lipid
peroxidation, causing significant damage to the affected tissues. Machinery to
repair the damage is then initiated, triggering inflammatory response at both local
and systemic levels.
Thus, CS-associated microvascular dysfunction and the resulting tissue
damage appear to be attributable to at least two mechanisms stemming from the
elevated ICP: tissue ischemia due to disruption of the normal microvasculature,
followed by reperfusion-induced inflammatory reaction due to neutrophil
activation (Figure 1.4).

1.5.1 Tissue Ischemia
While the actual pathophysiological mechanism generating tissue
ischemia is not known, three major theories have attempted to explain the
microvascular dysfunction and ischemia, as they relate to tissue pressure and
CS: critical closing pressure, microvascular occlusion, and arterio-venous
gradient.

1.5.1.1

Critical Closing Pressure Theory

The main assumption in the critical closing pressure theory is that the
active closure of arterioles would occur at a critical pressure secondary to a drop
in transmural pressure (i.e. the difference between the intravascular and tissue
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Capillary Bed

Venule
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Figure 1.4.

Microcirculatory dysfunction in compartment syndrome. Hypoperfusion of the capillary beds (i.e. low-flow ischemia) generates
tissue injury (brown cells), which, in turn, activates leukocytes in
post-sinusoidal
leukocytes.

venules

and

results

in

inflammation.

LKC,
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pressures) (Burton 1951). Arterioles, due to their small size, would experience
high tension, and thus require high arteriolar tissue pressure gradient to maintain
patency. Thus, CS would be caused by either extreme elevation of pressure, or a
significant reduction in the arteriolar tissue pressure gradient, producing arteriolar
collapse (Ashton 1975), thereby rendering the tissue ischemic.
No supporting evidence for the theory, however, was produced when
Vollmar et al (1999) tested the response of arterioles, capillaries and postcapillary venules of various diameters to graded pressure elevation. Using the
skinfold chamber in Syrian gold hamsters, the study was not able to demonstrate
any signs of arteriolar spasm or collapse (Vollmar, Westermann et al. 1999).

1.5.1.2

Microvascular Occlusion Theory

The main assumption of the microvascular occlusion theory is that CS
results from the capillary occlusion as a consequence to an increase in the
absolute compartment pressure (Hargens, Akeson et al. 1978). Thus, in
response to an increase in the tissue pressure above the normal resting capillary
pressure, there should be a concomitant reduction in capillary blood flow,
producing muscle ischemia and subsequent tissue necrosis. Therefore, even a
modest increase in pressure would result in critical impairment of capillary
patency, leading to microvascular compromise.
The theory was, at least partially, discredited when the direct observation
of rodent cremaster muscle subjected to sequential elevation of pressure did not
produce vessel collapse, even when the pressure had been increased to a level
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causing complete arrest of capillary flow; instead intraluminal pressure had also
appeared to have increased to prevent the collapse of the vessel (Hartsock,
O'Farrell et al. 1998).

1.5.1.3

Arterio-Venous Gradient Theory

The main prediction of arterio-venous (AV) theory is that an increase in
tissue pressure, as seen in CS, would result in a net decrease of blood flow due
to concomitant reduction of the AV pressure gradient (Matsen, Wyss et al. 1980).
An increase in pressure would result in a rise in the intraluminal pressure – and
the flow from arteries (i.e. high pressure) to veins (i.e. low pressure) depends on
the pressure gradient maintenance. Thus, an elevation of ICP would diminish the
AV gradient, reducing muscle blood flow and damaging the muscle. In addition,
the decrease in AV gradient would also diminish the rate of clearance of the
venous blood, causing fluid leakage into the interstitium, with edema ensuing,
thereby elevating compartment pressure (Matsen and Krugmire 1978).
The theory appears to be supported, at least in part, by the experiments
on hamster striated muscle by Vollmar et al (Vollmar, Westermann et al. 1999).
Using graded external pressure changes, Vollmar found that minimal increase in
external pressure could halt the flow through capillaries and venules while
maintaining arterial blood flow. Venules responded by decreasing diameter and
flow; reestablishment of a pressure gradient, by relieving the external pressure,
was able to restore blood flow. The study demonstrated the vulnerability of the
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microvasculature to pressure fluctuation, and the need for pressure gradient to
generate flow from capillaries to venules.
The drawback of the AV gradient theory is that it relies on the assumption
that the microvasculature passively responds to pressure. It does not account for
the local adaptive responses of vasodilation, shunting of blood, endothelial
structural changes, or the role of inflammation in the process (Gourgiotis, Villias
et al. 2007).

1.5.2 Reperfusion and Inflammation
Reperfusion of previously ischemic tissue has been shown to elicit a
strong inflammatory response in the microvasculature, characterized by
vasodilation, production of inflammatory cytokines/chemokines, activation of
complement cascade and leukocyte infiltration (Harris, Walker et al. 1986,
Carden, Smith et al. 1990, Potter, Dietrich et al. 1993, Forbes, Carson et al.
1995, Gute, Ishida et al. 1998, Ley 2008, Gillani, Cao et al. 2011). As a result,
there is an increase in the production of reactive oxygen species (ROS) and
soluble inflammatory mediators, enhanced adhesion of leukocytes and platelets
to vascular endothelium and increased microvascular permeability. All of these
then culminate in tissue damage and can lead to impaired organ function.
Leukocyte recruitment to the site of injury (i.e. post-ischemic tissue),
particularly neutrophils, occurs within the post-capillary venules (Forbes, Harris et
al. 1996, Harris and Skalak 1996). A number of different cells are activated when
ischemic tissues reperfuse with well-oxygenated blood: cells within the blood
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vessel wall (endothelial cells) (Lefer, Tsao et al. 1991, Sabido, Milazzo et al.
1994), those of perivascular compartment (macrophages) (Gute, Ishida et al.
1998, Ley, Laudanna et al. 2007), and neutrophils (a class of polymorphonuclear
(PMN) leukocytes) (Carden, Smith et al. 1990, Ley, Laudanna et al. 2007).
Endothelial cells assume inflammatory phenotype: increased production of ROS,
release of inflammatory cytokines, and changes in adhesion molecule expression
to bind leukocytes (Seekamp, Warren et al. 1993, Schlag, Harris et al. 2001, Ley,
Laudanna et al. 2007, Gillani, Cao et al. 2011).

1.5.2.1

Endothelial Activation

Resting endothelial cells are largely un-interactive with leukocytes and
actually maintain leukocyte quiescence (Ley, Laudanna et al. 2007), probably
due to the fact that adhesion molecules found at sites of inflammation are not
expressed (like E-selectin or VCAM-1), or expressed at very low levels (like
ICAM-1), and sequestered internally (like P-selectin).
Activation of the endothelial cells in response to reperfusion injury consists
of three stages: immediate (within minutes), acute (within hours) and chronic
(within days) (Ley and Reutershan 2006). Each step serves a different function,
with the ultimate goal being the repair of the damaged tissue.
Immediate endothelial activation is triggered by many inflammatory
chemokines, and results in endothelial degranulation, as well as endothelial cell
contraction (Maier and Bulger 1996). P-selectin, normally stored within the
Weibel-Palade bodies within the cytoplasm, is brought to the endothelial surface.
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Its function is to facilitate leukocyte recruitment (Weibel and Palade 1964), by
interacting with the P-selectin glycoprotein ligand-1 (PSGL-1) on white blood
cells.
Acute

endothelial

activation

is

characterized

by

increased

gene

transcription and production of E-selectin as well as ICAM-1 (Kurose, Anderson
et al. 1994, Gute, Ishida et al. 1998, Ley, Laudanna et al. 2007). Proinflammatory cytokines, particularly TNF-α and IL-1β are known triggers for this
step.
Chronic endothelial activation serves as a remodelling process. While no
intravital video microscopy data on leukocyte behaviour or blood flow during this
phase exists, the process appears to be reversible once the cause of
inflammation is resolved (Ley, Laudanna et al. 2007).

1.5.2.2

Increased Vascular Permeability

Endothelial cell activation triggers massive endothelial cell contraction,
producing gaps between the adjacent endothelial cells. This results in increased
vascular permeability for plasma proteins, producing protein-rich exudate in the
extravascular tissue (Michel and Curry 1999). While it may augment the release
of antibodies into the affected site, it also causes tissue edema and swelling,
resulting in (temporary) loss of function and pain; this effect is most likely
mediated by bradykinin, histamine and leukotrienes release (McDonald, Thurston
et al. 1999).
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1.5.2.3

Vasomotor Response

Strong vasodilatory response usually accompanies acute inflammation,
resulting in several-fold increase in the blood flow to the inflamed tissue (Ley
2008). The principal mediator appears to be nitric oxide (NO), derived from the
endothelium (Moncada, Radomski et al. 1988) In addition to increased oxygen
delivery, vasodilation also increases the delivery of nutrients, glucose and
leukocytes themselves. Leukocytes use glycolysis to produce energy (Ley and
Reutershan 2006), not oxidative phosphorylation; thus vasodilation may also
serve as a means of glucose delivery, to supply the neutrophil requirements.
Moreover, vasodilation-triggered blood flow alterations most likely produce
changes in shear, which may then facilitate better leukocyte-endothelial
interaction.

1.5.2.4

Cytokine Release

Inflammation is regulated by the release of chemokines and cytokines (a
subset of chemokines), both at tissue level and systemically (Jan and Lowry
2009). Of the 45 or so known chemokines, some 20 have been shown to have
pro-inflammatory effects; a majority of them appear to promote neutrophil
infiltration. Of the inflammatory mediators, TNF-α, IL-1β and IL-6 are three of the
most important cytokines playing a role in reperfusion injury (Seekamp, Warren
et al. 1993, Jan and Lowry 2009).
TNF-α is a cell signalling protein that is produced by many cell types,
particularly by activated macrophages and neutrophils. Although the circulating
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half-life of TNF-α is brief (Beutler, Milsark et al. 1985), its activity elicits many
metabolic and immunomodulatory functions. Upon binding to TNF-α receptor, the
cytokine is able to induce inflammation and apoptosis by controlling the
expression of transcription factor NF-κB, MAPK (particularly the stress-related
JNK group) and proteolytic caspases (Seekamp, Warren et al. 1993, Roebuck,
Carpenter et al. 1999, Ley 2008). While there appears to be a lot of extensive
cross-talk among the different pathways, such complicated signalling probably
ensures that various cells with vastly diverse functions and conditions can all
respond appropriately to inflammation.
IL-1β is produced by activated macrophages, monocytes, endothelial
cells, fibroblasts, and appears to be involved in cell proliferation, differentiation
and apoptosis. It mediates an inflammatory sequence similar to that of TNF-α (Yi
and Ulich 1992).
IL-6 has pleiotropic functions in different organs and tissues. It is produced
by macrophages and T-cells to stimulate immune response after trauma
(Gebhard, Pfetsch et al. 2000), by osteoblasts to stimulate osteoclast formation
(Hashizume and Mihara 2011), as well as by the muscle in response to
contraction (Munoz-Canoves, Scheele et al. 2013), in response to inflammatory
mediators, such as TNF-α and IL-1. It is a very long-lived cytokine that can be
considered both pro- and anti-inflammatory, depending on the type of injury and
the involved tissue. Its counter-regulatory function on the inflammatory cascade
appears to be through the inhibition of TNF-α and IL-1 (Song and Kellum 2005).
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1.5.2.5

Leukocyte Activation

Activated leukocytes display a very specific multistep behavioural
sequence of leukocyte adhesion cascade, first described by Rudolph Wagner, a
prominent pathologist of the nineteenth century (Wagner 1839). Both activated
leukocytes and activated endothelium mediate this process by expressing
different classes of adhesion molecules (selectins, integrins, Ig superfamily) in a
temporally-coordinated fashion. The current paradigm consists of several steps:
(1) capture or tethering by the endothelium, where leukocyte makes the first
contact with the endothelium; (2) rolling along the endothelium, during which
leukocytes sample chemokines presented by the endothelium (slow rolling); (3)
chemokine release, which then triggers (4) firm adhesion; (5) adhesion
strengthening, which then leads to (6) integrin clustering; and in the presence of
appropriate endothelial/leukocyte stimuli, (7) transmigration occurs; the final
result is (8) extravasation into the affected tissue (Ley, Laudanna et al. 2007)
(Figure 1.5).
Initial leukocyte capture and rolling appear to be mediated by selectins (Lselectin on leukocytes, P-selectin and E-selectin on endothelial cells); slow rolling
by integrins; lastly, firm adhesion and extravasation by the adhesion molecules of
Ig superfamily: ICAM-1 (binds CD11/CD18, Mac-1 and LFA-1) on endothelium,
VCAM-1 (binds VLA-4) on the endothelial surface, PECAM-1 on neutrophils
(Albelda, Muller et al. 1991, Barreiro, Yanez-Mo et al. 2002, Yang, Froio et al.
2005). Neutrophil accumulation appears to be the cause (not a consequence) of
ischemia-reperfusion-induced endothelial barrier failure.
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Figure 1.5.

Leukocyte activation sequence in inflammation. Activated
leukocyte

paradigm

consists

of

leukocyte

capture/tethering,

leukocyte rolling, firm adhesion, arrest and extravasation. The
sequence is mediated by various adhesion molecules (selectins,
integrins, Ig superfamily).
Adapted from Ley, Laudanna et al (2007).
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Leukocyte rolling serves to sufficiently reduce the velocity of leukocyte
movement along the endothelium, to allow for firm adhesion. Thus, the
upregulation of P-selectin expression is very rapid (within 15-30 minutes of
activation), as this molecule is normally stored in the pre-formed pools within the
Weibel-Palade bodies of the endothelium, from where it can be rapidly mobilized
to the cell surface in response to stimuli (e.g. reactive oxygen species,
leukotrienes, histamine). E-selectin, on the other hand, is under transcriptional
control, and as such, requires up to 3 hours to achieve peak expression. Lselectin is constitutively expressed on the leukocytes on the microvillus cell
surface protrusions. Upon activation, leukocyte L-selectin interacts with
endothelial cell P- and E-selectins, mediating leukocyte rolling (Ley, Laudanna et
al. 2007). As leukocyte activation progresses, L-selectin is then rapidly shed from
the cell surface via a protease-dependent mechanism.
The transition of rolling to firm arrest can be triggered by arrest
chemokines (e.g. IL-8, GRO, MCP-1, MIP-1α). Firm adhesion and/or
transendothelial migration are mediated by ICAM-1, VCAM-1, and PECAM-1
expressed on the surface of the endothelium, under the control of transcription
factors NFκB and AP-1, resulting in increased expression of ICAM-1 and VCAM1 within 4 to 6 hours. These molecules engage with leukocyte counter-receptors
(i.e. CD11/CD18, Mac-1, LFA-1 and VLA-4) to mediate firm adhesion and/or
transendothelial migration. CD11 (a and b) are constitutively expressed within
most leukocytes, where they are stored in granules, and can be rapidly (i.e.
within minutes) mobilized to the surface of leukocytes. The simultaneous rapid
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up-regulation of CD11/CD18 and shedding of L-selectin on leukocytes upon
activation enables leukocytes to rapidly transition between the rolling and firmly
adherent states (Ley 2008).
Leukocyte

transmigration

can

be

triggered

by

chemoattractant

transendothelial gradient. The whole process can take up to 25 minutes.
Emigrating leukocytes encounter three distinct barriers: endothelial cells,
endothelial basement membrane and pericytes. While the migration through the
endothelial cell barrier can be rapid (within less than 2 minutes), penetration of
the endothelial basement membrane takes much longer (upwards of 5-15
minutes). The process is driven by differential expression of adhesion molecules
on the leukocytes and endothelial junctions. These include PECAM-1, ICAM-1,
ICAM-2, JAM-A, JAM-B and JAM-C. Different molecules mediate leukocyte
transmigration in either a stimulus-specific or leukocyte specific manner (Ley
2008).

1.5.2.6

Reactive Oxygen Species (ROS)

ROS are small molecules that are highly reactive due to the presence of
unpaired outer orbit electrons. Oxygen radicals are produced as a byproduct of
oxygen metabolism, and by anaerobic processes. The main areas of ROS
production include mitochondrial electron transport chain, peroxisomal fatty acid
metabolism, cytochrome P450 and the respiratory burst of phagocytic cells (Jan
and Lowry 2009). Under normal conditions, host cells are protected from the
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damaging effects of ROS by endogenous anti-oxidants such as superoxide
dismutase, catalase and glutathione peroxidase.
Ischemia results in many changes to normal intracellular metabolism. One
of these is the accumulation of hypoxanthine due to inadequate oxidative
phosphorylation of ATP (Smith, Carden et al. 1989, Idstrom, Soussi et al. 1990);
another is the conversion of xanthine dehydrogenase (normally kept oxidized by
NAD+-dependent mechanism) into xanthine oxidase (Granger 1988). Upon reintroduction of oxygen (i.e. reperfusion), xanthine oxidase will convert molecular
oxygen into ROS, such as superoxide and hydroxyl radicals; additionally,
superoxide will react with nitric oxide, producing peroxynitrites. ROS are known
to

attack

cell

membrane

lipids

(lipid

peroxidation),

proteins

and

glycosaminoglycans causing further tissue damage, which, in turn, triggers the
inflammatory cascade by bringing leukocytes (neutrophils) to the affected tissue.
Neutrophils themselves are equipped with enzymatic machinery that is
capable of producing respiratory burst: oxygen-, nitrogen- and chlorine-derived
free radicals (Bellavite 1988, Weiss 1989, Hampton, Kettle et al. 1998). Activated
neutrophil accumulation, and their subsequent degranulation (which leads to the
release of myeloperoxidase, a free-radical producing enzyme) will then ultimately
be the cause of endothelial barrier failure.
Unfortunately, while inflammation and ROS production serve a useful
function (i.e. clean up of the diseased/dead cells and tissue repair),
overwhelming inflammation will contribute to the extensive tissue and organ
damage.
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1.6

HEME METABOLISM AND OXIDATIVE STRESS
As multicellular life developed the ability to sustain itself by the use of

oxygen gas (which is inherently toxic), it also had to evolve mechanisms that
would allow it to survive oxidative stress. One of the most ubiquitous means to do
this is that of heme oxygenase (HO), an enzyme whose presence and function is
absolutely critical to the living organisms. HO deficiency in mammals is lethal –
only one case of a human child deficient in this enzyme had been identified; the
child did not survive beyond the age of 3 years (Yachie, Niida et al. 1999).

1.6.1 Heme Oxygenase
HO degrades heme by cleaving the heme ring at the α-methene bridge to
form equimolar amounts of biliverdin (which is immediately converted into
bilirubin by the enzyme biliverdin reductase), free iron and carbon monoxide
(CO) (Ryter, Alam et al. 2006) (Figure 1.6). The correlation of endogenous CO
found in the blood with hemoglobin-derived heme degradation, and the α-carbon
selectivity of this process, predates the discovery of HO by several decades
(Hallberg 1955).
It was Tenhunen et al who first characterized HO, a distinct enzyme
system responsible for heme degradation (Tenhunen, Marver et al. 1968).
Subsequently,

three

separate

isoforms

have

since

been

defined:

the

constitutively expressed HO-2 and HO-3, and the inducible HO-1 (Maines,
Trakshel et al. 1986, McCoubrey, Huang et al. 1997).
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HO

CO
Fe2+

Biliverdin-IXα

BVR

Bilirubin

Figure 1.6.

Heme degradation pathway. Hemoglobin-derived heme is broken
down into biliverdin by heme oxygenase (HO), which is then rapidly
converted into bilirubin by biliverdin reductase (BVR). Carbon
monoxide (CO) and free iron (Fe2+) are generated by this reaction.
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Normally, stress-induced proteins are generated or activated by an
organism in response to stressors such as fever, heat, infection, toxins or
radiation (Choi and Otterbein 2002). Not only do they protect cells from
immediate stress, but also fortify the organism to withstand future stresses
originating from a different source. In the 1980s, a 32kD mammalian stress
protein, known as the heat shock protein-32 (HSP32), had been identified
(Shibahara, Muller et al. 1987). HSP32 was later proven to be HO-1, the
inducible form of HO (Keyse and Tyrrell 1989).
Several studies have demonstrated that upregulation of HO, either by the
use of various protoporphyrins (heme PPIX, cobalt PPIX) (Maines and Kappas
1977), or by transfecting animals with adenovirus containing HO gene construct,
can be beneficial in protecting tissues from ischemia-reperfusion injury
(Otterbein, Kolls et al. 1999, Otterbein, Lee et al. 1999, McCarter, Badhwar et al.
2004). Conversely, inhibition of HO (by pharmacological or gene knockout
means) was found to be detrimental, leading to the conclusion that upregulation
of HO provides protective benefits to the tissue (Dungey, Badhwar et al. 2006).
Clinically speaking, however, upregulation of HO by adenoviral transfer may not
be a feasible method to be employed in patients; therefore, the downstream
byproducts of the HO-catalyzed heme degradation pathway have been examined
for their contribution to the observed protective effects. Since HO activity results
in production of bilirubin and CO, research has focused on the examination of the
potential beneficial role of these compounds, particularly CO.
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1.6.2 Carbon Monoxide
CO is a low-molecular weight diatomic molecule that occurs in nature as
an odourless gas. CO is considered a ubiquitous pollutant, arising primarily from
the partial combustion of organic molecules by oxidation of natural hydrocarbon
pools or burning fossil fuels, automobile emissions, catastrophic events (e.g.
volcanic emissions and forest fires), plant metabolism and oceanic activity.
CO is relatively stable in biological systems. It functions as heme iron
ligand,

and

forms

complexes

with

a

number

of

hemoproteins

and

metalloenzymes (Coburn 1979, Maines 1997), binding only to reduced (ferrous)
iron centres (Omura and Sato 1964).

1.6.2.1

CO Toxicity

Due to its invisibility and lack of odour, CO presents an especially
dangerous inhalation hazard. Common causes of exposure are due to improper
use of furnaces, engines, heaters, or incomplete combustion (i.e. in inadequately
ventilated areas). Clinical manifestations of CO poisoning include dizziness,
drowsiness, headache, vomiting and loss of motor coordination; prolonged
exposure causes respiratory difficulty, disorientation, chest pain, loss of
consciousness, coma and death (Weaver 1999).
While symptoms of hypoxic CO poisoning begin to appear at 20%
carboxyhemoglobin (COHb) levels, death likely occurs in the range of 50-80%
COHb (Weaver 1999). Inhalation studies have revealed that CO can cause
oxidative damage in the brain, as demonstrated by an increase in lipid
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peroxidation (Thom 1990) and apoptotic cell death (Piantadosi, Zhang et al.
1997).
In 1857, Claude Bernard first realized that CO is capable of binding heme
within hemoglobin, leading to formation of COHb (Bernard 1857). In 1912,
Douglas demonstrated that the binding of CO to hemoglobin is reversible
(Douglas, Haldane et al. 1912). The affinity of CO for heme within hemoglobin
has been shown to be approximately 240 times that of oxygen (Weaver 1999).
There are four oxygen-binding sites within one molecule of hemoglobin at which
CO competes for occupancy. It has been demonstrated that half saturation (i.e.
the partial occupation of the binding sites by two CO molecules) inhibits the
release of oxygen from the remaining heme groups. This results in a left shift of
the oxy-hemoglobin dissociation curve, reducing the oxygen-carrying capacity of
the blood, thus generating the anemic hypoxia that appears to account for the
asphyxiating properties of CO (Weaver 1999).
The formation of COHb complex is reversible by the out-competition of CO
in favour of oxygen. In some severe cases, hyperbaric oxygen therapy has been
successfully applied as an antidote to CO poisoning (Weaver 1999).

1.6.2.2

Endogenous Sources of CO

A considerable amount of CO arises endogenously, as a byproduct of
metabolism. At least 86% originates from heme metabolism, while the remaining
fractions may arise from other metabolic processes, including lipid oxidation and
xenobiotic metabolism (Vreman, Wong et al. 2000, Archakov, Karuzina et al.
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2002). It was Coburn in 1967, who first demonstrated that CO in the body is
derived from metabolic conversion of hemoglobin (Coburn, Williams et al. 1967),
and estimated the rate of endogenous CO production at around 0.42ml/h
(Coburn 1967).
Under normal conditions, in the absence of significant ambient CO, the
majority of blood COHb comes from endogenous production, and corresponds to
blood CO levels of 0.4-1% (Vreman, Wong et al. 2000). The values increase in
the presence of CO in the environmental background: for example, cigarette
smokers display, on average, 3-8% COHb (Vreman, Wong et al. 2000).
Certain pathological or toxicological conditions have been shown to lead
to upregulation of HO-1 expression, which would produce increased blood CO
levels: inflammation, physical stress, and environmental exposure to a variety of
agents. As an example, several studies have demonstrated that the exhaled
breath of patients suffering from asthma or COPD (i.e. pro-inflammatory
conditions) contains increased levels of CO (Zayasu, Sekizawa et al. 1997,
Kawane 2002).

1.6.3 Biological Effects of Carbon Monoxide
It appears that CO has profound influence on intracellular signaling
processes, which culminate in anti-inflammatory, anti-proliferative, anti-apoptotic,
and anti-coagulative effects. The physiological outcomes of CO action have been
related to its endogenous production by both the constitutive (HO-2 and HO-3)
and inducible HO (HO-1) activity. While it remains unclear whether exogenous
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application of CO represents true physiological levels, it has been demonstrated
that it can produce the effects similar to those that can be achieved by the
induction of HO-1 protein.

1.6.3.1

Cellular Signalling

CO, as a gaseous molecule, has a very low reactivity; therefore, it can
reach various cellular and molecular targets with great ease. Nevertheless, todate, very few mechanisms have been defined over which CO has particular
influence. CO has high binding affinity for transition metals and heme proteins
containing iron in ferrous form (Fe2+) (Kajimura, Fukuda et al. 2010), particularly
hemoglobin and myoglobin. The selectivity depends on the intrinsic reactivity of
ferrous heme, the chemical nature and geometry of the ligand, as well as steric
constraint and electrostatic interactions of the bound ligand on the distal side of
heme. The most common mode of action of CO in the biological systems
appears to be the modulation of soluble guanylate cyclase (sGC) and the
subsequent production of cGMP (Ryter and Otterbein 2004). The binding of
heme iron within sGC by CO stimulates its activity, which, in turn, leads to
several-fold increase in cGMP. For example, direct treatment of vascular smooth
muscle cells with CO resulted in an increase in cellular levels of cGMP; hypoxia
(which would cause an induction of HO-1, thus endogenous production of CO)
also produced the same effect (Morita, Perrella et al. 1995). However, unlike NO
(another potent activator of sGC), CO causes only a minor increase in the activity
of this enzyme, due to the formation of a 6-coordinate complex (rather than 5-
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coordinate complex, as is the case with NO – which causes more than 100-fold
activation of the enzyme). When both CO and NO are present simultaneously at
the site, NO will bind sGC with much greater affinity than CO; in addition, CO will
modestly but significantly attenuate the activation of NOS, thus serving as a
partial antagonist to NO-induced sGC effects (Kajimura, Fukuda et al. 2010).
Although sGC appears to be the most common cellular signalling pathway
implicated in CO action, other intermediaries may also be involved. While these
represent a downstream rather than primary target, as they do not bind CO
directly, they include the modulation of various MAPK activation and stimulation
of calcium-dependent potassium channel activity (Ryter, Otterbein et al. 2002).
Large conductance calcium and voltage-activated potassium channel
(BKCa), implicated in the control of hypoxic response in the carotid body, the
control of vessel relaxation and neuronal activity (Jaggar, Li et al. 2005), is
another target for CO action. Additionally, other ion channels have also been
found to be regulated by CO: epithelial sodium channels (Althaus, Fronius et al.
2009), ligand-gated P2X receptors (Wilkinson, Gadeberg et al. 2009), L-type
calcium channels (Scragg, Dallas et al. 2008) and tandem P domain potassium
channels (Dallas, Scragg et al. 2008).
Studies suggest that cystathionine β-synthase, one of the enzymes
responsible for the synthesis of endogenously-produced hydrogen sulfide
(another biologically active signalling gaseous molecule) may act as a CO sensor
in vivo (Kajimura, Fukuda et al. 2010). There appears to be a lot of cross-talk
between CO and other gas-transducing biologic systems (i.e. nitric oxide, oxygen
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and hydrogen sulfide), although the exact purpose, control and mechanisms of
this action still remain to be fully elucidated.

1.6.3.2

Vasodilation

CO appears to exert a variable and multimodal effect on vasodilation,
which involves at least several mechanisms. The dilatory effects are usually
attributed to the direct, endothelium-independent effects on vascular smooth
muscle cells (including the modulation of sGC and cGMP, as well as the effect on
the potassium channels), while indirect effects appear to affect the expression of
endothelial-derived vasoconstrictors and myogenic factors (Motterlini and
Otterbein 2010).
In 1978, Sylvester at al demonstrated that application of CO resulted in
dilatation of pulmonary artery and a reversal of hypoxia-induced vasoconstriction
in isolated perfused porcine lung (Sylvester and McGowan 1978). McFaul and
McGrath demonstrated that CO was capable of reversing methoxamine-induced
vasoconstriction in rat coronaries (McFaul and McGrath 1987). These effects
have since been confirmed in rat thoracic aorta, pig, rabbit and dog coronary
arteries (Lin and McGrath 1988, Graser, Vedernikov et al. 1990, Furchgott and
Jothianandan 1991). Intact endothelium was not required in any of the above;
tissue hypoxia caused by CO was also excluded as the driving force behind the
observed effects.
Although activation of sGC and subsequent increase in cGMP plays a
major role in CO-induced vasodilation in aorta, cGMP-independent mechanisms
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of vasodilation have also been demonstrated in peripheral vasculature in some
experiments, where CO appeared to directly activate BKCa, calcium-dependent
potassium channels (Wang, Wang et al. 1997); inhibition studies using
ryanodine, a known calcium release channel blocker, have shown that COinduced vasodilation could be inhibited by this treatment (Jaggar, Leffler et al.
2002). Limited evidence has also been found that would suggest the direct
association of HO-2 with large-capacity potassium channels in the carotid body
(Williams, Wootton et al. 2004); however, it still remains to be confirmed whether
the same mechanism would occur in peripheral vasculature.
Additionally, neural CO may also play an indirect role in vasoregulation by
signalling in the autonomous nervous system (Verma, Hirsch et al. 1993).

1.6.3.3

Anti-Inflammatory Effects

Many studies, both in vitro and in vivo, have demonstrated that exogenous
application of CO produces potent anti-inflammatory effects. For example, in an
in vitro model of sepsis, stimulation of macrophages with LPS led to an increase
in production of pro-inflammatory cytokines, particularly TNF-α (Otterbein, Bach
et al. 2000). Exogenous administration of low dose CO inhibited this response,
and when given as a pre-treatment, it also inhibited the expression of additional
pro-inflammatory cytokines (IL-1β, MIP-1β) while augmenting the expression of
anti-inflammatory cytokine IL-10.
Beneficial effects of exogenous application of CO in systemic inflammation
have also been documented in vivo. Similar to HO-1 overexpression, Ott et al
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(2005) and Scott et al (2009) demonstrated that low-dose inhaled CO was able to
prevent microvascular dysfunction in the liver and small intestine following
ischemia-reperfusion-induced systemic inflammatory response syndrome (SIRS),
respectively (Ott, Scott et al. 2005, Scott, Cukiernik et al. 2009). Song et al
demonstrated anti-inflammatory effects of CO in orthotopic lung transplant (Song,
Kubo et al. 2003).

1.6.3.4

Anti-Apoptotic Effects

Cell death can be classified according to its morphological appearance,
enzymological criteria, functional aspects or immunological characteristics.
Apoptosis describes a specific morphological aspect, characterized by roundingup of the cell, retraction of pseudopods, pyknosis, chromatin condensation,
karyorrhexis, little or no ultrastructural modifications of cytoplasmic organelles,
plasma membrane blebbing (although its integrity is maintained until the final
stages of the process), and engulfment by resident phagocytes (Kroemer,
Galluzzi et al. 2009). Apoptosis is mediated by the activation of proteolytic
caspases. Under inflammatory conditions, increased recruitment of neutrophils to
the site of injury contributes to the induction of apoptotic signalling through
oxidative and proteolytic stress.
Many studies have demonstrated the anti-apoptotic effects of CO to-date,
both in vivo and in vitro. Similar to overexpression of HO-1, TNF-α-induced
apoptosis has been shown to be abolished in an in vitro model in mouse
fibroblasts and endothelial cells (Petrache, Otterbein et al. 2000). In the
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endothelial cell model, p38 MAPK pathway appeared to be involved (Brouard,
Otterbein et al. 2000).
In several in vivo models of disease and/or tissue injury (e.g. ischemiareperfusion, lung transplantation), a low dose of CO pretreatment led to net antiapoptotic effects (Ryter, Alam et al. 2006), although higher concentrations of CO
(i.e. at CO poisoning levels) produced pro-apoptotic brain injury in a rat
(Piantadosi, Zhang et al. 1997).

1.6.3.5

Anti-Proliferative Effects

The inhibitory effects of CO on cell growth were examined by Morita et al
(Morita, Perrella et al. 1995). They found that HO-1-induced endogenous CO
production, triggered by hypoxia, inhibited vascular smooth muscle cell
proliferation. The effect appeared to be due to cGMP-dependent downregulation
of the expression of endothelial-derived mitogens, such as platelet-derived
growth factor and endothelin-1. These investigators were also the first to suggest
that CO inhibited cell growth by influencing the expression and/or activation of
cell cycle-related factors, particularly transcription factor E2F (Morita, Perrella et
al. 1995).

1.6.4 Carbon Monoxide Releasing Molecules (CO-RMs)
Given the observed beneficial effects of HO and a possible therapeutic
application of exogenous CO gas, the need for a better method of CO delivery
had, by this point, become apparent. The first breakthrough occurred when
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Motterlini et al synthesized a novel class of transition metal carbonyls, capable of
releasing CO on demand (Motterlini, Clark et al. 2002). These carbon monoxidereleasing molecules (CO-RMs) are capable of delivering CO to the tissues in a
controlled manner, and they do so without the detrimental formation of COHb
(Motterlini, Clark et al. 2002), thus providing an alternative approach to CO/HO
delivery (rather than adenoviral transfer or inhalational CO). In addition to
providing a much better method of CO delivery, these compounds also provide
the means for further mechanistic insight into the behaviour of CO in biological
systems.
Most CO-RMs contain a central metal core (manganese, ruthenium, iron,
boron) to which carbonyl groups are attached (Table 1.1). The general formula
for a CO-RM is [Mx(CO)y]n.
The first CO-RM to be synthesized, CORM-1 (formula [Mn2(CO)10]), is a
rapid CO releaser (Motterlini 2007). The molecule contains manganese in its
centre, but is hydrophobic and requires photo-activation to initiate the CO
release, thereby making its applicability limited to in vitro use only. The second
CO-RM prototype, CORM-2 (formula [Ru(CO3Cl2)], contains ruthenium metal
dimer at its centre. CO is rapidly released by dissolving CORM-2 in an organic
solvent (e.g. DMSO), by ligand substitution; again, hydrophobic character or the
molecule makes its use in the clinical setting rather limited (Motterlini 2007).
The first water-soluble CO-RM to be synthesized was CORM-3 (formula
[Ru(CO)3Cl(glycinate)]), also a ruthenium-based compound. CORM-3 is relatively
stable in water, but promptly releases CO by ligand substitution when it comes in
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Table 1.1.

Most common carbon monoxide-releasing molecules (CORMs). CORM-1 and CORM-2 are fast CO releasers, but not watersoluble. CORM-3 and CORM-A1 are water-soluble.
Adapted from Motterlini et al (2009).

Name

Chemical Structure

Solubility

CO Release

CORM-1

DMSO

Light-dependent
Fast (t1/2<1min)
1M CO/mole CO-RM

CORM-2

DMSO

Ligand substitution
Fast (t1/2=1min)
0.7M CO/mole CO-RM

CORM-3

Water

Ligand substitution
Fast (t1/2=1min)
1M CO/mole CO-RM

CORM-A1

Water

pH dependent
Slow (t1/2=21min)
1M CO/mole CO-RM

CORM-F3

DMSO

Metal oxidation
Slow (t1/2=55min)
0.25M CO/mole CORM
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contact with biological stimuli directly interacting with ruthenium metal (Motterlini
2007). It is stable at an acidic pH (i.e. less than pH 5), and rapidly releases
equimolar amounts of CO in physiological conditions.
In parallel, a second class of CO-RM chemicals able to generate CO in
aqueous solutions was soon manufactured: CORM-A1 (formula [Na2H3BCO2])
and CORM-401. Unlike CORM-3, CORM-A1 does not contain transition metal at
its centre, but a boron-bound carboxylic group that can slowly liberate CO
through hydrolysis under physiological conditions; the release of CO is initiated
by a pH shift, rather than by ligand substitution. CORM-A1, however, is a very
slow CO releaser, thus giving it a very long half-life (t1/2=21min); this property
makes its clinical use rather limited. CORM-401 contains manganese at its
centre, instead of ruthenium (Crook, Mann et al. 2011). Upon activation by
deprotonation in physiological solution, it releases three moles of CO per one
mole of CORM-401 (Crook, Mann et al. 2011). While its long half-life is similar to
that

of

CORM-1A

(i.e.

approximately

21

minutes)

(Fayad-Kobeissi,

Ratovonantenaina et al. 2016), making it a slow CO releaser, the fact that it does
not contain any heavy metals not normally found in the body, and that it releases
three times as much CO makes it an attractive alternative option for future clinical
explorations.
The

release

spectroscopically,

of
by

CO

from

monitoring

each
the

CO-RM
conversion

has
of

been

validated

myoglobin

into

carboxymyoglobin (Motterlini 2007), while the biological effects have been
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confirmed in numerous experiments by observing lack of effect with the
deactivated form of the compound.

1.6.5 CORM-3
Carbon monoxide releasing molecule-3 (CORM-3) is a water-soluble CO
donor. Originally, the molecule was synthesised by Motterlini et al by glycination
of the water-insoluble CORM-2. CORM-3 is stable at an acidic pH, and rapidly
releases equimolar amounts of CO in physiological conditions.
Beneficial effects of CORM-3 have been demonstrated in multiple in vitro
and in vivo studies. For example, vascular inflammation in endothelial cells,
particularly that involving oxidative burst of PMNs (Masini, Vannacci et al. 2008,
Song, Bergstrasser et al. 2009, Bergstraesser, Hoeger et al. 2012), bacterial
activity (Davidge, Sanguinetti et al. 2009, Desmard, Davidge et al. 2009),
leukocyte-endothelial interaction under flow in acute pancreatitis (Urquhart,
Rosignoli et al. 2007) and inflammatory response induced by LPS and/or IFN-γ
(Sawle, Foresti et al. 2005, Bani-Hani, Greenstein et al. 2006, Bani-Hani,
Greenstein et al. 2006) were all reduced by the application of CORM-3 in many
in vitro experiments. Additionally, CORM-3 has been demonstrated to affect
multiple cell types and pathways that coordinate the inflammatory cascade:
production of TNF-α, fibrinogen/fibrin, cellular infiltration, ICAM-1 expression and
activation of transcription factors (NFκB, MAPK) have been reported to be
significantly diminished in in vivo models of vascular thrombosis (Kramkowski,
Leszczynska et al. 2012), hemorrhagic stroke (Yabluchanskiy, Sawle et al.
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2012), polymicrobial sepsis (Lancel, Hassoun et al. 2009, Tsoyi, Lee et al. 2009),
I/R injury (Katada, Bihari et al. 2009, Katada, Bihari et al. 2010, Caumartin,
Stephen et al. 2011), arthritis (Ibanez, Alcaraz et al. 2012), xenotransplantation
(Vadori, Seveso et al. 2009), neuropathic pain due to nerve injury (Hervera,
Leanez et al. 2012), post-operative ileus (De Backer, Elinck et al. 2009) and
cutaneous wound healing (Ahanger, Prawez et al. 2011) in animals treated with
CORM-3.
Interestingly, in relation to the pathology studied, the mode of action and
efficacy of CORM-3 appear to depend on the timing of administration. CORM-3
pretreatment (5 minutes) or post-treatment (3 days) after the onset of
hemorrhage in the rat model of hemorrhagic stroke provided protective effects.
On the contrary, administration of CORM-3 three hours after the stroke (the
timing corresponds to the acute phase of the disease process) resulted in
exacerbated damage (Yabluchanskiy, Sawle et al. 2012).
The mechanisms of CORM-3 action appear to be linked not only to its
anti-inflammatory properties, but also stimulation of mitochondrial biogenesis and
the control of oxidative stress. CORM-3 administration was able to conserve
cardiac mitochondrial function by preserving membrane potential and respiration;
it also led to the induction of mitochondrial biogenesis in sepsis-mediated cardiac
damage and metabolic syndrome-like disorder (Lancel, Hassoun et al. 2009,
Lancel, Montaigne et al. 2012), while inhibiting NADPH activity and
overproduction of superoxide anion (Taille, El-Benna et al. 2005, Lo Iacono,
Boczkowski et al. 2011).
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1.7

AIM OF THIS THESIS
While the pathophysiology of CS is not well understood, ischemia-

reperfusion injury appears to be a major driving force behind the observed
detrimental outcomes. The effects of complete ischemia (where the onset is
known, as all circulation is cleanly cut off) and subsequent reperfusion injury
have been extensively described in the literature; we borrow from these studies
in our attempt to design rational therapeutic approaches to CS.
In response to the initial limb trauma, tissue edema develops. Rigidity of
fascia prevents muscle compartments from expanding, resulting in the elevation
of ICP and compression of the microvasculature, with tissue ischemia as the end
result. However, unlike complete ischemia, CS appears in the face of patent
vessels – after all, distal pulses are present in the majority of CS patients. Thus,
the macrocirculation within the involved compartments is still intact, while the
microcirculation becomes dysfunctional. Although some degree of microvascular
perfusion may still be maintained, the metabolic demands for oxygen and
nutrients cannot be fully met; ‘low-flow’ ischemic state leads to ROS and toxic
metabolite formation, initiating local inflammatory response much earlier than that
seen in complete ischemia. Subsequent cytokine release leads to early local
leukocyte activation (particularly neutrophils) (Lawendy, Bihari et al. 2015), also
triggering systemic inflammatory response coupled with remote organ injury
(Lawendy, Bihari et al. 2016). In CS, ischemia and reperfusion phases happen
almost concurrently, not only making it impossible to pinpoint the exact timing of
CS onset, but initiating the reperfusion injury much earlier than that of complete
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ischemia, with the degree of severity correlated to the duration of CS (Lawendy,
Sanders et al. 2011).
While different tissues have different tolerance for the survival of hypoxia,
irreversible damage occurs within 6-8 hours, making it crucial that fasciotomy is
carried out within that surgical window. Given the unclear nature of the CS onset
and severe consequences of missed CS, the necessity of developing therapy
aimed at prolongation of surgical interval becomes obvious.
Exogenous application of CO appears to be beneficial in animal models of
ischemia-reperfusion injury, but it has never been tried in the context of low-flow
ischemia (i.e. CS). The purpose of this thesis was to test CO as a possible
therapeutic agent for the treatment of CS.
We hypothesized that exogenous application of carbon monoxide (either
in inhalational form, or as CORM-3 derived CO) would be of immense benefit in
acute compartment syndrome. We believe that CO could be used as an adjunct
to fasciotomy; it may have the capacity to at least prolong the surgical window, if
not dispense with the need for fasciotomy altogether.
CORM-3 as CO donor was chosen due to its water solubility and rapid CO
release upon activation. It is also important to note that, for the purpose of this
thesis, the terms ‘elevated ICP’ and ‘CS’ are used interchangeably; however, CS
is a clinical definition, and as such, can only be applied to humans.
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CHAPTER 2

THE EFFECT OF EXOGENOUS APPLICATION OF CARBON MONOXIDE ON
SKELETAL MUSCLE MICROCIRCULATION IN THE RAT MODEL OF ACUTE
LIMB COMPARTMENT SYNDROME.

A portion of this chapter formed the basis for the patent application titled
‘Therapeutic Use of Carbon Monoxide in Acute Limb Compartment Syndrome’,
awarded to Dr. Lawendy and his Trauma lab research team.
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CHAPTER 2: THE EFFECT OF EXOGENOUS APPLICATION OF CARBON
MONOXIDE ON SKELETAL MUSCLE MICROCIRCULATION IN
THE

RAT

MODEL

OF

ACUTE

LIMB

COMPARTMENT

SYNDROME.

2.1 INTRODUCTION
Acute

limb

compartment

syndrome

(CS),

a

complication

of

musculoskeletal trauma, results from an increase in pressure within a closed
osseofascial compartment, leading to muscle-threatening and limb-threatening
ischemia (Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al.
1978, Rorabeck and Clarke 1978, Matsen 1980, Hartsock, O'Farrell et al. 1998).
Emergency fasciotomy, to fully decompress all the tissues in the involved
compartments, remains the only effective treatment and current gold-standard
surgical therapy, but it must be performed in a timely manner, before the injury to
the tissues becomes permanent. Despite ongoing research dedicated to
understanding the pathophysiology of CS, the mechanisms of CS-induced tissue
damage are still poorly understood, making therapeutic targets rather limited.
CS, as a form of ischemia-reperfusion (I/R) injury, results in significant
microvascular dysfunction within the affected muscle (Lawendy, Sanders et al.
2011). Leukocytes appear to play a major role in the pathophysiology of this
condition (Lawendy, Bihari et al. 2015). However, unlike complete ischemia, CS
occurs in the face of patent vessels (i.e. low-flow ischemia), making it impossible
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to pinpoint the exact time when the metabolic demand of the tissue exceeds the
actual supply of oxygen, thereby triggering oxidative stress, cytokine release,
inflammation and consequent tissue damage.
Previously, the upregulation of heat shock proteins, particularly heme
oxygenase (HO), has been shown to be beneficial in various models of
reperfusion injury (Nie, McCarter et al. 2002, McCarter, Scott et al. 2003,
Akamatsu, Haga et al. 2004, McCarter, Badhwar et al. 2004, Lee, Gao et al.
2007). HO is a rate-limiting enzyme involved in catabolic degradation of heme
into biliverdin and carbon monoxide (CO) (Tenhunen, Marver et al. 1968).
Numerous

studies

have

demonstrated

potent

cytoprotective

and

anti-

inflammatory effects of HO/CO in various models (Motterlini and Otterbein 2010),
making HO a potential therapeutic target. While systemic upregulation of HO
(e.g. by the use of adenoviral transfer) may not be clinically feasible,
administration of its byproducts, particularly CO, on the other hand, can be
accomplished with relative ease.
Several studies have demonstrated that exogenous administration of lowdose CO by inhalation offers both protection to microvascular perfusion, and antiinflammatory benefits during systemic inflammation (Nakao, Kimizuka et al. 2003,
Hegazi, Rao et al. 2005, Mazzola, Forni et al. 2005, Ott, Scott et al. 2005, Scott,
Cukiernik et al. 2009), sepsis (Mazzola, Forni et al. 2005, Koulouras, Li et al.
2011), and organ preservation for transplantation (Neto, Nakao et al. 2004,
Hanto, Maki et al. 2010). However, the possible therapeutic application and
efficacy of CO have never been assessed in CS.
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The purpose of this study was to test the effect of inhalational CO on the
severity of microvascular dysfunction following CS. It was hypothesized that
application of CO may be beneficial by reducing the degree of microvascular
perfusion deficits, inflammation, and tissue injury normally seen in CS. The
ultimate goal of this study is the development of pharmacological adjunctive
therapy that would allow the prolongation of the fasciotomy surgical window, or
completely eliminate the need for it.

2.2 MATERIALS AND METHODS
2.2.1 Animal Preparation
The experimental protocol was approved by the Council on Animal Care of
the University of Western Ontario (Appendix III), and has been previously
described in detail (Lawendy, Sanders et al. 2011). Briefly, male Wistar rats
(body weight 180-250g) were anesthetized by inhalational isoflurane (5%
induction, 2% maintenance) in 1:1 oxygen/nitrogen mixture. Left carotid artery
was cannulated to allow for the monitoring of systemic blood pressure, fluid
administration and blood sampling.
Compartment pressure monitoring probe (Synthes, Westchester PA) was
inserted into the posterior compartment via gauge 16 angiocatheter (BD), while
gauge 24 angiocatheter (BD) attached to an IV line was placed into the anterior
compartment of the rat hind limb (Figure 2.1). CS was induced by an infusion of
isotonic saline, leading to an elevation of intra-compartmental pressure (ICP) to

90

Figure 2.1

Schematics of the experimental setup of a rat model of
compartment

syndrome.

Elevation

of

intra-compartmental

pressure to 30-40mmHg was achieved by an infusion of isotonic
saline into the anterior compartment of the rat hind limb. Elevated
compartment pressure was continuously monitored and maintained
for 2 hours, producing compartment syndrome-like conditions.
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30-40 mmHg. Elevated ICP was maintained for 2 hours. Fasciotomy was
performed to decompress the hind limb compartments; the muscles were allowed
to reperfuse for 45 minutes, followed by intravital video microscopy (IVVM).

2.2.2 Exogenous Application of CO
CO was exogenously applied to animals at fasciotomy, by inhalation. The
inhaled gas mixture contained 250ppm CO in medical air, pumped into the
facemask through the anesthesia circuit. Inhalation of CO to animals commenced
right before fasciotomy; animals were subjected to inhalational CO during the
whole reperfusion period of 45 minutes.

2.2.3 Experimental Groups
Animals were randomly assigned into one of the four groups: (1) sham
(n=4), (2) sham under CO inhalation (n=4), (3) CS under normal air (n=4) and (4)
CS followed by CO inhalation (n=4). Sham animals underwent all procedures as
CS animals, but the ICP was maintained at baseline level (0mmHg).
At the conclusion of the experiment, systemic levels of carboxyhemoglobin
(COHb) were assessed in all animals.

2.2.4 Intravital Video Microscopy
The extensor digitorum longus (EDL) muscle was dissected to the level of
its distal tendon, which was tied with a suture and cut from its bony insertion. The
animal was transferred onto the stage of an inverted microscope (Nikon); the
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EDL was reflected into a saline bath containing 5µg/ml each of the fluorescent
vital dyes bisbenzimide (BB; exc. 343nm, em. 483nm) and ethidium bromide (EB;
exc. 482nm, em. 616nm). BB stains the nuclei of all cells while EB stains the
nuclei of only those cells with damaged cell membrane; thus, EB/BB ratio
provided an index of tissue injury.
Microvascular perfusion and leukocytes within the post-capillary venules
were recorded by translumination with 20x and 40x objectives, respectively, in
five adjacent fields of view. Fluorescence microscopy was used to visualize the
BB and EB from the same fields of view that had been selected for the
measurement of capillary perfusion. At the conclusion of the experiment, rats
were euthanized by an overdose of anesthetic agent.

2.2.5 Offline Video Analysis
Capillary perfusion was assessed by counting the number of continuouslyperfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries
that crossed three parallel lines drawn perpendicular to the capillary axis on the
video monitor, and was expressed as % of total capillaries. Tissue injury was
assessed by counting the number of EB- and BB-labelled nuclei, and expressed
as EB/BB ratio. Leukocyte activation was assessed by counting the numbers of
rolling and adherent leukocytes in post-capillary venules and expressed per unit
area (i.e. 1000µm2). Venular area was measured using ImageJ (NIH, Bethesda,
MD). A leukocyte was considered adherent if it remained stationary for at least
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30 seconds, and a cell was considered rolling if it remained in contact with the
wall of the vessel during its movement.

2.2.6 Statistical Analysis
All parameters were expressed as mean ± SEM and analyzed using oneway ANOVA, with Bonferroni post-hoc test as needed. p<0.05 was considered
statistically significant.

2.3 RESULTS
2.3.1 Microvascular Perfusion
Elevation of ICP led to significant changes in microvascular perfusion, as
shown in Figure 2.2. The number of continuously-perfused capillaries decreased
from 74±6% in sham to 22±3% in CS group (p<0.0001), while the number of nonperfused capillaries increased from 12±3% in sham to 54±3% in CS group.
Inhalation of CO, commenced upon fasciotomy, was able to restore the number
of perfused capillaries to 57±3% (p<0.001). Inhalational CO had no effect on
capillary perfusion in sham animals (76±2%, not significant).

2.3.2 Tissue Injury
Elevation of ICP resulted in a significant increase in muscle tissue injury,
as measured by EB/BB ratio, from 0.05±0.03 in sham to 0.31±0.05 in CS group
(p<0.001). Inhalation of CO significantly decreased tissue injury to 0.02±0.02
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Figure 2.2.

Sham

Sham+CO

CS

CS+CO

The effect of CO inhalation on skeletal muscle microvascular
perfusion following CS. Two hours of elevated ICP were followed
by fasciotomy, 45min reperfusion coupled with CO inhalation, and
IVVM. CS-associated perfusion changes were partially reversed by
CO inhalation (*p<0.001 from sham and sham+CO; †p<0.001 from
CS; see the text for additional details). CPC, continuously-perfused
capillaries; IPC, intermittently-perfused capillaries; NPC, nonperfused capillaries.
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Figure 2.3. The effect of CO inhalation on skeletal muscle tissue injury
following CS. Two hours of elevated ICP were followed by
fasciotomy, 45min reperfusion coupled with CO inhalation, and
IVVM. CS-associated tissue injury was reversed by CO inhalation
(*p<0.001 from sham and sham+CO; †p<0.001 from CS).
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(p<0.0001) (Figure 2.3). CO by itself had no effect on tissue injury (0.02±0.02,
not significant).

2.3.3 Inflammation
Elevation of ICP resulted in leukocyte activation, as demonstrated by an
increase in adhesion to the vascular endothelium. Leukocyte adherence in the
post-capillary venules of the skeletal muscle was significantly increased from
1.9±0.5 in sham to 17.5±0.9 leukocytes/30s/1000µm2 in CS group (p<0.0001).
Leukocyte

rolling

only

moderately

increased

from

1.7±0.7

to

3.3±0.7

leukocytes/30s/1000µm2. Inhalation of CO led to a significant, 10-fold decrease
in CS-triggered leukocyte adherence (0.6±0.2 adherent leukocytes/30s/1000µm2,
p<0.001), while having no statistically significant effect on leukocyte rolling
(2.0±0.6 rolling leukocytes/30s/1000µm2, not significant) (Figure 2.4).

2.3.4 Systemic COHb Level
Inhalation of CO led to significant increase in carboxyhemoglobin (COHb)
levels in both sham and CS animals (7.6±1.6% in CS+CO and 7.4±1.3% in
sham+CO, respectively versus 0.3±0.1% in sham, p<0.0001) (Figure 2.5).
Elevation of ICP by itself did not produce any changes in COHb (0.4±0.2%, not
significant).
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Figure 2.4. The effect of CO inhalation on leukocyte adhesive interactions
with endothelium of skeletal muscle microvasculature in CSchallenged rat. Two hours of elevated ICP were followed by
fasciotomy and 45min reperfusion coupled with CO inhalation.
Leukocyte adhesion (A) and rolling (B) were assessed by IVVM.
CO inhalation was able to prevent leukocyte adhesion within the
post-capillary venules (*p<0.001 from sham and sham+CO;
†p<0.001 from CS).
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Figure 2.5. The effect of inhaled CO on systemic COHb levels. Two hours
of elevated ICP were followed by fasciotomy and 45min reperfusion
under CO inhalation. Inhalation of CO caused a significant increase
in COHb, while elevation of ICP by itself had no effect (*p<0.0001
from sham and CS).
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2.4 DISCUSSION
Compartment syndrome is a challenging complication of musculoskeletal
trauma. Therapeutic applications, aside from the gold-standard fasciotomy, are
limited, and only address the sequelae of CS rather than pathophysiological
mechanisms leading to CS formation (Olson and Glasgow 2005). In the present
study, we demonstrated the benefit of inhalational carbon monoxide on improving
capillary perfusion, reducing cellular damage and leukocyte recruitment following
compartment syndrome and fascial release.
CO is a signalling molecule produced endogenously by the degradation of
heme, a reaction catalyzed by inducible and constitutively expressed heme
oxygenases (HO-1 and HO-2, respectively) (Otterbein 2009). CO has been
shown to generate vasodilatory effects, mitigate intracellular apoptosis and
suppress inflammatory pathways in various models of inflammation, including
ischemia-reperfusion (Otterbein 2002, Motterlini 2007). In our study, exogenous
application of CO by inhalation demonstrated a beneficial effect by preserving
microvascular flow in CS-challenged muscle.
Continuous perfusion is characterized by the non-stop passage of blood
through the capillary bed, supplying the tissue with the necessary oxygen and
nutrients. Any derangement in the blood movement (i.e. shift to intermittency or
no flow) compromises gas exchange, and results in ischemia (Lawendy, Sanders
et al. 2011). In our study, we demonstrated that CO inhalation was capable of
improving the capillary perfusion, restoring the number of continuously-perfused
capillaries almost to sham levels (Figure 2.2). Moreover, CO inhalation was very
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effective in restoring tissue injury levels back to baseline levels, as those seen in
the sham group (Figure 2.3). Thus, CO appeared to provide a substantial
protective effect within the CS-challenged muscle. To the best of our knowledge,
this study is the first to demonstrate such potent protective effects of CO in the
context of acute CS.
CS pathophysiology is, at least in part, driven by I/R injury. The effects of
complete ischemia on the skeletal muscle have been well documented in
literature, with predictable alterations in the microcirculation (Harman 1948,
Strock and Majno 1969, Labbe, Lindsay et al. 1987, Belkin, Brown et al. 1988,
Lindsay, Liauw et al. 1990, Hickey, Hurley et al. 1992, Sabido, Milazzo et al.
1994). Ischemia results in a shift of the cellular metabolism into oxidative mode,
producing pro-inflammatory environment (Gute, Ishida et al. 1998, Gillani, Cao et
al. 2011). Upon the restoration of blood flow (i.e. reperfusion), pro-inflammatory
mediators (e.g. reactive oxygen species (ROS), cytokines/chemokines, platelet
activating factor (PAF), etc.) released from the activated vascular endothelial
cells and leukocytes enter the circulation, leading to systemic activation of
leukocytes and subsequent recruitment into the reperfused tissue (Hernandez,
Grisham et al. 1987, Kubes, Suzuki et al. 1990, Schlag, Harris et al. 2001).
During inflammation, leukocyte extravasation from the blood is controlled by wellcoordinated adhesive interactions between leukocytes and vascular endothelial
cells, which involves rolling (P-, E-, L-selectins), firm adhesion (integrins, ICAM-1,
VCAM-1) and migration across the endothelium (PECAM-1, CD99, JAMs) (Ley,
Laudanna et al. 2007).
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Activated leukocytes produce ROS and proteolytic enzymes that cause
further cellular damage and increased vascular permeability to plasma proteins,
thereby contributing to the formation of progressive edema (Sexton, Korthuis et
al. 1990, Forbes, Carson et al. 1995, Rubin, Romaschin et al. 1996, Kurose,
Argenbright et al. 1997, Gute, Ishida et al. 1998). In the context of CS, fluid
accumulation in the muscle will lead to an increase in the interstitial pressure,
compressing the neighbouring capillaries and causing further shift to nonperfusion (Lawendy, Sanders et al. 2011).
In our rat model of CS, the blood flow through the capillary beds was not
completely blocked; rather, the elevated ICP created a low-flow ischemic state,
with reperfusion injury happening almost concurrently with ischemia. Upon
fasciotomy, the full restoration of blood flow resulted in additional reperfusion
damage, further accentuating the CS-induced microvascular dysfunction. We
observed a substantial inflammatory response, characterized by an increase in
leukocyte adhesion under conditions of flow, and recruitment of activated
leukocytes into muscle vasculature in response to elevation of ICP and
fasciotomy (Figure 2.4). CO inhalation led to a complete inhibition of leukocyte
activation, with respect to suppressed leukocyte adhesion within post-capillary
venules (Figure 2.4). This was coupled with more than 75% inhibition of tissue
injury (Figure 2.3), implying that inflammation (i.e. overwhelming leukocyte
recruitment) imparts a considerable pathological process driving the CSassociated parenchymal damage. Indeed, activated leukocytes have been shown
to be one of the most significant contributors to the parenchymal injury seen in
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CS (Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2015); the findings
parallel those obtained from the models of reperfusion injury after complete
ischemia (Forbes, Harris et al. 1996, Gute, Ishida et al. 1998). Given the potent
anti-inflammatory nature of CO (Otterbein, Bach et al. 2000, Otterbein 2002,
Song, Kubo et al. 2003, Motterlini, Haas et al. 2012), our data provides further
confirmation of the critical role of inflammation in the pathophysiology of CS.
Despite some key findings, it is important to note that while inhalation of
CO significantly improved the overall microvascular perfusion in CS-challenged
rats, some degree of perfusion derangement still remained (Figure 2.2). This
suggests that the microvascular dysfunction and pathophysiology of CS may also
be driven by other, not yet understood, factor(s).
Elevated levels of COHb may represent a serious challenge when
considering inhaled CO as a potential therapy for treatment of CS. Affinity of CO
for hemoglobin is approximately 240 times higher than that for oxygen (Weaver
1999); in our study, 45 minute inhalation of 250ppm CO resulted in an increase
of COHb to 8%, in both sham and CS-challenged rats (Figure 2.5). It is important
to note, however, that similar levels (i.e. 3-8% COHb) are detected in the blood of
cigarette smokers (Vreman, Wong et al. 2000). While such level of COHb in
normal, healthy subjects is unlikely to be toxic, it may not be negligible in trauma
patients, majority of whom already experience insufficient levels of oxygenation.
This study, as a proof of concept, demonstrates that exogenous
application of CO may be of benefit in patients at risk of acute CS. While an
increase in COHb level may not be inconsequential, with the rapid advancements
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in the development of transition metal carbonyls, pharmacological means of CO
delivery might open further avenues for research into prolongation of the surgical
window and tissue preservation.
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CHAPTER 3: THE SEVERITY OF MICROVASCULAR DYSFUNCTION DUE TO
COMPARTMENT

SYNDROME

IS

DIMINISHED

BY

THE

SYSTEMIC APPLICATION OF CO-RELEASING MOLECULE-3
(CORM-3).

3.1 INTRODUCTION
Acute limb compartment syndrome (CS), a potentially devastating
complication of musculoskeletal trauma, is characterized by an increase in
pressure within a closed osseofascial compartment, resulting in musclethreatening and ultimately limb-threatening ischemia (Matsen 1975, Whitesides,
Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978,
Matsen 1980, Hartsock, O'Farrell et al. 1998). Fasciotomy, to fully decompress
all the muscles in the involved compartments, remains the only effective
treatment and current gold-standard surgical therapy. Despite a large body of
literature

dedicated

to

understanding

the

pathophysiology

of

CS,

the

mechanisms of CS-induced tissue damage are rather poorly understood.
Extremity CS occurs once swelling within a muscle compartment develops
to such a degree that the tissue perfusion becomes compromised. The
established view of the pathophysiological process of CS development is that
increasing compartmental pressure compromises microcirculatory perfusion, thus
restricting oxygen and nutrient delivery to vital tissues, ultimately resulting in
cellular anoxia and severe tissue necrosis (Sheridan and Matsen 1975,
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Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978, Matsen, Winquist et
al. 1980). Unlike complete ischemia, CS causes myonecrosis in the face of
patent vessels.

As such, the pathologic contribution of inflammation to the

pathophysiology of CS is being increasingly recognized; studies from our group
(Lawendy, Sanders et al. 2011) and others (Sadasivan, Carden et al. 1997,
Kalns, Cox et al. 2011) have broadly implicated leukocytes as playing a primary
role in both microvascular and parenchymal injury during CS.
Despite active investigation, few therapeutic options have been shown to
be effective. Recently, carbon monoxide (CO), a byproduct of heme oxygenase
(HO) activity has been shown to offer both protection to microvascular perfusion,
and anti-inflammatory benefits during systemic inflammation (Nakao, Kimizuka et
al. 2003, Hegazi, Rao et al. 2005, Mazzola, Forni et al. 2005, Ott, Scott et al.
2005, Scott, Cukiernik et al. 2009). Although the exogenous administration of CO
via inhalation (250ppm) has been shown beneficial during systemic inflammatory
response syndrome (Ott, Scott et al. 2005, Scott, Cukiernik et al. 2009), such
method of administration results in increased carboxyhemoglobin (COHb) levels,
thus presenting a potential threat to the host.
Lately, transitional metal carbonyls, CO-releasing molecules (CO-RMs)
have been used to deliver CO in a controlled manner without significantly altering
COHb (Motterlini, Clark et al. 2002, Clark, Naughton et al. 2003, Motterlini 2007).
The major advantage of using CO-RMs versus inhaled CO is the ability to control
CO delivery without significantly increasing COHb, and choice of various routes
(intravenous, intraperitoneal, subcutaneous or tissue superfusion) of CO
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administration to target specific organs/tissues. Consequently, CO-RMs have
received an increased attention for the potential pharmaceutical application
(Motterlini, Clark et al. 2002, Motterlini 2007, Motterlini and Otterbein 2010). CORMs have been shown to act pharmacologically in rat aortic and cardiac tissue,
where liberation of CO produced vasorelaxant effects, decreased myocardial
ischemia/reperfusion damage, and reduced inflammatory response in LPSstimulated macrophages (Clark, Naughton et al. 2003, Cepinskas, Katada et al.
2008, Mizuguchi, Stephen et al. 2009, Katada, Bihari et al. 2010).
The purpose of this study was to investigate the effects of CO, liberated
from a novel, water-soluble CO donor, CORM-3, on the microvascular function of
CS-challenged muscle, using our clinically relevant rodent model of CS
(Lawendy, Sanders et al. 2011). The ultimate goal is the development of a
pharmacologic adjunctive treatment for compartment syndrome, which would
reduce the morbidity and disability in patients.

3.2 MATERIALS AND METHODS
3.2.1 Animal Preparation
The experimental protocol was approved by the Council on Animal Care of
the University of Western Ontario (Appendix III), and has been previously
described in detail (Lawendy, Sanders et al. 2011). Briefly, male Wistar rats
(body weight 180-250g) were anesthetized by inhalational isoflurane (5%
induction, 2% maintenance) in 1:1 oxygen/nitrogen mixture. Left carotid artery
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was cannulated to allow for the monitoring of systemic blood pressure, fluid
administration and blood sampling.
Compartment pressure monitoring probe (Synthes, Westchester PA) was
inserted into the posterior compartment via gauge 16 angiocatheter (BD), while
gauge 24 angiocatheter (BD) attached to an IV line was placed into the anterior
compartment of the rat hind limb. CS was induced by an infusion of isotonic
saline, leading to an elevation of intra-compartmental pressure (ICP) to 30 mmHg.
Elevated ICP was maintained for 2 hours. Fasciotomy was performed to
decompress the hind limb compartments; the muscles were allowed to reperfuse
for 45 minutes, followed by intravital video microscopy.

3.2.2 CORM-3 Synthesis
A

water-soluble

CORM-3

(tricarbonylchloro-glycinate-ruthenium(II),

[Ru(CO)3Cl-glycinate]; molecular weight 295 gmol-1) was synthesized by us, in
accordance with the previously-published method (Motterlini and Otterbein 2010).
CORM-3 (10mg/ml stock solution) was prepared fresh by dissolving CORM-3 in
isotonic saline just prior to injection. As a control, inactive CORM-3 (iCORM-3)
was generated by dissolving CORM-3 in saline 72 hours prior to the experiment
and allowing it to release all CO from the solution (Clark, Naughton et al. 2003).

3.2.3 Experimental Groups
Rats were randomly assigned to one of four experimental groups: sham
(n=4), CS (n=4), CS+CORM-3 (n=8) and CS+iCORM-3 (n=8). CO-releasing
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molecule-3 (CORM-3), or its inactive form (iCORM-3), was administered to
animals undergoing CS upon fasciotomy at the dose of 10mg/kg, IP. Sham
animals underwent all the procedures as CS groups, but they did not receive
saline infusion into the anterior compartment of the hind limb, and the ICP was
maintained at the baseline level (0mmHg).

3.2.4 Intravital Video Microscopy (IVVM)
The extensor digitorum longus (EDL) muscle was dissected to the level of
its distal tendon, which was tied with a suture and cut from its bony insertion. The
animal was transferred onto the stage of an inverted microscope (Nikon); the
EDL was reflected into a saline bath containing 5µg/ml each of the fluorescent
vital dyes bisbenzimide (BB; exc. 343nm, em. 483nm) and ethidium bromide (EB;
exc. 482nm, em. 616nm). BB stains the nuclei of all cells while EB stains the
nuclei of only those cells with damaged cell membrane. Thus, EB/BB ratio
provided an index of tissue injury.
Microvascular perfusion and leukocytes within the post-capillary venules
were recorded by translumination with 20x and 40x objectives, respectively, in
five adjacent fields of view. Fluorescence microscopy was used to visualize the
BB and EB from the same fields of view that had been selected for the
measurement of capillary perfusion. At the conclusion of the experiment, rats
were euthanized by an overdose of anesthetic agent.

114
3.2.5 Offline Video Analysis
Capillary perfusion was assessed by counting the number of continuouslyperfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries
that crossed three parallel lines drawn perpendicular to the capillary axis on the
video monitor, and was expressed as % of total capillaries. Tissue injury was
assessed by counting the number of EB- and BB-labelled nuclei, and expressed
as EB/BB ratio. Leukocyte activation was assessed by counting the numbers of
rolling and adherent leukocytes in post-capillary venules and expressed per unit
area (i.e. 1000µm2). Venular area was measured using ImageJ (NIH, Bethesda,
MD). A leukocyte was considered adherent if it remained stationary for at least
30 seconds, and a cell was considered rolling if it remained in contact with the
wall of the vessel during its movement.

3.2.6 Serum Tumor Necrosis Factor Alpha (TNF-α) Measurements
TNF-α levels were measured from arterial blood samples drawn at 9 time
points: (1) baseline, (2) 15 minutes into CS, (3) 45 minutes into CS, (4) 90
minutes into CS, (5) 2 hours into CS – just prior to fasciotomy and CORM-3 (or
iCORM-3) injection, (6) 10 minutes post-fasciotomy, (7) 20 minutes post
fasciotomy, (8) 30 minutes post fasciotomy, (9) 45 minutes post fasciotomy, just
before IVVM. TNF-α was assessed using enzyme-linked immunosorbent assay
(ELISA, Pierce Biotechnology, c/o Thermo Scientific, Rockford, IL) according to
manufacturer’s instructions. The TNF-α ELISA was sensitive to less than 5 pg/mL.
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3.2.7 Statistical Analysis
All parameters were expressed as mean ± SEM and analyzed using oneway ANOVA. p<0.05 was considered statistically significant.

3.3 RESULTS
3.3.1 Systemic Leukocyte Count and Carboxyhemoglobin (COHb)
Elevation of ICP, coupled with subsequent fasciotomy and 45 minutes of
reperfusion, led to a small, but significant rise in leukocyte count; CORM-3
treatment was able to decrease the severity of this response (Table 3.1).
Application of CORM-3 or iCORM-3 had no effect on COHb levels (Table 3.1).

3.3.2 Microvascular Perfusion
Elevation of ICP resulted in significant changes to microvascular perfusion,
as shown in Figure 3.1. The number of continuously-perfused capillaries
decreased from 76±4% in sham to 23±2% in CS+iCORM-3 (p<0.0001), while the
number of non-perfused capillaries increased from 13±2% in sham to 55±2% in
CS+iCORM-3 (p<0.0001). CORM-3 treatment was able to restore the number of
continuously-perfused capillaries to 57±5% (p<0.001), while iCORM-3 had no
effect.
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Table 3.1.

The effects of CORM-3 on systemic leukocyte count and COHb
levels. Two hours of elevated ICP were followed by fasciotomy,
injection of CORM-3 (or iCORM-3) and 45min reperfusion. CSassociated rise in systemic leukocyte count was reversed by
CORM-3 application (*p<0.01 from sham; †p<0.05 from CS and
CS+iCORM-3). CORM-3 and iCORM-3 caused no changes in
systemic levels of COHb. LKC, leukocyte counts; COHb,
carboxyhemoglobin.

LKC
(Units x109/L)

Hemoglobin
(g/L)

COHb
(%)

Sham

1.5 ± 0.2

125.0 ± 2.3

1.5 ± 0.2

CS+iCORM-3

4.1 ± 0.7*

124.8 ± 2.9

1.6 ± 0.1

CS+CORM-3

2.3 ± 0.2†

129.5 ± 2.7

1.6 ± 0.1
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*

*

†

100

CPC
IPC
NPC

% Total

75

50

25

0

Sham

CS

CS+iCORM-3 CS+CORM-3

Figure 3.1. The effect of CORM-3 on skeletal muscle microvascular
perfusion following CS. Two hours of elevated ICP were followed
by fasciotomy, injection of CORM-3 (or its inactive form, iCORM-3),
45min reperfusion and IVVM. CS-associated perfusion changes
were reversed by CORM-3 application (one-way ANOVA p<0.05;
*p<0.001 from sham; †p<0.001 from CS and CS+iCORM-3; see the
text for additional details). CPC, continuously-perfused capillaries;
IPC,

intermittently-perfused

capillaries.

capillaries;

NPC,

non-perfused
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3.3.3 Tissue Injury
Muscle injury, as measured by EB/BB ratio, significantly increased from
0.05±0.03 in sham to 0.31±0.05 (p<0.0001) in CS+iCORM-3 group. CORM-3
treatment was able to diminish tissue injury to 0.07±0.01 (p<0.001) (Figure 3.2).

3.3.4 Serum TNF-α
Elevation of ICP led to a progressive serum TNF-α release, reaching its
maximum level at 2 hours (just prior to fasciotomy; p<0.01) (Figure 3.3). TNF-α
levels continued to rise in the post-fasciotomy/reperfusion period in animals
treated with iCORM-3. In contrast, CORM-3 injection effectively prevented the
latter response at 30 and 45 minutes post-fasciotomy (p<0.001) (Figure 3.3).

3.3.5 Inflammation
Elevation of ICP led to significant leukocyte activation, as demonstrated by
the adhesive interactions with vascular endothelium. Leukocyte adherence in the
post-capillary venules of the skeletal muscle was increased from 1.8±0.5 in sham
to 13.7±0.9 leukocytes/30s/1000µm2 in CS+iCORM-3 (p<0.0001). Leukocyte
rolling, while not statistically significant, also increased from 1.7±0.6 to 3.3±0.7
leukocytes/30s/1000µm2. CORM-3 treatment led to a significant, 8-fold decrease
in leukocyte adherence, while having no effect on leukocyte rolling (0.6±0.3
adherent

leukocytes/30s/1000µm2,

p<0.001

and

3.0±0.8

leukocytes/30s/1000µm2, not significant, respectively) (Figure 3.4).

rolling
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*
*

0.4

EB/BB

0.3

0.2

†

0.1

0.0

Sham

CS

CS+iCORM-3 CS+CORM-3

Figure 3.2. The effect of CORM-3 on skeletal muscle tissue injury
following CS. Two hours of elevated ICP were followed by
fasciotomy, injection of CORM-3 (or its inactive form, iCORM-3),
45min reperfusion, and IVVM. CS-associated tissue injury was
reversed by CORM-3 application (one-way ANOVA p<0.05;
*p<0.001 from sham; †p<0.001 from CS and CS+iCORM-3).
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CS+iCORM-3
CS+CORM-3

1500

†

*

1000

T=45min

T=30min

T=20min

T=10min

F; T=0min

90min CS

45min CS

0

15min CS

500

Baseline

Serum TNF-α (pg/ml)

2000

CORM-3/iCORM-3 injection

Figure 3.3. The effect of CORM-3 on serum TNF-α levels in CS. Two hours
of elevated ICP were followed by fasciotomy, injection of CORM-3
(or its inactive form, iCORM-3) and 45min reperfusion. Serum TNFα levels were assessed at each time point indicated. Any further
post-fasciotomy TNF-α elevation was reversed by CORM-3
application (one-way ANOVA p<0.05; *p<0.01 from baseline;
†p<0.001 from CS+iCORM-3). F, fasciotomy.
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Figure 3.4. The effect of CORM-3 on modulation of leukocyte recruitment
to the skeletal muscle vasculature following CS. (A) Leukocyte
adhesion; (B) leukocyte rolling. Two hours of elevated ICP were
followed by fasciotomy, injection of CORM-3 (or its inactive form,
iCORM-3), 45min reperfusion and IVVM. CORM-3 application was
able to prevent leukocyte adhesion within the post-capillary venules.
(one-way ANOVA p<0.05; *p<0.001 from sham; †p<0.001 from CS
and CS+iCORM-3).
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3.4 DISCUSSION
Compartment syndrome poses a challenging problem. Aside from the gold
standard of fasciotomy and supportive treatment to prevent other systemic
sequelae during the recovery period, few other treatment modalities exist (Olson
and Glasgow 2005). In the present study, we demonstrated the benefit of
supraphysiologic levels of carbon monoxide in improving capillary perfusion,
reducing cellular damage and leukocyte adherence following compartment
syndrome and fascial release. While the benefits of this compound have been
well described in the literature, finding a suitable method of administration to
reduce additional risk to the host has posed a long-standing problem. CO
delivery via transitional metal carbonyls is a recent discovery and has shown to
provide the vasorelaxant, antiapoptotic, and anti-inflammatory effects without the
risk of elevated carboxyhemoglobin seen previously through inhalation (Guo,
Stein et al. 2004, Motterlini and Otterbein 2010). This method of CO delivery may
provide a useful pharmacologic agent in the treatment of patients at risk for, or
recovering from, compartment syndrome.
CO is a signalling molecule produced endogenously by the degradation of
heme, catalyzed by heme oxygenases (HO-1 and HO-2) (Otterbein 2009). CO
can exert vasodilatory effects, mitigate intracellular apoptosis, suppress
inflammatory pathways and have anti-ischemic effects (Motterlini 2007). In our
study, CORM-3 (a water-soluble formulation, administered IP) demonstrates a
beneficial effect in preserving microvascular flow in CS-challenged muscle.
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Continuous perfusion is defined as a physiologic flow through the capillary
bed, whereas intermittent perfusion results from a marked decrease in red blood
cell flow (Lawendy, Sanders et al. 2011). Non-perfused capillaries are seen when
no red cell movement is observed. The change from continuous perfusion to a
predominantly non-perfused profile demonstrates a pathologic shift in the
microvascular bed in response to CS. In the current study, animals treated with
CORM-3 had shown significant improvement in capillary perfusion rates,
restoring the number of continuously-perfused capillaries to levels comparable to
those of the sham group (Figure 3.1). Microvascular perfusion was virtually
unchanged at 2 hours of elevated ICP in the presence of CORM-3, suggesting a
substantial protective role of exogenously applied CO in the maintenance of
skeletal muscle blood flow during CS. To the best of our knowledge, this study is
the first to demonstrate such potent protective effects of CORM-3 in an acute and
overwhelming inflammatory onset, such as CS. Moreover, administration of
CORM-3 was very effective in restoring tissue injury levels back to baseline
levels, as those seen in the sham group (Figure 3.2).
Ischemia-reperfusion injury, a major component of CS pathophysiology,
produces a pro-inflammatory environment, resulting in the upregulation of
cytokines and chemokines, both systemically and within the affected tissues
(Forbes, Carson et al. 1995). Inflammation-relevant cytokines/chemokines,
particularly those produced during the acute phase of inflammatory response
(TNF-α, IL-1β, IL-6, IL-8), in turn, stimulate leukocyte activation (primarily
polymorphonuclear leukocytes, PMN) and recruitment into the inflamed tissues.
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Once activated, leukocytes produce reactive oxygen species (ROS) and release
proteolytic enzymes that (individually or concurrently) cause cellular damage and
contribute to the increased vascular permeability, as well as subsequent
formation of edema. As a result, increased interstitial pressure compresses
adjacent capillaries, creating non-perfused segments (Kurose, Anderson et al.
1994, Forbes, Harris et al. 1996, Gute, Ishida et al. 1998). In our study, we
observed a marked increase in the levels of circulating TNF-α (one of the most
potent pro-inflammatory cytokines) in CS-challenged animals, particularly postfasciotomy. This was associated with overwhelming leukocyte recruitment to the
CS-challenged muscle, as demonstrated by adherent leukocytes in the postcapillary venules (Figure 3.4). Interestingly, the increase in number of adherent
leukocytes was completely prevented in animals treated with CORM-3, but not its
inactive counterpart, iCORM-3. It is important to note that the decrease in
leukocyte recruitment to CS-challenged muscle correlated with the CORM-3dependent suppression of serum TNF-α levels (Figure 3.3).
The exact mechanisms of CORM-3-derived protection/anti-inflammatory
effects in our CS model are, at the moment, unknown. However, given the
complex and multi-component nature of CS pathophysiology (ischemic episode,
oxidative stress, cytokine production, local and systemic responses), it is
plausible to assume that the beneficial effects of CORM-3-derived CO are most
likely due to its simultaneous action on multiple targets in various cell types. In
this regard, our current findings are all in agreement with previous studies
showing that CORM-3 is able to reduce pro-inflammatory cytokine production,
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and, therefore, cytokine-dependent upregulation of leukocyte-endothelium
adhesive interaction (Song, Bergstrasser et al. 2009, Vadori, Seveso et al. 2009,
Katada, Bihari et al. 2010, Mizuguchi, Capretta et al. 2010, Bergstraesser,
Hoeger et al. 2012). The identity of adhesion molecules expressed by the
leukocytes and/or endothelial cells due to CS remain to be elucidated; however,
our data (i.e. CORM-3 ability to reduce the leukocyte adhesion to post-capillary
venule endothelium in CS-challenged animals) suggests that CORM-3 may
directly or indirectly interfere with the expression of Ig-superfamily adhesion
molecules (such as ICAM-1, VCAM-1, etc.) on endothelial cells. The lack of
significant changes in leukocyte rolling in CORM-3-treated animals suggests that
CORM-3 does not modulate expression/function of selectins (E-selectin, Pselectin or L-selectin), molecules responsible primarily for the leukocyte rolling
but not adhesion to the vascular endothelium per se (Ley, Laudanna et al. 2007).
Previous studies have demonstrated that CORM-3 suppresses oxidative
stress in vascular endothelial cells (Mizuguchi, Capretta et al. 2010), cardiac
myocytes (Lancel, Hassoun et al. 2009) and inflammatory cells (PMN and
macrophages) (Mizuguchi, Stephen et al. 2009); this effect may be responsible
for our observation of CORM-3-dependent suppression of acute skeletal muscle
cell injury during CS (Figure 3.2). In addition, CORM-3-dependents protection of
vascular perfusion could also be attributed to the potent vasodilatory properties
of CO (Foresti, Hammad et al. 2004), which could improve capillary flow of the
affected tissue in the post-fasciotomy state. Previous studies have demonstrated

126
CO-dependent modulation of the blood vessel tone through the mechanisms
involving soluble guanylate cyclase signalling (Motterlini and Otterbein 2010).
While the results of our experiments look promising, the study is not
without limitations. Although a rodent model of compartment syndrome has many
benefits (it is reliable, small and cost effective), with relatively simple regulation of
both compartment pressure and blood pressure, its limitations are equally as
important. First we employed an absolute compartment threshold of 30 mmHg,
which may not be as severe an insult in a human model; thus the severity of our
rat CS model may be relatively mild compared to a full-scale CS in humans.
Given the differences in size and metabolic parameters, rats appear to be more
sensitive to ischemic injury (unpublished observation); however, it remains to be
seen how the severity of CS in rats compares to that in humans. In addition, the
timing of CORM-3 administration may have to be optimized. In our study, CORM3 was administered once, at fasciotomy; we did not study the effects of CORM-3
beyond 1 hour post-administration. It is highly unlikely that one injection of
CORM-3 would prevent CS, but it might be able to prolong the surgical window,
in case of delayed fasciotomy. Future studies are needed to examine the effect
of CORM-3 administration on CS injury, but without fasciotomy. Unfortunately,
direct method of visualization of microvasculature in rats requires fasciotomy;
thus, any future studies will have to employ indirect means of assessing the
tissue damage (e.g. functional gait assessment).
The potential toxicity of CORM-3 is yet to be established. While very little
data exists on the safety of the systemic CORM-3 administration in large animals,
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preclinical studies employing non-human primates suggest that there are few
side effects associated with both single and repeated injections (Vadori, Seveso
et al. 2009). In the future, CORM-3 may need to be tested in an animal more akin
to humans. Larger animals appear to be more sensitive to the effects of CORM-3
(Vadori, Seveso et al. 2009); thus a lower therapeutic dose may be sufficient,
minimizing potential side effects.
To our knowledge, this is the first study demonstrating the beneficial
effects of carbon monoxide, delivered by a carbon-monoxide releasing molecule,
in the treatment of acute compartment syndrome. While the exact mechanisms of
CORM-3 protective action remain to be determined, the obtained data strongly
indicate a potential therapeutic application of CORM-3 to patients at risk of
developing CS.
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CHAPTER 4

SYSTEMIC ADMINISTRATION OF CARBON MONOXIDE RELEASING
MOLECULE-3 (CORM-3) PROTECTS THE SKELETAL MUSCLE IN PORCINE
MODEL OF COMPARTMENT SYNDROME.

A version of this chapter was submitted for publication to Critical Care Medicine
(2017).
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CHAPTER 4: SYSTEMIC ADMINISTRATION OF CARBON MONOXIDE
RELEASING

MOLECULE-3

SKELETAL

MUSCLE

IN

(CORM-3)
PORCINE

PROTECTS

THE

MODEL

OF

COMPARTMENT SYNDROME.

4.1

INTRODUCTION
Compartment syndrome (CS) is a serious and devastating complication of

musculoskeletal trauma. CS develops as a result of an increased pressure within
a closed osseofascial compartment, resulting in muscle-threatening and limbthreatening ischemia (Matsen 1975, Matsen 1980, Matsen, Winquist et al. 1980,
Hartsock, O'Farrell et al. 1998). Fasciotomy, to fully decompress all involved
compartments, remains the only gold standard surgical treatment, but the
surgery must be performed within a narrow window of 6-8 hours, before the
damage to the involved tissues becomes permanent (Mubarak and Owen 1977,
Mubarak, Owen et al. 1978, Hargens, Romine et al. 1979).
An

elevation

in

intra-compartmental

pressure

(ICP)

during

CS

compromises microcirculation (Hartsock, O'Farrell et al. 1998), restricting oxygen
and nutrient delivery to the point where metabolic demands of the tissue cannot
be met. This results in cellular anoxia and severe tissue necrosis; however,
unlike complete ischemia, it occurs in the face of patent vessels (Whitesides,
Haney et al. 1975). Reperfusion of previously ischemic tissue is known to trigger
severe inflammation, both local and systemic (Blaisdell 2002, Gillani, Cao et al.
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2011, Lawendy, Bihari et al. 2016, Bihari, Cepinskas et al. 2017). Since CS
appears to be a form of reperfusion injury, the contribution of inflammation to the
pathophysiology of CS is increasingly being recognized; studies from our group
and others have demonstrated that leukocytes appear to play a primary role in
producing both microvascular and parenchymal damage during CS (Sadasivan,
Carden et al. 1997, Gute, Ishida et al. 1998, Lawendy, Sanders et al. 2011,
Lawendy, Bihari et al. 2015). The effect appears to be mediated by the release of
pro-inflammatory cytokines, particularly TNF-α (Lawendy, Bihari et al. 2014,
Donohoe 2015).
Apart from fasciotomy, few therapeutic options have been shown to be
effective, primarily due to the lack of understanding the CS pathophysiology.
Recently, exogenous application of carbon monoxide (CO), a normal byproduct
of heme metabolism, has been shown to be protective to microvascular perfusion
and provide anti-inflammatory benefits during various ischemic and inflammatory
conditions (Otterbein, Bach et al. 2000, Ott, Scott et al. 2005, Scott, Cukiernik et
al. 2009). With the advent of development of water-soluble carbon monoxide
releasing molecules (CO-RMs), particularly CORM-3, CO can be safely delivered
to the tissue without significantly affecting the levels of carboxyhemoglobin
(COHb) (Motterlini and Otterbein 2010, Lawendy, Bihari et al. 2014).
Previously, we have demonstrated that CORM-3 application at fasciotomy
was able to diminish the CS-associated tissue injury and leukocyte activation, as
well as block the systemic release of pro-inflammatory cytokine TNF-α in a rat
model of CS (Lawendy, Bihari et al. 2014). Additionally, CORM-3 was capable of
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blocking the formation of reactive oxygen species (ROS) within the human
endothelial cells subjected to CS stimulus in the form of serum obtained from CS
patients (Bihari, Cepinskas et al. 2014). While the results of these studies are
promising, preclinical testing in a large, more human-like animal model of CS has
not been undertaken yet; in addition, the effects and mechanisms of CORM-3 on
modulation of CS-induced skeletal muscle injury and dysfunction remain to be
elucidated.
The purpose of this study was to test the effect of CORM-3 on the severity
of microvascular dysfunction, tissue injury and the activation of circulating
leukocytes in a pre-clinical setting, using porcine model of CS. The ultimate goal
is the development of a safe pharmacologic adjunctive treatment for
compartment syndrome, which would reduce the morbidity and disability in
patients.

4.2

MATERIALS AND METHODS

4.2.1 Animal Preparation
The

experimental

protocol

was

approved

by

the

Animal

Use

Subcommittee of the Council on Animal Care at the University of Western
Ontario. Male Yorkshire-Landrace pigs, body weight 49-60kg, were used for all
experiments. Anesthesia was induced by TKX (0.5mg/kg telazol, 0.5mg/kg
ketamine, 0.5mg/kg xylazine) injection. Animals were then intubated (ETT 6.58.0) and switched to mechanical ventilation (14-20 breaths/min) under
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inhalational isoflurane (1.5-3% maintenance) in 100% oxygen for the remainder
of the experiment. End-tidal CO2, heart rate, oxygen saturation and arterial blood
gases were continuously monitored.
Left femoral artery was cannulated percutaneously, using 6F introducer
(Medtronic), for the invasive blood pressure monitoring and arterial blood
sampling. A 24-gauge IV catheter (BD Insyte) was placed in the right auricular
vein for continuous fluid replacement and intravenous drug administration. Body
temperature was continuously monitored and kept at 38.0-38.5°C by BairHugger
thermal blanket.
Compartment pressure monitoring probe (Synthes, Westchester PA) was
inserted into the anterior compartment via gauge 16 angiocatheter (BD) of the pig
right hind limb; a gauge 16 needle (BD) attached to an IV line was also inserted
into the subfascial plane within the same compartment. The limb was then placed
in a plaster cast. CS was induced by an infusion of isotonic saline enriched with
0.4g/L bovine serum albumin, leading to an elevation of intra-compartmental
pressure (ICP) to 40-65 mmHg. Elevated ICP was maintained for 6 hours. A
single-incision fasciotomy was performed to decompress the hind limb
compartments; the muscles were allowed to reperfuse for 3 hours, followed by
imaging of the microvascular perfusion of tibialis anterior (TA) and peroneus
tertius (PT) muscles with a hand-held Cytoscan microscope equipped with
orthogonal polarization spectroscopy (OPS) (Cytometrics).
Thirty minutes prior to OPS imaging, animals were injected intravenously
with 50µg/kg each of the fluorescent vital dyes ethidium bromide (EB; exc.
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482nm, em. 616nm), bisbenzimide (BB; exc. 343nm, em. 483nm) and
carboxyfluorescein-labelled

in

vivo

marker

of

apoptosis

(FLIVO,

ImmunoChemistry Technologies; exc. 492nm, em. 517nm). Following the OPS
microscopy, TA and PT muscles were excised and fixed in 10% formalin for
further analysis. Pigs were then euthanized by an overdose of anesthetic agent.

4.2.2 CORM-3
A

water-soluble

CORM-3

(tricarbonylchloro-glycinate-ruthenium(II),

[Ru(CO)3Cl-glycinate]; molecular weight 295gmol-1), an equimolar CO donor, was
synthesized by us (Mizuguchi, Stephen et al. 2009), in accordance with a
previously-published method (Clark, Naughton et al. 2003). CORM-3 (10mg/ml
stock solution) was prepared fresh by dissolving CORM-3 in isotonic saline just
prior

to

injection.

spectrophotometrically,

CO
by

release

from

conversion

CORM-3
of

was

confirmed

deoxy-myoglobin

to

carbonmonoxymyoglobin. As a control, inactive CORM-3 (iCORM-3) was
generated by dissolving CORM-3 in saline 72 hours prior to the experiment and
allowing it to release all CO from the solution (lack of CO release was confirmed
by myoglobin-binding assay) (Clark, Naughton et al. 2003, Lawendy, Bihari et al.
2014).

4.2.3 Experimental Design
Following induction of anesthesia, intubation and placement of all
catheters, animals were randomly assigned into one of the three experimental
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groups: Sham (n=4), CS+CORM-3 (n=4) and CS+iCORM-3 (n=4). CO-releasing
molecule-3 (CORM-3), or its inactive form (iCORM-3), was administered to
animals undergoing CS upon fasciotomy at the dose of 2mg/kg, IV.
Sham animals underwent all procedures, but the compartment pressure
was maintained at the baseline level (0mmHg). In addition, the contralateral limb
of each animal used in these experiments served as a control; it underwent all
the procedures as the experimental limb, but did not receive saline infusion into
the anterior compartment, and the ICP was maintained at the baseline level
(0mmHg).

4.2.4 OPS Imaging
The hand-held objective of Cytoscan OPS microscope (Cytometrics,
Devon, UK) was applied to the surface of the exposed TA and/or PT muscle,
recording microvascular perfusion using epi-illumination with green polarized light
at 10x objective, in five to ten adjacent fields of view. The microcirculation was
recorded with a digital recorder (Sony) and stored on DV tapes for offline
analysis.

4.2.4.1

Offline Video Analysis

Capillary perfusion was assessed by counting the number of continuouslyperfused (CPC), intermittently-perfused (IPC) and non-perfused (NPC) capillaries
that crossed three parallel lines drawn perpendicular to the capillary axis on the
video monitor, and was expressed as % of total capillaries.
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4.2.5 Tissue Leukocyte Infiltration and Necrosis
Following formalin fixation, TA and PT samples were processed and
embedded in paraffin; 5µm sections were cut with a microtome. Sections were
put on poly-L slides, cleared in xylene, rehydrated with graded alcohols and then
subjected to a standard H&E staining protocol.
Levels of tissue leukocyte infiltration and tissue necrosis were assessed
semi-quantitatively, by a blinded pathologist, Dr. Lee Ang of London Health
Sciences Centre, in 5 adjacent fields of view in each muscle sample using
conventional light microscopy. Histopathology grading scale ranged from 0 (no
leukocyte infiltration, no necrosis, i.e. normal tissue) to 3 (severe leukocyte
infiltration and/or severe tissue necrosis) (Table 4.1).

4.2.6 Tissue Injury and Apoptosis
Paraffin-embedded 5µm sections were cut with a microtome. Sections
were put on poly-L slides, cleared in xylene, rehydrated with graded alcohols and
mounted with Vectashield fluorescence mounting medium.
Levels of tissue injury (EB/BB) and apoptosis (FLIVO/BB) were quantified
using conventional fluorescence microscopy. EB stains the nuclei of only those
cells with damaged cell membrane, while BB stains the nuclei of all cells. FLIVO,
a non-toxic marker, stains only the cells with apoptosis-associated caspases
activation. Thus, EB/BB and FLIVO/BB ratios provided an index of tissue injury
and apoptosis, respectively.
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Table 4.1.

Histopathology grading scale for skeletal muscle tissue
leukocyte infiltration and necrosis in porcine model of CS.
Four grades were assigned by a blinded pathologist (Dr Lee Ang at
London Health Sciences Centre) to both leukocyte infiltration and
tissue necrosis, with 0 representing normal tissue and 3
corresponding to severe fiber necrosis and/or leukocyte infiltration.

Grade

Muscle Leukocyte Infiltration

Muscle Necrosis

0

Normal, no infiltration

Normal, no necrosis

1

Mild

Mild

2

Moderate

Moderate

3

Severe

Severe
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4.2.7 Systemic Leukocyte Isolation and Activation Assay
Systemic leukocyte activation was measured in arterial blood samples
drawn at 16 time points: (1) baseline, (2) 1 hour into CS, (3) 2 hours into CS, (4)
3 hours into CS, (5) 4 hours into CS, (6) 5 hours into CS, (7) 6 hours into CS –
just prior to fasciotomy and CORM-3 (or iCORM-3) injection, (8) 20 minutes postfasciotomy, (9) 40 minutes post-fasciotomy, (10) 60 minutes post fasciotomy,
(11) 75 minutes post-fasciotomy, (12) 90 minutes post-fasciotomy, (13) 105
minutes post-fasciotomy, (14) 2 hours post-fasciotomy, (15) 2.5 hours postfasciotomy, (16) 3 hours post-fasciotomy – just before OPS imaging.
Polymorphonuclear (PMN) leukocytes were isolated by density gradient
centrifugation (Histopaque-1077, Sigma), as previously described by us
(Mizuguchi, Stephen et al. 2009), followed by the lysing of red blood cells
(ammonium chloride solution). Isolated leukocytes were reconstituted in 0.1M
phosphate buffer saline, pH 7.4, adjusting the buffer volume to achieve the final
cell count of 1x109 leukocytes/ml. Leukocyte activation (i.e. superoxide (O2-)
production) was assessed by L-012 assay, and expressed as relative
luminescence units (RLU)/106 PMN.

4.2.8 Serum Tumor Necrosis Factor Alpha (TNF-α) Measurements
TNF-α levels in arterial blood samples were assessed using enzymelinked immunosorbent assay (ELISA, Pierce Biotechnology, c/o Thermo Scientific,
Rockford, IL) according to manufacturer’s instructions. The TNF-α detection limit
was 5pg/mL.
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4.2.9 Statistical Analysis
All parameters were expressed as mean ± SEM and analyzed using oneway ANOVA, repeated measures two-way ANOVA (systemic leukocyte activation,
serum TNF-α), or Kruskal-Wallis test (histopathology scores), with Bonferroni or
Dunn’s post-hoc test as appropriate (GraphPad Prism 6.0 for Mac). Sample size
calculation was performed using StatMate (GraphPad Software Inc., San Diego,
CA), with power set at 85%. p<0.05 was considered statistically significant.

4.3

RESULTS

4.3.1 Systemic Leukocyte Count and COHb
Elevation of ICP, coupled with subsequent fasciotomy and 3 hours of
reperfusion led to a significant rise in leukocyte count; CORM-3 treatment was
able to decrease the severity of the response (Table 4.2). Importantly, application
of CORM-3 or iCORM-3 had no effect on COHb levels (Table 4.2).

4.3.2 Organ Function
4.3.2.1 Liver Enzymes
Elevation of ICP led to a significant increase in aspartate transaminase
(AST), from 25.0±2.0U/L to 88.5±43.5U/L (p<0.05), and alkaline phosphatase
(ALP) (208.5±27.5U/L versus 107.5±16.5U/L in sham), while having no effect on
alanine transaminase (ALT) or bilirubin (Table 4.2). Systemic administration of
CORM-3 resulted in a significant decrease in AST to 41.5±1.2U/L (p<0.05) and
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Table 4.2.

The effect of CORM-3 on hematological and biochemical
parameters in porcine model of CS. CORM-3 at fasciotomy led to
a significant decrease in systemic leukocytes and creatinine levels
(*p<0.05 from sham and/or baseline, †p<0.05 from CS+iCORM-3)
Sham

CS+iCORM-3

CS+CORM-3

LKC (Units x109/L)

12.9 ± 1.9

20.2 ± 5.4*

8.1 ± 0.5†

Hemoglobin (g/L)

98.5 ± 7.5

97.3 ± 2.8

100.3 ± 2.3

COHb (%)

2.7 ± 0.1

2.0 ± 0.7

2.1 ± 0.5

Urea (mM)

6.0 ± 0.4

17.4 ± 4.4*

8.6 ± 0.6†

109.0 ± 1.0

191.5 ± 5.5*

128.5 ± 2.0†

Bilirubin (mM)
• Total
• Direct

2.5 ± 0.1
0.9 ± 0.1

3.7 ± 0.5
2.1 ± 0.5

4.6 ± 0.9
1.7 ± 0.3

ALT (U/L)

36.5 ± 0.5

32.5 ± 3.5

30.0 ± 2.9

AST (U/L)

25.0 ± 2.0

88.5 ± 43.5*

41.5 ± 1.2†

ALP (U/L)

107.5 ± 16.5

208.5 ± 27.5*

171.0 ± 13.5†

Lactate (mM)
• Baseline
• 6hr CS
• Final

0.44 ± 0.04
0.50 ± 0.16
0.54 ± 0.11

0.43 ± 0.18
1.60 ± 0.08*
3.07 ± 1.26*

0.40 ± 0.08
0.97 ± 0.23*†
1.93 ± 0.36*†

Creatinine (mM)
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ALP to 171.0±13.5U/L. No changes were observed in ALT or bilirubin due to
CORM-3 administration.

4.3.2.2 Kidney
Elevation of ICP led to a significant increase in blood urea and creatinine
levels, from 6.0±0.4mM and 109.0±1.0mM, respectively, in sham to 17.4±4.4mM
and 191.5±5.5mM, respectively in CS (p<0.05). Systemic administration of
CORM-3 at fasciotomy resulted in a significant decrease of both blood urea and
creatinine, to 8.6±0.6mM and 128.5±2.0mM, respectively (Table 4.2).

4.3.2.3 Skeletal Muscle - Lactate
Elevation of ICP resulted in a significant increase in systemic lactate levels,
from 0.43±0.18µmol/L at baseline, to 1.60±0.08µmol/L at 6hr CS (p<0.05).
Following reperfusion, lactate levels rose to 3.07±1.26µmol/L, while in sham
animals they remained unchanged from the baseline for the duration of the
experiment.
Administration of CORM-3 at fasciotomy resulted in significant decrease of
lactate levels measured at the conclusion of the experiment, to 1.93±0.36µmol/L
(p<0.05) (Table 4.2).

4.3.3 Systemic Leukocyte Activation and TNF-α Levels
Elevation of ICP led to a progressive increase in systemic leukocyte
activation, from the baseline of 1.0±0.0 RLU/106 PMNs to 1.4±2.0 RLU/106 PMNs,
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4.1±2.1 RLU/106 PMNs, 6.2±2.9 RLU/106 PMNs, 13.5±6.3 RLU/106 PMNs,
16.5±7.9 RLU/106 PMNs and 14.7±5.7 RLU/106 PMNs at 1hr, 2hr, 3hr, 4hr, 5hr
and 6hr, respectively (Figure 4.1A). Fasciotomy resulted in a transient decrease
in leukocyte activation to 8.8±2.4 RLU/106 PMNs, followed by gradual
progressive increase to 7.5±4.7 RLU/106 PMNs, 10.2±6.0 RLU/106 PMNs,
11.2±5.8 RLU/106 PMNs, 15.2±3.3 RLU/106 PMNs, 16.5±1.0 RLU/106 PMNs,
21.1±1.1 RLU/106 PMNs, 22.9±4.4 RLU/106 PMNs and 38.1±11.3 RLU/106
PMNs at 20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min and
180min, respectively (p<0.05). Application of CORM-3 at fasciotomy decreased
leukocyte activation to 5.5±2.5 RLU/106 PMNs, 6.3±2.9 RLU/106 PMNs, 6.0±3.4
RLU/106 PMNs, 6.3±3.5 RLU/106 PMNs, 6.2±3.1 RLU/106 PMNs, 6.9±3.8
RLU/106 PMNs, 7.4±3.2 RLU/106 PMNs, 10.4±5.5 RLU/106 PMNs and 11.1±5.8
RLU/106 PMNs at 20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min
and 180min, respectively (p<0.05 from CS control group) (Figure 4.1B).
Elevation of ICP led to a progressive increase in systemic levels of proinflammatory cytokine TNF-α, from the baseline level of 8.9±5.8pg/ml to
14.6±7.1pg/ml, 20.8±8.2pg/ml, 30.9±7.8pg/ml, 48.7±5.0pg/ml, 72.5±11.9pg/ml
and 99.2±22.1pg/ml at 1hr, 2hr, 3hr, 4hr, 5hr and 6hr, respectively (Figure 4.2A).
Following fasciotomy, TNF-α levels continued to rise to 117.9±31.9pg/ml,
147.6±41.6pg/ml,

164.6±38.5pg/ml,

196.7±55.6pg/ml,

211.6±56.9pg/ml,

164.0±50.1pg/ml, 184.1±68.3pg/ml, 208.2±65.5pg/ml and 251.2±47.3pg/ml at
20min, 40min, 60min, 75min, 90min, 105min, 120min, 150min and 180min,
respectively. Application of CORM-3 (but not iCORM-3) at fasciotomy completely

A

B

Figure 4.1.

Leukocyte Activation (O2- Production) Leukocyte Activation (O2 Production)
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The effect of CORM-3 on systemic leukocyte activation in
porcine model of CS. Elevated ICP resulted in (A) a progressive
increase in leukocyte (PMN) activation, as assessed by O2production; (B) fasciotomy resulted in a further circulating PMN
activation, which was prevented by CORM-3 treatment; (repeated
measures ANOVA; *p<0.001 from PRE, †p<0.05 from iCORM-3).
PRE, pre-CS (i.e. baseline).
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blocked the systemic TNF-α production by 20min reperfusion and for the
remainder of the experiment (p<0.05) (Figure 4.2B).

4.3.4 Microvascular Perfusion
Six hours of elevated ICP, followed by fasciotomy and 3 hours of
reperfusion resulted in 44±1% CPC versus 76±4% in sham (p<0.001) and 39±3%
NPC in CS versus 13±2% in sham (p<0.001) (Figure 4.3). Application of CORM3 (but not iCORM-3) at fasciotomy partially restored the microvascular perfusion
to 68±3% CPC (p<0.001) and 25±3% NPC (p<0.05), while having no effect on
the perfusion of the control limb (data not shown).

4.3.5 Tissue Injury and Apoptosis
Six hours of elevated ICP, coupled with fasciotomy and 3 hours of
reperfusion resulted in EB/BB tissue injury index of 0.31±0.07 in CS versus
0.17±0.03 in sham (p<0.05) (Figure 4.4A), and FLIVO/BB apoptosis index of
0.26±0.06 in CS versus 0.13±0.03 in sham (p<0.05) (Figure 4.4B).
Systemic application of CORM-3 at fasciotomy resulted in EB/BB tissue
injury index of 0.13±0.04 (p<0.05 from CS+iCORM-3) and FLIVO/BB apoptosis
index of 0.12±0.03 (p<0.05 from CS+iCORM-3), while having no effect on the
control limb (Figure 4.4).
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Figure 4.2.

The effect of CORM-3 on serum TNF-α levels in porcine model
of CS. (A) Elevated ICP resulted in a progressive increase in
systemic TNF-α; (B) fasciotomy further upregulated circulating
levels of TNF-α, which was effectively prevented by CORM-3
treatment (repeated measures ANOVA; *p<0.001 from PRE;
†p<0.001 from CS+iCORM-3).
PRE, pre-CS (i.e. baseline).

148

Capillary Perfusion (% Total)

*

†

100

CPC
IPC
NPC

75
50
25

Figure 4.3.

0

Sham

CS+iCORM-3 CS+CORM-3

The effect of CORM-3 on skeletal muscle perfusion in porcine
model of CS. Six hours of elevated ICP, coupled with fasciotomy
and 3 hours of reperfusion resulted in severe microvascular
perfusion deficit (indicated by a decreased number of CPC and an
increased number of NPC); CORM-3 effectively reversed the
microvascular perfusion deficit (one-way ANOVA; *p<0.05 from
control, †p<0.05 from CS+iCORM-3; see the text for additional
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significant increase in both (A) tissue injury and (B) apoptosis; the
phenomenon was completely blocked by CORM-3 treatment (oneway ANOVA; *p<0.05 from control, †p<0.05 from CS+iCORM-3).
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4.3.6 Tissue Leukocyte Infiltration and Necrosis
Elevation of ICP led to a histopathology leukocyte infiltration score of 2.5
(moderate to severe) versus 0 (none) in sham and control (p<0.05). Systemic
administration of CORM-3 at fasciotomy resulted in a significant decrease of
leukocyte infiltration to 1.5 (mild to moderate) within the skeletal muscle (Figure
4.5).
Elevation of ICP produced a histopathology tissue necrosis score of 2
(moderate) versus 0 (none) in contralateral limb and/or sham muscle (p<0.05).
Systemic administration of CORM-3 at fasciotomy resulted in necrosis
histological score of 1 (mild) within the skeletal muscle (p<0.05) (Figure 4.5).

4.4

DISCUSSION
Acute CS remains a challenging problem in the field of traumatology, not

the least because the pathophysiology behind the CS injury is not well
understood. Despite ongoing research, fasciotomy and supportive therapy to
prevent other systemic sequelae during the recovery period remain the only goldstandard treatment choices of CS (McQueen, Gaston et al. 2000, Cascio,
Pateder et al. 2005, Mithoefer, Lhowe et al. 2006, Ritenour, Dorlac et al. 2008,
Farber, Tan et al. 2011, Dover, Memon et al. 2012).
In the current study, we demonstrated for the first time an improvement in
skeletal muscle microvascular perfusion, inhibition of inflammation (both systemic
and local) and attenuation of tissue injury, as well as apoptosis, by the systemic
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The effect of CORM-3 on skeletal muscle tissue necrosis and
leukocyte infiltration in porcine model of CS. Six hours of
elevated ICP, coupled with fasciotomy and 3 hours of reperfusion
resulted in a significant increase in leukocyte infiltration (open bars)
and tissue necrosis (solid bars) in skeletal muscle; CORM-3
treatment significantly reduced both leukocyte infiltration and tissue
necrosis (Kruskall-Wallis ANOVA; *p<0.01 from sham, †p<0.05
from CS+iCORM-3).
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administration of carbon monoxide (derived from a water-soluble CO donor,
CORM-3) in a pre-clinical setting in a large animal model of CS.
CO, a gaseous signalling molecule produced endogenously, as a
byproduct of heme degradation pathway (Ryter, Otterbein et al. 2002), has been
shown to exhibit vasodilatory, anti-apoptotic and anti-inflammatory effects in
various animal models (Motterlini and Otterbein 2010, Lawendy, Bihari et al.
2014). Nevertheless, therapeutic administration of CO via inhalation is hampered
by the production of COHb, limiting its clinical applicability. It has been shown
previously that, despite some beneficial effects, CO inhalation in humans
(500ppm for 1 hour) increased COHb in the range of 1.2-7% (Mayr, Spiel et al.
2005). Similar findings were obtained from in vivo animal models, where COHb
of 5-6% were obtained (Ott, Scott et al. 2005), some even reaching 15-25%
(Fujita, Toda et al. 2001), depending on the experimental conditions.
Recently, transitional metal carbonyls, CO-RMs, have been developed as
means of CO delivery in biological systems, with minimal or no effect on COHb
formation (Clark, Naughton et al. 2003, Guo, Stein et al. 2004, Katada, Bihari et
al. 2010, Lawendy, Bihari et al. 2014), making them potential candidates for
therapeutic agents. Availability of water-soluble CO-RMs capable of liberating
CO under physiological conditions makes their use even more attractive, due to
the ease of application and no production of toxic levels of COHb (Lawendy,
Bihari et al. 2014) (Table 4.1). In this regard, CO-RM-mediated protection against
ischemia-reperfusion-induced injury to the heart (Clark, Naughton et al. 2003,
Guo, Stein et al. 2004), kidney (Caumartin, Stephen et al. 2011), liver (Wei, Chen
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et al. 2010) and intestine (Katada, Bihari et al. 2010), as well as the efficacy of
CO-RMs to suppress severe systemic inflammatory conditions (e.g. sepsis) have
been demonstrated (Mizuguchi, Stephen et al. 2009, Katada, Bihari et al. 2010).
Continuous perfusion is required in order to provide nutrients and oxygen
to all tissues. CS has been shown to lead to a hypo-perfusion state within the
affected compartment(s), to a point where the metabolic demands of the tissue
cannot be met. This generates tissue ischemia, albeit a reduced-flow (rather than
a complete) one (Blaisdell 2002, Lawendy, Sanders et al. 2011). Additionally,
because not all microcirculation is shut down, a degree of reperfusion happens at
the same time, producing a reperfusion injury concurrent with ischemia; this
appears to be even more damaging than a complete ischemia itself (Better,
Abassi et al. 1990, Gute, Ishida et al. 1998). Ischemia-reperfusion injury is
comprised of a complex chain of events, leading to upregulation of the proinflammatory phenotype, and subsequent inflammatory interactions between the
vascular endothelial cells, cells of the interstitium (e.g. fibroblasts, myofibroblasts,
smooth muscle cells) and circulating cells (leukocytes). In turn, this leads to
impaired vascular cell integrity, increased vascular permeability, and formation of
edema (Sabido, Milazzo et al. 1994, Gute, Ishida et al. 1998, Hua, Al-Badawi et
al. 2005). As a result, the ensuing increased interstitial pressure compresses
adjacent capillaries, diminishing the continuous perfusion and increasing the
degree of non-perfusion. The temporal changes in microvascular perfusion (i.e.
the no-reflow phenomenon) appear to be caused not just by passive alterations
in external pressure caused by edema, but also spastic changes in the
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vasculature, leading to vasoconstriction (Nanobashvili, Neumayer et al. 2003).
The non-perfused capillaries potentiate further damage by contributing to the
endothelial cell swelling, capillary narrowing due to edema and increased
intravascular blood viscosity from hemoconcentration (Tuma, Durian et al. 2008).
An increase of non-perfused capillaries from those being continuously
perfused is a characteristic response of microvasculature to CS. In the current
study, animals treated with CORM-3 had shown significant improvement in
capillary perfusion, restoring the number of continuously-perfused capillaries, to a
level well above that of the CS group (Figure 4.3). Thus, the exogenously applied
CO, in the form of CORM-3, appeared to provide a significant protection in the
maintenance of skeletal muscle blood flow. While it is unlikely that CORM-3derived CO would have directly prevented ischemia-reperfusion-induced
formation of edema, the potent vasodilatory properties of CO (mediated by
soluble guanylate cyclase) (Foresti, Hammad et al. 2004) could explain the
diminished spasticity of the microvasculature, resulting in the decreased severity
of the no-reflow phenomenon and improved capillary flow of the affected tissue in
the post-fasciotomy state (Motterlini and Otterbein 2010).
The parenchymal damage seen in CS appears to be associated, at least
in part, with the direct microvascular dysfunction (resulting in severe hypoxia),
and subsequent inflammation (recruitment of PMN and generation of oxidative
stress) (Forbes, Carson et al. 1995, Gute, Ishida et al. 1998) that leads to the
depletion of tissue ATP and initiation of tissue necrosis (Lindsay, Liauw et al.
1990). In our experiments, CS resulted in severe tissue injury, necrosis, tissue
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and apoptosis within the muscle; all markers of tissue injury and dysfunction
were significantly diminished in CORM-3-treated animals, suggesting a
substantial protective role of exogenously applied CO (Figure 4.4 and Figure 4.5).
The tissue protective effects of CORM-3 may be attributed, at least in part,
to its ability to interfere with the levels of oxidative stress in vascular endothelial
cells (Mizuguchi, Capretta et al. 2010), cardiac myocytes (Lancel, Montaigne et
al. 2012), and inflammatory cells (PMN, macrophages) (Sawle, Foresti et al.
2005, Mizuguchi, Stephen et al. 2009). While CO and CORM-3 (as well as other
CO-RMs) may not act as free radical scavengers themselves, they may suppress
the oxidative stress by interfering with the activity of heme-containing redox
enzymes (e.g. cytochrome c oxidase, NADPH oxidase, etc.) (Kajimura, Fukuda
et al. 2010). CORM-3 appears to be a potent inhibitor of myeloperoxidase activity
(a PMN-derived enzyme responsible for the production of both hydrogen
peroxide and hypochlorous acid – two of the most potent oxidizers in biological
systems) (Patterson, Fraser et al. 2014), thus it may suppress/inhibit leukocyte
(i.e. PMN)-induced oxidative damage/dysfunction to the vascular endothelium
and interstitial cells.
Production of the pro-inflammatory cytokines within the tissue(s) and in
the circulation, and a subsequent activation of leukocytes are considered key
events contributing to induction/amplification of the inflammatory response under
various conditions, including CS (Forbes, Harris et al. 1996, Sadasivan, Carden
et al. 1997, Hua, Al-Badawi et al. 2005, Galasso, Schiekofer et al. 2014,
Lawendy, Bihari et al. 2014, Lawendy, Bihari et al. 2016, Bihari, Cepinskas et al.
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2017). It is well accepted that the production of acute-phase inflammationrelevant cytokines/chemokines (e.g. TNF-α, IL-1β, IL-6, IL-8) leads to PMN
activation and recruitment into inflamed tissues (Gute, Ishida et al. 1998).
Activated leukocytes, through the induction of oxidative and proteolytic stress,
impair surrounding cell viability (Toyokuni 1999), and thus contribute to the tissue
injury, dysfunction and a subsequent development of systemic inflammation and
remote organ injury (Brock, Lawlor et al. 1999).
In our study, we observed a marked increase in the levels of circulating
TNF-α (one of the most potent pro-inflammatory cytokines) in animals
undergoing CS, particularly post-fasciotomy. This was associated with
overwhelming

systemic

leukocyte

activation,

as

well

as

leukocyte

recruitment/infiltration within the CS-challenged muscle. Additionally, the effects
could also be noticed in the diminished function of other organs, particularly the
kidney and liver. Interestingly, the increase in tissue leukocyte infiltration was
significantly diminished in animals treated with CORM-3, but not its inactive
counterpart, iCORM-3. It is important to note that the decrease in leukocyte
recruitment to CS-challenged muscle correlated with the CORM-3-dependent
suppression of serum TNF-α and leukocyte activation in circulation (Figures 4.1
and 4.2). These findings are in line with our previous studies indicating that
leukopenia diminished the degree of CS-associated tissue injury in a rodent
model of CS (Lawendy, Bihari et al. 2015).
While the exact mechanism(s) of CORM-3-induced protective/antiinflammatory effects are yet not completely understood, given the complex and
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multi-component nature of CS pathophysiology (ischemic episode, oxidative
stress, cytokine production, local and systemic responses), it is plausible to
assume that the beneficial effects of the systemically administered CORM-3 may
be related to the ability of CO to act simultaneously on multiple cellular and
molecular targets (Otterbein, Bach et al. 2000, Ryter, Otterbein et al. 2002,
Kajimura, Fukuda et al. 2010, Motterlini, Haas et al. 2012). Our current findings
are in agreement with previous studies demonstrating CO-RM-dependent
suppression of both vascular endothelial cell and leukocyte pro-adhesive
phenotypes (e.g. reduced expression of adhesion molecules ICAM-1, VCAM-1,
E-selectin,

CD11b,

L-selectin),

and

subsequent

reduction/prevention

of

leukocyte-endothelium adhesive interaction (Urquhart, Rosignoli et al. 2007,
Cepinskas, Katada et al. 2008, Mizuguchi, Stephen et al. 2009, Song,
Bergstrasser et al. 2009, Vadori, Seveso et al. 2009, Mizuguchi, Capretta et al.
2010, Bergstraesser, Hoeger et al. 2012). As leukocytes are a significant
contributor to tissue damage, any inhibition of leukocyte activation and/or
reduced recruitment of these cells to the tissue(s) would reduce the magnitude of
leukocyte-induced tissue injury and dysfunction (Patterson, Fraser et al. 2014).
Whether CORM-3 preferentially interferes with the inflammatory activation of
leukocyte or vascular endothelial cell (or both) in the model of limb CS used in
this study remains to be determined.
While the results of our study are novel and look promising, there are
some limitations that need to be addressed. First, we used only a single
concentration of CORM-3 and a single route of administration (i.e. IV). Different
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dosage, frequency, and alternative routes of CORM-3 administration (e.g.
topical) may provide different dynamics of CORM-3-dependent protection.
Second, despite the fact that CO-RMs (e.g. CORM-3) used at micromolar
concentrations show no cytotoxic effects in cultured vascular endothelial cells
and PMN (data not shown), the potential toxicity of various concentrations of
CORM-3 in vivo is yet to be determined. Very little data exists on the safety of the
systemic CORM-3 administration in large animals, although preclinical studies
employing non-human primates suggest that there are few side effects
associated with both single and repeated injections (Vadori, Seveso et al. 2009).
As larger animals appear to be more sensitive to the effects of CORM-3 (Vadori,
Seveso et al. 2009, Lawendy, Bihari et al. 2014) (for example, rats required 10
times the dose necessary to elicit a response in a pig), a lower therapeutic dose
may be sufficient if this substance is to be used in humans, thus minimizing
potential side effects. In support to the above, our previously published study
using rodent model of CS (Lawendy, Bihari et al. 2014) and data presented in the
current study indicate that, at concentrations that offer potent protective/antiinflammatory effects, CORM-3 does not appear to be harmful with respect to
hepatotoxicity and formation of toxic levels of COHb (Table 4.2).
In summary, this is the first study demonstrating the beneficial effects of
CORM-3-derived CO as a therapeutic agent capable of mitigating the extent of
acute CS-induced microvascular dysfunction in the skeletal muscle in a large
animal model of CS. Our findings indicate that CORM-3 offers strong
protective/anti-inflammatory effects by diminishing the post-fasciotomy tissue
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injury to the skeletal muscle, and thus may potentially be used as a
pharmacological adjunct therapy to fasciotomy.

4.5
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CHAPTER 5

CARBON MONOXIDE-RELEASING MOLECULE-3 (CORM-3) OFFERS
PROTECTION IN AN IN VITRO MODEL OF COMPARTMENT SYNDROME.

A version of this chapter will be submitted for publication to Microcirculation
(2017).
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CHAPTER 5: CARBON MONOXIDE-RELEASING MOLECULE-3 (CORM-3)
OFFERS

PROTECTION

IN

AN

IN

VITRO

MODEL

OF

COMPARTMENT SYNDROME.

5.1

INTRODUCTION
Compartment

syndrome

(CS)

is

a

devastating

complication

of

musculoskeletal trauma. CS develops when the pressure within the closed
osseofascial compartment rises, producing muscle-threatening and limbthreatening ischemia (Whitesides, Haney et al. 1975, Matsen 1980, Mubarak and
Hargens 1983, McQueen, Christie et al. 1996). Fasciotomy, to fully decompress
all affected compartments, remains the only gold-standard surgical therapy
(Eaton and Green 1972, Rorabeck 1984), but the procedure must be carried out
within 6-8 hours of CS onset, before the damage to the affected limb becomes
permanent.
An increase in extremity compartmental pressure during CS compromises
microcirculatory perfusion, thus restricting oxygen and nutrient delivery to vital
tissues, resulting in cellular anoxia and severe tissue necrosis (Whitesides,
Haney et al. 1975, Hargens, Schmidt et al. 1981, Matsen and Rorabeck 1989).
Unlike complete ischemia, CS causes myonecrosis in the face of patent vessels.
As such, the pathologic contribution of inflammation to the pathophysiology of CS
is being increasingly recognized; studies from our group (Lawendy, Sanders et al.
2011, Lawendy, Bihari et al. 2015) and others (Sadasivan, Carden et al. 1997,

167
Kalns, Cox et al. 2011) have broadly implicated leukocytes as playing a primary
role in both microvascular and parenchymal injury during CS.
Few therapeutic options have been shown to be effective. Recently,
carbon monoxide (CO), a byproduct of heme oxygenase (HO) activity, has been
shown to offer both protection to microvascular perfusion, and anti-inflammatory
benefits during systemic inflammation. While exogenous administration of CO via
inhalation results in increased carboxyhemoglobin (COHb) levels (presenting a
potential threat to the host), transitional metal carbonyls, CO-releasing molecules
(CO-RMs) can be used to deliver CO in a controlled manner without significantly
altering COHb (Motterlini, Clark et al. 2002, Clark, Naughton et al. 2003,
Motterlini 2007). While most CO-RMs are only soluble in organic solvents,
carbon monoxide releasing molecule-3 (CORM-3) is water soluble (Motterlini and
Otterbein 2010), making it well suited to clinical applications.
It has been demonstrated that application of CORM-3 at fasciotomy was
able to diminish the CS-associated tissue injury and leukocyte activation, as well
as block the systemic release of pro-inflammatory cytokine TNF-α in a rodent and
porcine models of CS (Lawendy, Bihari et al. 2014, Bihari, Cepinskas et al. 2015).
While the results of the animal studies look promising, CORM-3 would have to be
thoroughly tested before being used as a therapeutic agent in human patients.
Moreover, the actual effects and cellular mechanisms of CORM-3-derived CO
protection still remain to be elucidated.
The purpose of this study was to lay the foundation for the translation of
the animal studies into human subjects: to test the effect of CORM-3-derived CO
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on human endothelial cells. We undertook the task of developing an in vitro
model of CS, in order to investigate the mechanisms of CORM-3-derived CO
protection on human vascular endothelial cells. The ultimate goal is the
development of a safe pharmacologic adjunctive treatment for compartment
syndrome, which would reduce the morbidity and disability in patients.

5.2

MATERIALS AND METHODS

5.2.1 Reagents
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and
Dulbecco’s PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life
Technologies Inc., Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained
from Molecular Probes Inc. (Eugene, OR), and L-012 was purchased from Wako
Pure Chemical (Osaka, Japan). Sera of CS patients (acquired at fasciotomy)
(Appendix IV) (N=12) and healthy volunteers (N=6) were obtained from venous
blood by whole blood coagulation and subsequent centrifugation at 1,500xg for
20min, as per standard operating procedures (Gillio-Meina, Cepinskas et al.
2012), and stored at -80°C until use. A water-soluble CORM-3 (tricarbonylchloroglycinate-ruthenium(II), [Ru(CO)3Cl-glycinate]; molecular weight 295 gmol-1) was
synthesized by us (Mizuguchi, Stephen et al. 2009), in accordance with the
previously-published method (Motterlini, Clark et al. 2002). CORM-3 (100µM
stock solution) was always prepared fresh by dissolving CORM-3 in M199 just
prior to use. Inactive CORM-3 (iCORM-3) was generated by leaving CORM-3
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solution for 72hrs at room temperature, to liberate all CO from the molecule, as
previously described (Clark, Naughton et al. 2003).

5.2.2 Cells
Human vascular endothelial cells (HUVECs), isolated from human
umbilical veins by collagenase treatment (Cepinskas, Savickiene et al. 2003),
were grown to confluence on fibronectin-coated cellware (12-well plates,
transwell inserts with 3µm and/or 1µm diameter pores, 96-well plates and
parallel-flow perfusion microslides). HUVECs at passages 1-3 were used for all
of the experiments.
Human neutrophils (PMNs) were isolated from the venous blood of
healthy adults by 1% Dextran (Sigma, Mississauga, ON) sedimentation and
gradient separation on Histopaque-1077 (Sigma, Mississauga, ON), as
previously described (Kuhns, Long Priel et al. 2015). PMN viability was confirmed
by Trypan blue dye exclusion test.

5.2.3 In vitro Model of CS
HUVECs were stimulated for 3 or 6 hours with human serum (40% v/v,
diluted in isotonic saline) isolated from CS patients (N=12) (Appendix IV). Sera of
healthy human volunteers (N=6) were used as a time-matched control. All
experiments were performed in triplicate, in the presence of CORM-3 (100µM), or
its inactive form, iCORM-3.
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5.2.5 Reactive Oxygen Species (ROS) Production
The production of ROS in HUVECs was measured by intracellular
oxidation of DHR-123, a pan-oxidant-sensitive fluorochrome, as previously
described (Mizuguchi, Stephen et al. 2009). HUVECs (1x106 cells), grown to
confluence in 12-well fibronectin-coated plates, were loaded with DHR-123
(10µM) for 45min, and then stimulated for 3 hours with CS serum or serum
obtained from healthy volunteers, in the presence of CORM-3, or its inactive
counterpart, iCORM-3. After stimulation, cells were washed with PBS, lysed in
0.5%

CHAPS

buffer

and

analysed

spectrofluorometrically

(FR-1501

spectrofluorometer, Shimadzu) at excitation/emission wavelengths of 495/523nm.
Protein concentration in the cell lysate was assessed by DC protein assay
(BioRad, Mississauga, ON). ROS production was expressed as DHR-123
fluorescence intensity (FI) per mg protein.
In parallel, levels of extracellular ROS production by PMNs were assessed
using L-012, an O2--sensitive chemiluminescence probe, as previously described
(Mizuguchi, Stephen et al. 2009). Briefly, freshly isolated PMNs (1x106 cells)
were resuspended in 120µl DPBS containing 5.5mM glucose and 100µM L-012.
Cells were placed in Lumitrac 96-well plates (Greiner Bio-One); subsequently,
PMNs were stimulated in the presence of CORM-3 (or iCORM-3) by the CS
serum

or

serum

of

healthy

volunteers,

continuously

recording

chemiluminescence intensity over 30 minutes at 37°C in a Victor-3 Multilabel
plate reader (Perkin-Elmer). Superoxide production was expressed as relative
luminescence units (RLU)/106 PMN.
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5.2.5 Measurement of the Endothelial Monolayer Integrity
HUVECs were grown to confluence on fibronectin-coated transwell inserts
(1µm diameter pores) (BD Falcon). Cells were stimulated with CS serum or
serum obtained from healthy volunteers in the presence of CORM-3 (or iCORM3). The integrity of the endothelial layer was assessed by measuring the transendothelial electrical resistance (TEER) using EndOhm chamber method
(EndOhm-6, World Precision Instruments) following 1hr, 3hr and 6hr serum
exposure, and expressed as Ωcm2. Changes in TEER (ΔTEER) from the
baseline were evaluated at each time point.

5.2.6 Quantification of Apoptosis
HUVECs grown on black fibronectin-coated 96-well plates with clear
bottom (Greiner Bio-One) were stimulated with CS serum or serum obtained from
healthy volunteers for 6 hours, in the presence of CORM-3 (or iCORM-3). Levels
of the activation of active caspases were assessed by FAM-FLICA poly caspase
apoptosis kit (Immunochemistry Technologies, LLC), as per manufacturer’s
instructions. Briefly, cells were incubated with FAM-FLICA poly caspase reagent
for one hour at 37°C, washed and immediately assessed for fluorescence using
Victor-3 plate reader (Perkin-Elmer), at excitation/emission wavelengths of
480nm/530nm. Levels of apoptosis were expressed as relative fluorescence
units (RFU) (i.e. fluorescence intensity/104).
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5.2.7 PMN Rolling/Adhesion Assay
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI0.4;
ibidi, Madison, WI) were stimulated with CS serum or serum of healthy
volunteers for 6 hours in the presence of CORM-3 or iCORM-3. Following this,
microslides with HUVECs were placed into an air-heated chamber (37°C)
attached to an inverted phase-contrast microscope (Diaphot 300, Nikon).
Following the 10min wash with M199 in the presence of CORM-3 or iCORM-3 at
a shear stress of 1dyn/cm2 using syringe pump (Harvard Apparatus, St. Laurent,
QC), PMNs (1x106/ml) isolated from healthy adults were added to the perfusion
medium and the perfusion was continued for 15 minutes at the same shear
stress. PMN-HUVECs adhesive interactions (i.e. rolling, adhesion) were captured
in six random fields of view (10s/field) with a digital CCD camera (Sony Corp.,
Japan) connected to a computer, and analyzed offline. PMNs with velocity less
than 100µm/s were considered “rolling”. Adhesion was defined as PMNs that
remained stationary for at least 10s. PMN rolling/adhesion was expressed as a
number of PMN/mm2.

5.2.8 Transendothelial PMN Migration Assay
HUVECs were grown to confluence on the apical aspect of fibronectincoated transwell inserts (3µm diameter pores) (BD Falcon), and stimulated with
CS serum or serum of healthy volunteers placed in the basal compartment of the
inserts (mimicking the interstitial aspect of the blood vessel) for 6 hours, in the
presence of CORM-3 or iCORM-3.
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For the PMN migration assay, 5x107 PMN/ml, isolated from healthy
volunteers, were radiolabelled with 50µCi Na51CrO4 in PBS for 60 minutes at
37°C (Cepinskas, Katada et al. 2008). Radiolabelled PMNs (5x105 cells/insert)
were added to HUVEC monolayer; PMN transendothelial migration was
assessed 60min later. PMN migration was quantified as follows: %migration =
basal fluid (cpm)/[wash fluid (cpm)+membrane lysate (cpm)+basal fluid (cpm)].
The amount of radioactivity in the samples was assessed by a γ-counter (Wallac
1480 Wizard, Turku, Finland).

5.2.9 Statistical Analysis
All parameters were expressed as means ± standard error of the mean
(SEM), and analyzed using two-way analysis of variance (ANOVA) (GraphPad
Prism, v. 5.0, San Diego, CA), with Bonferroni post-hoc test as needed. p<0.05
was considered statistically significant.

5.3

RESULTS

5.3.1 ROS Production
Incubation of HUVECs with 40% human CS serum induced a significant
increase in the production of ROS within the endothelial cells, as shown in Figure
5.1. DHR-123 fluorescence intensity increased from 644.8±114.5 FI/mg protein in
cells treated with serum of healthy volunteers to 1059.6±56.3 FI/mg protein in CS
serum-treated

endothelial

cells (p<0.01). CORM-3 treatment completely

DHR123 Oxidation (FI/mg protein)
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Figure 5.1. The effect of CORM-3 on the oxidative stress response in
human vascular endothelial cells, elicited by stimulation with
human CS serum. HUVECs were stimulated by patients’ CS
serum for 3 hours in the presence of CORM-3 (or its inactive form,
iCORM-3), and the levels of ROS production were assessed by
DHR-123 assay. CS serum-induced ROS production was reversed
by CORM-3 application (two-way ANOVA p<0.05; *p<0.001 from
control; †p<0.001 from CS serum+iCORM-3; N=6 per group).
Serum of healthy patients served as a control.

175
prevented CS serum-induced ROS production (640.6±89.7 FI/mg protein versus
1061.1±53.6 FI/mg protein in iCORM-3 group, p<0.01), while it had no effect on
control or un-stimulated endothelial cells (Figure 5.1).
Incubation of naïve PMNs with CS serum led to an increase in
extracellular ROS production, as assessed by the oxidation of superoxidesensitive probe, L-012. Superoxide production by the CS serum-challenged
PMNs persisted for up to 24 minutes, with the most profound increase observed
at 2-8 minute time points after the addition of sera to PMNs (Figure 5.2).
Superoxide production increased from 13.4±2.4 RLU/106 PMN in healthy serumstimulated PMNs to 36.1±5.9 RLU/106 PMN in CS-serum stimulated PMNs
(p<0.001) (Figure 5.2). The presence of CORM-3 resulted in a significant
decrease of superoxide production in CS-stimulated PMNs (10.1±4.6 RLU/106
PMN, p<0.001), while having no appreciable significant effect on PMNs treated
with the serum of healthy patients (9.0±2.7 RLU/106 PMN) (Figure 5.2).

5.3.2 Transendothelial Electrical Resistance (TEER)
Incubation of HUVECs with CS serum produced a gradual decrease in
TEER, from the baseline of 55.3±3.3Ωcm2 to 26.2±3.2Ωcm2 20.0±4.7Ωcm2 and
12.2±3.2Ωcm2 at 1hr, 3hr and 6hr stimulation, respectively (Figure 5.3), resulting
in ΔTEER of 28.0±7.0Ωcm2, 34.3±7.5Ωcm2 and 41.8±6.47.5Ωcm2, respectively,
when

compared

to

baseline.

TEER

remained

virtually

unchanged

at

53.7±3.2Ωcm2 in the endothelial cells treated with the serum of healthy
volunteers for the duration of the experiment. CORM-3 treatment significantly
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Figure 5.2. The effect of CORM-3 on leukocyte activation (quantified by
the production of superoxide by PMNs), in response to
stimulation with human CS serum. Naïve PMNs were stimulated
with patients’ CS sera in the presence of CORM-3 (or its inactive
form, iCORM-3), and the levels of superoxide production were
assessed by L-012 assay. CS serum-associated PMN superoxide
production was reversed by CORM-3 application (two-way
repeated measures ANOVA p<0.05; *p<0.001 from healthy serum;
†p<0.001 from CS serum+iCORM-3; N=10 per group). Serum of
healthy patients served as a control.
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Figure 5.3. The effect of CORM-3 on the integrity of human vascular
endothelial cell monolayer following stimulation with CS
serum. HUVECs were stimulated by patients’ CS sera for up to 6
hours in the presence of CORM-3 (or its inactive form, iCORM-3),
measuring transendothelial electrical resistance (TEER). CS serumassociated decrease in TEER was diminished by CORM-3
application (two-way repeated measures ANOVA p<0.05; *p<0.01
from control; †p<0.01 from CS serum+iCORM-3; N=6 per group).
Serum of healthy patients served as a control.
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diminished the magnitude of changes in TEER to 37.3±2.0Ωcm2, 39.9±3.7Ωcm2
and 35.9±5.3Ωcm2 (ΔTEER of 6.2±2.3Ωcm2, 7.2±3.1Ωcm2 and 12.9±2.8Ωcm2
from the baseline, respectively) at 1hr, 3hr and 6hr, respectively (p<0.01 from CS
serum+iCORM-3), while having no effect on cells incubated with serum of
healthy volunteers (Figure 5.3).

5.3.3 Apoptosis
Incubation of HUVECs with human CS serum led to a significant increase
in the activation of caspases, as shown in Figure 5.4 (10.3±1.0 RFU versus
2.4±0.7 RFU in control, p<0.001). CORM-3 treatment resulted in a significant
decrease in the caspases activation to 4.0±0.4 RFU (p<0.001), while having no
effect on control or untreated endothelial cells (Figure 5.4) Treatment of HUVECs
with serum of healthy volunteers produced no changes in the activity of caspases
in both CORM-3 and iCORM-3 groups.

5.3.4 PMN Rolling/Adhesion
Incubation of HUVECs with CS serum resulted in a marked increase in
PMN activation behaviour, from 0.5±0.1 rolling PMNs/0.1mm2 and 4.7±0.7
adherent PMNs/0.1mm2 in control to 2.3±0.3 rolling PMNs/0.1mm2 and 17.0±1.8
adherent PMNs/0.1mm2 in CS serum-treated HUVECs (p<0.001) (Figure 5.5).
While iCORM-3 treatment had no effect, CORM-3 treatment of HUVECs resulted
in a significant decrease in PMN rolling and adhesion in CS serum-treated cells
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Figure 5.4. The effect of CORM-3 on the level of apoptosis in human
vascular endothelial cells, elicited by stimulation with human
CS serum. HUVECs were stimulated by patients’ CS sera for 6
hours in the presence of CORM-3 (or its inactive form, iCORM-3),
and the levels of active caspases were assessed by FAM-FLICA
polycaspase assay. CS serum-induced activation of caspases
(apoptosis) was inhibited by CORM-3 application (two-way ANOVA
p<0.05; *p<0.001 from control; †p<0.001 from CS serum+iCORM3; N=6 per group). Serum of healthy patients served as a control.
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Figure 5.5. The effect of CORM-3 on leukocyte (A) rolling and (B) adhesion
in response to stimulation of the human vascular endothelial
cells by CS serum. HUVECs were stimulated with CS patients’
sera for 6 hours, followed by application of healthy PMNs, while
being superfused at a constant rate of 1dyn/cm2 with M199, in the
presence of CORM-3 or iCORM-3. CS serum-induced PMN rolling
and adhesion were significantly diminished by CORM-3 application
(two-way ANOVA p<0.05; *p<0.001 from control and healthy
serum; †p<0.001 from CS serum+iCORM-3, N=10 per group). PMN,
polymorphonuclear cells.
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(0.4±0.1 rolling PMN/0.1mm2 and 7.2±0.9 adherent PMN/0.1mm2, p<0.001)
(Figure 5.5). Inactive CORM-3 treatment had no effect on PMN rolling/adhesion.

5.3.5 PMN Migration
In order to mimic changes occurring at the vascular-interstitial interface
during the clinical conditions of compartment syndrome (i.e. impaired vascular
function resulting in accumulation of serum in the interstitium and formation of
severe edema (Blaisdell 2002)), HUVECs were grown on the apical aspect of the
permeable supports (transwell inserts) and stimulated for 6 hours with the CS
serum or serum obtained from healthy volunteers placed in to the basal
compartment of the inserts, in the presence of CORM-3 or iCORM-3 (100µM).
Subsequently,

51

Cr-labeled PMNs were added to the apical aspect of HUVEC

monolayer and allowed to migrate across the HUVECs for 60 minutes.
Stimulation of HUVECs with CS serum in the basal compartment
(representing interstitial aspect) led to an increased PMN migration across
HUVECs, from 10.0±2.0% in control to 43±0.1% in CS serum-treated cells
(p<0.05), as shown in Figure 5.6. The presence of CORM-3/iCORM-3 in the
absence of serum had no effect on PMN migration; however, CORM-3 treatment
completely prevented CS serum-induced PMN migration across the endothelial
cells (18.5±0.5% versus 43.5±0.5% in iCORM-3 group, p<0.05). Stimulation of
HUVECs with serum of healthy subjects had no significant effect on transendothelial PMN migration in both CORM-3 and iCORM-3 groups (11.0±1.8%,
n.s.).
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The effect of CORM-3 on transendothelial leukocyte migration
in response to stimulation of human vascular endothelial cells
with CS serum. Na51CrO4-labelled human PMNs (5x105 cells) were
added to the top of stimulated HUVECs (grown on apical surface)
and allowed to migrate for 60min in response to CS serum (basal
compartment), in the presence of CORM-3 (or iCORM-3). The
amount of

51

Cr radioactivity was assessed and percentage of PMN

migration was calculated. CS stimulus-associated PMN migration
was significantly diminished by CORM-3 application (two-way
ANOVA p<0.05; *p<0.05 from control; †p<0.05 from CS+iCORM-3,
N=3 per group). PMN, polymorphonuclear cells.
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5.4

DISCUSSION
CS poses a challenging clinical problem associated with significant patient

disability (Giannoudis, Nicolopoulos et al. 2002). Few treatment modalities exist,
apart from the gold standard of fasciotomy (Olson and Glasgow 2005). While
some supportive therapies have shown limited potential in animal models
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), their use is hindered
by the lack of understanding of the originating mechanism(s) of CS injury.
CS is comprised of a complex chain of events, leading to upregulation of
pro-inflammatory phenotype and subsequent inflammatory interactions between
the vascular endothelial cells and leukocytes. As a result, impaired vascular cell
integrity, increased vascular permeability and edema ensue (Sabido, Milazzo et
al. 1994). One of the key features of CS appears to be an overwhelming
production of pro-inflammatory mediators, and an accumulation of leukocytes in
the affected limb. Leukocyte recruitment to the site of injury is an entirely normal
host response (to remove pathogens or dead cells), but the extensive
accumulation of PMNs and subsequent production of cytotoxic ROS, followed by
the release of proteolytic enzymes contribute significantly to the extensive
parenchymal damage seen in CS. Activated leukocytes impair surrounding cell
viability (Toyokuni 1999), thus contributing to the tissue injury, dysfunction and
subsequent development of systemic inflammation.
Recent findings indicate that CO, either produced by the inducible form of
HO (i.e. HO-1) or administered by inhalation (100-250ppm) offers potent antiinflammatory effects (Motterlini and Otterbein 2010). Nevertheless, the clinical
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applicability of inhaled CO is limited due to a rapid formation of toxic levels
(higher than 10%) of COHb (Ryter, Alam et al. 2006, De Backer, Elinck et al.
2009). To overcome this limitation, transitional metal carbonyls, CO-releasing
molecules (CO-RMs), have been developed that allow delivery of CO in a
controlled manner without significant effects on COHb formation (<3-5%COHb)
(Motterlini, Mann et al. 2005, Motterlini 2007, De Backer, Elinck et al. 2009) The
major advantage of using CO-RMs (e.g. the water soluble CORM-3) over the
inhaled CO gas is the ability to control CO delivery and choice of various routes
(IV, IP, SC or tissue superfusion) of CO administration to target specific
organs/tissues. It has been demonstrated that CORM-derived CO offers
cytoprotective/anti-inflammatory effects in animal models of inflammation and
injury such as ischemia/reperfusion (Guo, Stein et al. 2004, Katada, Bihari et al.
2010), pulmonary hypertension (Zuckerbraun, Chin et al. 2006), transplantation
(Song, Kubo et al. 2003, Caumartin, Stephen et al. 2011) and sepsis (Cepinskas,
Katada et al. 2008, Mizuguchi, Stephen et al. 2009). Research aimed at
understanding the mechanisms of CO-mediated protection suggests the role of
soluble guanylate cyclase (Ndisang, Tabien et al. 2004, Failli, Vannacci et al.
2012), mitogen-activated protein kinases (MAPK) (Otterbein, Bach et al. 2000),
phosphatidylinositol 3-kinase (PI3K), and NF-κB signaling pathways (Cepinskas,
Katada et al. 2008). Hence, the actions mediated by CO appear to invoke unique
stimulus-dependent signaling mechanism(s) in various cell types and organs.
The studies addressing the role of CO-RMs in modulation of inflammatory
response in compartment syndrome are extremely poorly investigated. Recently,
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we have developed an experimental small animal model of CS (Lawendy,
Sanders et al. 2011) and demonstrated potent protective effects of CORM-3
through the suppression of CS-induced inflammation, tissue injury and
microvascular

perfusion

deficits

(Lawendy,

Bihari

et

al.

2014).

The

cellular/molecular aspects of CS-induced tissue injury and dysfunction are also
poorly understood. Moreover, no previous studies have used human material to
assess vascular endothelial cell and/or leukocyte inflammatory activation in
response to stimulation with CS-relevant stimulus.
In the present study, we attempted to mimic the CS conditions in vitro,
employing human vascular endothelial cells, human leukocytes and serum
obtained from CS patients (as a CS-relevant stimulus) in order to assess the proinflammatory potential of CS, as well as mechanisms of CORM-3 protection via
its effect on modulation of cellular responses. To our knowledge, this is the first
study to model CS in cell culture; not only does it permit the exploration of the
mechanistic aspects of CS, but it allows for interventions currently not possible
(or unethical) in humans.
Incubation of endothelial cells (HUVECs) with serum obtained from CS
patients resulted in a significant increase in intracellular production of ROS
(Figure 5.1). It can be surmised that increased ROS production in response to
CS is due, at least in part, to the upregulation of pro-inflammatory cytokines
found in the CS serum (Donohoe 2015). Cytokines are known to induce oxidative
stress, leading to cellular membrane compromise, changes in internal protein
structure and downstream effects on enzymes (Sprague and Khalil 2009).
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Similarly, incubation of naïve PMNs with CS serum resulted in the same type of
response – significant PMN activation, as evidenced by an increase in the
superoxide production (Figure 5.2).
Application of CORM-3, but not of iCORM-3, was able to effectively
diminish the CS serum-induced ROS production in both the endothelial cells and
PMNs. The latter may be the result of CORM-3-dependent suppression of ROSgenerating pathways, such as inhibition of heme-containing redox enzymes (e.g.
cytochrome c oxidase, NADPH oxidase (Babior, Lambeth et al. 2002), and/or
myeloperoxidase (Patterson, Fraser et al. 2014). It is important to note that
CORM-3 also interferes with PMN proteolytic potential by reducing the levels of
cell surface-bound elastase in an inflammatory stimulus-activated PMN, thus
reducing/preventing PMN tissue infiltration and proteolytic injury (Mizuguchi,
Stephen et al. 2009).
Under normal circumstances, intact endothelium provides a semi-selective
barrier between the vessel lumen and surrounding tissue, controlling the passage
of materials and the transit of leukocytes between the blood and interstitial space.
In vivo, excessive increase in permeability of the endothelial monolayer may lead
to tissue edema, creating non-perfused segments within the capillary system,
thus further contributing to ischemia and the microvascular dysfunction (Sabido,
Milazzo et al. 1994). In this regard, exposure of human endothelial cells to CS
serum led to a significant, progressive breakdown of endothelial barrier, as
evidenced by a decrease in trans-endothelial electrical resistance (Figure 5.3),
suggesting the presence of potent injurious substances present in the circulation
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of CS patients. Unlike plasma obtained from patients with pronounced systemic
response (e.g. diabetic ketoacidosis), which had failed to impair the integrity of
HUVECs (Omatsu, Cepinskas et al. 2014), CS serum appears to contain strong
injurious and pro-inflammatory compounds that produce detrimental effect on
cellular integrity.
On the other hand, it is important to note that CS serum-induced
impairment of endothelial cell integrity was coupled with endothelial cell
apoptosis, as evidenced by activation of multiple caspases (marker of apoptosis)
(Figure 5.4). Application of CORM-3 (but not iCORM-3) prevented both CS
serum-induced decrease in HUVEC monolayer integrity and induction of cell
apoptosis.
Increased oxidative stress through ROS-based signalling (Toyokuni 1999)
can modify endothelial cell cytoskeleton (e.g. F-actin assembly) and associated
adherens junction protein function (e.g. VE-cadherin, β-catenin) (Corada, Liao et
al. 2001, Giannotta, Trani et al. 2013), contributing to the breakdown of
endothelial barrier. ROS also play a critical role in activation of the proinflammatory pathways, as well as activation of caspases (e.g. caspase-3)
responsible for the induction of cell apoptosis (Elmore 2007). Given that CS
produces a strong pro-oxidant and pro-inflammatory environment (characterized
by the presence of ROS and inflammatory cytokines, particularly TNF-α
(Lawendy, Bihari et al. 2014, Lawendy, Bihari et al. 2015)), it is plausible to
assume that both intrinsic (mitochondria/cytochrome c-mediated) and extrinsic
(TNF-α receptor-mediated) apoptotic pathways would be activated (Elmore 2007).
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Therefore, the protective effects of CORM-3 associated with endothelial cell
barrier function and/or cell apoptosis may be, at least in part, due to CORM-3dependent suppression of oxidant-generating redox system(s). It remains to be
determined which specific redox system in the endothelial cells and/or PMN is
affected by CORM-3.
In our study, the application of CS serum to human endothelial cells led to
a significant increase in leukocyte rolling and adhesion (Figure 5.5), a key feature
of leukocyte and/or vascular endothelial cell inflammatory activation (Butcher
1991, Ley, Laudanna et al. 2007). These results support our recent findings
demonstrating significant accumulation of leukocytes in the microcirculation of
the skeletal muscle of CS animals (Lawendy, Sanders et al. 2011, Bihari,
Cepinskas et al. 2015). The potency of CS serum in the induction of PMN
adhesion to endothelial cells in vitro was greater in comparison to that observed
in

sepsis-relevant

stimulus

(lipopolysaccharide

(LPS)-challenged

human

cerebrovascular endothelial cells) (Serizawa, Patterson et al. 2015) or endothelial
cells stimulated with plasma of diabetic ketoacidosis patients (Omatsu,
Cepinskas et al. 2014).
PMN recruitment to the inflamed tissues involves a series of complex, yet
well coordinated PMN-endothelial cell adhesive interactions (PMN rolling, firm
adhesion and migration across the endothelial barrier (Ley, Laudanna et al.
2007)). It is well accepted that adhesion molecules expressed on the vascular
endothelium (e.g. P-selectin, E-selectin, ICAM-1, VCAM-1) and their ligands on
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PMNs (e.g. L-selectin, sialyl-LewisX, β2 integrins) play a critical role in leukocyte
recruitment.
In the current study, treatment of human endothelial cells with CORM-3
effectively reduced PMN rolling and adhesion to CS serum-stimulated HUVECs
(Figure 5.5), replicating our in vivo animal data (Lawendy, Bihari et al. 2014,
Bihari, Cepinskas et al. 2015). The exact mechanism(s) of CORM-3-induced
suppression of the vascular endothelial cell pro-adhesive phenotype in an in vitro
model of CS is not clear, yet it warrants further investigation. While previous
studies in the field indicate that CO-RMs can modulate activation or expression
of adhesion molecules on both the PMN and vascular endothelial cells, the
experimental data appear to be rather controversial. It has been demonstrated
that CORM-2 (DMSO-soluble CO-RM) suppressed tissue levels of intercellular
adhesion molecule-1 (ICAM-1) in the liver of septic mice, as well as subsequent
PMN adhesion to LPS-stimulated HUVECs (Cepinskas, Katada et al. 2008). In
addition, CORM-2 effectively reduced tissue levels of E-selectin and ICAM-1 in
the small intestine of mice undergoing ischemia-reperfusion (Katada, Bihari et al.
2010). Studies in vitro indicate that CORM-2 reduces high glucose-induced
expression of ICAM-1 in HUVECs (Nizamutdinova, Kim et al. 2009). CORM-3dependent inhibition of E-selectin and VCAM-1 expression in TNF-α-stimulated
HUVECs has also been demonstrated (Song, Bergstrasser et al. 2009). On the
other hand, and contrary to the above, CORM-3 failed to suppress ICAM-1 and
E-selectin expression in TNF-α-stimulated HUVECs (Urquhart, Rosignoli et al.
2007) or LPS-stimulated human cerebrovascular endothelial cells, while showing
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high effectiveness in reducing expression of VCAM-1 (Serizawa, Patterson et al.
2015). Finally, it has been found that CORM-3 suppressed PMN-HUVEC
adhesive interaction by reducing CD11b (aMβ2-integrin) surface levels in platelet
activating factor (PAF)-stimulated PMN (Urquhart, Rosignoli et al. 2007).
Following firm leukocyte adhesion to the vascular endothelium, PMN
migration into the interstitium is driven primarily by chemokines (e.g. CXCL1,
CXCL8) and other chemotactic substances (e.g. PAF, leukotriene B4); these are
produced by vascular endothelial cells and/or interstitial cells, such as
macrophages, pericytes and fibroblasts. PMN migration across the vascular
barrier is controlled by PECAM-1 (CD31), CD99 and JAM-A/B/C adhesion
molecules, expressed on both leukocytes and the endothelial cells (Ley,
Laudanna et al. 2007). It has been demonstrated that excessive migration of
leukocytes

(particularly

neutrophils)

across

the

vascular

endothelium

compromises microvessel integrity; this is associated with the disruption of the
endothelial cell adherens/tight junctions and degradation of basement membrane
(Cepinskas, Sandig et al. 1999, Cepinskas, Savickiene et al. 2003, Granger and
Senchekova 2010). As a result, fluid (i.e. plasma) is allowed to pass into the
parenchyma, contributing to edema formation (Giannotta, Trani et al. 2013).
In our current study, basolateral stimulation of endothelial cells with the
serum of CS patients (to mimic vascular-interstitial interface) resulted in
significant increase in PMN transendothelial migration, the phenomenon that was
effectively prevented by CORM-3 treatment (Figure 5.6). These findings suggest
that CS serum may upregulate expression or activation of adhesion molecules
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involved in PMN migration (e.g. CD31, JAM-C). Alternatively, CS serum may
induce production of chemokines by the endothelial cells, or it itself contains
sufficient amount of chemotactic molecules promoting PMN transendothelial
migration. In fact, the pro-inflammatory potential of plasma obtained from patients
with severe systemic inflammatory disorders was demonstrated, showing that the
levels of pro-inflammatory cytokines IL-6 and CCL2 (MCP-1), as well as
chemokines CXCL8 (IL-8), CCL4 (MIP-1β), and CXCL1 (GRO-α) are markedly
upregulated in the circulation of human patients with severe sepsis. In addition,
the circulating levels of IL-6, CXCL1 (GRO-α), CXCL8 (IL-8), and CXCL10 (IP10) chemokines have also been detected in the plasma of diabetic ketoacidosis
patients (Omatsu, Cepinskas et al. 2014). While we have previously
demonstrated, in a rat model, that CS resulted in upregulation of proinflammatory cytokines and chemokines (Donohoe 2015), it remains to be
determined whether pro-inflammatory cytokines/chemokines can be found in the
serum of human CS patients.
In summary, this is the first study demonstrating the beneficial effects of
carbon monoxide, delivered by CORM-3, in an in vitro human model of
compartment syndrome. It represents the first step in an attempt to translate the
promising results obtained from animal studies into human patients. While the
exact mechanisms of CORM-3 protective action remain to be determined, the
obtained data strongly indicate a potential therapeutic application of CORM-3 to
patients at risk of developing CS.
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6.1

OVERVIEW OF RESULTS

6.1.1 Pathophysiology of CS and Current Therapeutic Considerations
Ever since the first description of limb ischemic contracture by Richard von
Volkmann (von Volkmann 1881), CS has been recognized as one of the most
devastating complications of musculoskeletal trauma, resulting in severe acute
myonecrosis, with significant patient disability as an outcome. An attempt to
highlight the major conceptual contributions to the current state of knowledge of
CS and current therapeutic approaches was undertaken in Chapter 1. While the
pathophysiology of the condition has not been completely elucidated, CS
appears to occur as a consequence of ischemia-reperfusion injury secondary to
an elevation of ICP. An increase in intra-compartmental pressure creates hypoperfused state, where oxygen and nutrient delivery to the tissue is limited,
resulting in cellular anoxia and tissue necrosis (Sheridan and Matsen 1975,
Whitesides, Haney et al. 1975, Sheridan, Matsen et al. 1977, Rorabeck and
Clarke 1978). As a consequence, severe inflammatory response occurs, further
contributing to the ischemia-induced microvascular dysfunction (Sadasivan,
Carden et al. 1997, Lawendy, Sanders et al. 2011). Unlike complete ischemia,
however, CS occurs in the face of patent vessels, since distal pulse is often
present (Seddon 1966); the low-flow ischemic state appears to be even more
injurious than complete ischemia, with severe acidosis and metabolic stress
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rendering a more severe degree of the muscle deterioration (Heppenstall, Scott
et al. 1986).
CS constitutes surgical emergency, with fasciotomy as the only current
gold-standard treatment. Fasciotomy, to decompress all tissues in the involved
compartments must be carried out in a timely manner (within a surgical window
of 6-8 hours), before the damage becomes permanent. Due to the uncertainty of
the actual onset of CS (the condition does not develop instantaneously) and the
lack of objective diagnostic test (CS diagnosis is based on a subjective clinical
exam), targeting the window may not be easy – hence the need for prolongation
of surgical window.

6.1.2 Carbon Monoxide and CS
It has been known for some time that ischemia results in an upregulation
of protective stress-induced proteins, particularly HO (Otterbein, Lee et al. 1999,
Petrache, Otterbein et al. 2000, Sato, Balla et al. 2001). While the global
upregulation of HO may not be feasible clinically, exogenous application of its
endproducts, particularly CO, can be accomplished with relative ease.
The effect of inhalational CO on the extent of CS-induced microvascular
dysfunction in a rat model of CS is described in Chapter 2. Since CS poses great
challenge to study in humans, various animal models have been developed to
investigate the condition (Jepson 1926, Sheridan and Matsen 1975, Sadasivan,
Carden et al. 1997, Vollmar, Westermann et al. 1999, Kalns, Cox et al. 2011,
Lawendy, Sanders et al. 2011). The rat model (Lawendy, Sanders et al. 2011)
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was chosen due to its relative ease of preparation, excellent reproducibility and
low cost. Most importantly, rat model of CS allowed for the use of IVVM as a realtime analysis of microcirculation.
Direct imaging of the microcirculation by IVVM validated significant
perfusion derangements, marked tissue injury and extensive leukocyte activation
in response to 2 hours of elevated ICP; these effects were suppressed by
administration of CO or CORM-3 at fasciotomy. Two hours were chosen based
on previous studies, demonstrating that 1 hour of ischemia in a rodent
approximates 4 hours of ischemia in human (Sheridan, Matsen et al. 1977,
Hulbert, Pamplona et al. 2007). The CO dose of 250ppm was chosen on the
basis of previous research demonstrating its effectiveness in suppressing various
pathological inflammatory conditions (Otterbein, Mantell et al. 1999, Otterbein,
Bach et al. 2000, Moore, Otterbein et al. 2003, Ott, Scott et al. 2005, Scott,
Cukiernik et al. 2009).
In our study, exogenous application of CO resulted in a significant
improvement in microvascular perfusion, complete inhibition of leukocyte
activation and tissue injury in CS-challenged animals; however, inhalation of CO
significantly elevated COHb.

6.1.2.1 CORM-3 as a Source of CO
With the synthesis of a novel class of transition metal carbonyls, COreleasing

molecules

(CO-RMs)

(Motterlini,

Mann

et

al.

2005),

as

a

pharmacological means of CO delivery, a new avenue of research opened up,
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allowing application of CO directly to the tissues (i.e. bypassing the inhalational
component). The effect of exogenous application of CO in the form of injectable
CORM-3 on the severity of microvascular dysfunction due to CS is described in
Chapter 3. CORM-3 was selected because of its excellent water solubility and
rapid release of CO under physiological conditions, upon administration. Ex vivo
studies indicate that CORM-3 is an equimolar CO donor (Motterlini, Clark et al.
2002); the CORM-3 dose of 10mg/kg was chosen based on our inhalational CO
studies (250ppm), to deliver the equivalent amount of CO.
In our study, systemic application of CORM-3 at fasciotomy resulted in a
significant improvement in muscle perfusion, 4-fold decrease in tissue injury, 8fold decrease in leukocyte activation, coupled with abolishment of CS-induced
TNF-α release, all without any changes in blood levels of COHb.

6.1.3 Preclinical Testing of CORM-3 in Porcine CS
While the results of rat CS experiments show promise, it would be quite a
leap to apply these to human subjects. Hence, the effect of CORM-3 was tested
in a pre-clinical setting, using a large animal model – an animal more akin to
human (i.e. pig), described in Chapter 4. Rodents respond differently to CO than
humans (previous inhalational CO studies in humans using bacterial sepsis failed
to demonstrate any significant effects of inhaled CO on the LPS-induced
systemic response) (Mayr, Spiel et al. 2005). The purpose of the study described
in this thesis was to evaluate the effect of CORM-3 on the severity of
microvascular dysfunction in pigs undergoing CS.

203
We found that six hours of elevated compartment pressure in pigs resulted
in severe microvascular perfusion deficit, progressive release of TNF-α coupled
with significant systemic leukocyte activation, as well as a large increase in tissue
necrosis, apoptosis and leukocyte infiltration (tissue inflammation). In addition,
some end-organ damage was also observed (particularly in the kidney).
Systemic administration of CORM-3 led to a marked decrease in tissue
inflammation coupled with some improvement in microvascular dysfunction,
lessening of tissue necrosis and a large decrease in tissue apoptosis.
Systemically, CORM-3 blocked CS-induced increase in circulating TNF-α levels,
coupled with complete abolishment of systemic leukocyte activation. Additionally,
CORM-3 also attenuated the severity of end organ dysfunction (i.e. kidney).

6.1.4 Human in vitro Model
In order to translate the results of animal experimentation, human CS was
modelled in vitro, as described in Chapter 5. This study was designed to test the
effect of CORM-3 on the cultured primary human vascular endothelial cells
stimulated with CS-like conditions, attempting to provide a broad mechanistic
insight into CS in terms of oxidative stress and leukocyte activation. The model
did not involve elevation of hydrostatic pressure; rather, the CS-like conditions
were mimicked by the use of serum obtained from CS patients, covering only the
inflammatory component of CS pathophysiology. As such, the model may not
accurately and completely mimic conditions that CS patients experience.
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In our study, we found that CS challenge of the endothelial cells, in the
form of serum isolated from CS patients, resulted in an increase in oxidative
stress in the endothelial cells (as evidenced by increased ROS production),
breakdown of endothelial layer integrity (changes in trans-endothelial electrical
resistance), and significant upregulation of pro-adhesive phenotype, leading to
changes in leukocyte-endothelial interactions (increased leukocyte adhesion and
rolling, leukocyte transmigration). Application of CORM-3 was able to diminish
the severity of both the oxidative stress and endothelial activation necessary for
leukocyte recruitment within the endothelial cells.
Our findings suggest that CORM-3 has potent anti-oxidant and antiinflammatory properties. While not a free-radical scavenger, it may have the
ability to suppress the oxidative stress indirectly (e.g. by modulating the activity of
redox enzymes), minimizing the extent of endothelial injury.

6.2

LIMITATIONS AND FUTURE DIRECTIONS
The significance of the results described this thesis lies, in part, with the

demonstration of the protective effects of CORM-3 on the severity of outcomes in
multiple models of CS: that of a rat, pig and human. While the data looks
promising, the studies were not without limitations. First, we used only a single
concentration of CORM-3 and a single route of administration in each species
(i.e. IP in rats, IV in pigs, direct exposure in human endothelial cells). Different

205
dosage, frequency, and alternative routes of CORM-3 administration may provide
different dynamics of CORM-3-dependent protection.
Second, despite the fact that the use of CORM-3 at micromolar
concentrations shows no cytotoxic effects in cultured vascular endothelial cells
and leukocytes, the potential toxicity of various concentrations of CORM-3 in vivo
is yet to be determined. Very little data exists on the safety of the systemic
CORM-3 administration in large animals, although they appear to be more
sensitive to the effects of CORM-3. The data presented in our studies indicate
that, at concentrations that offer potent anti-inflammatory effects, CORM-3 does
not appear to be harmful with respect to hepatotoxicity and formation of toxic
levels of COHb. However, CORM-3 is a ruthenium-based molecule; ruthenium is
a transition metal that does not naturally occur in human body (Emsley 2003).
Although ruthenium is relatively inert to other chemicals, heavy metal toxicity and
effects on the DNA (Bergamo and Sava 2011) are still of major concern.
Finally, the studies described here did not examine the effects of CORM-3
on pathophysiology of CS in a very detailed mechanistic manner, primarily due to
the lack of availability of genetically modified animals. The main purpose was to
test the potential therapeutic applicability of CORM-3 in a rather crude approach:
does it work or not?
In the future, the evaluation of the effect of CORM-3 on the magnitude of
functional deficits following CS would be of immense benefit. The studies that
evaluate gait could be accomplished in rats with relative ease using automated
gait analysis (e.g. the CatWalkTM system), currently available to us.
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Another avenue of research could explore the role of CORM-3 in tissue
repair and muscle regeneration. The concepts of developmental biology could be
applied to tissue engineering and stem cell production. Successful muscle
regeneration requires careful regulation of inflammation to clear up the debris,
and the initiation of activation of muscle satellite cells (the normally quiescent
muscle precursors) (Tidball 2011). Given that different classes of macrophages
fulfill different function (M1 type furthers inflammation, while M2 type promotes
tissue repair) the role of CORM-3 on the differential expression (induction or
modulation) of M1 and M2 phenotypes could be explored.
Finally, the first transition into an actual patient could be undertaken, by
evaluating the efficacy of topical application of CORM-3 following fasciotomy.

6.3

CONCLUSIONS
The data in this thesis indicates that CORM-3 has strong anti-

inflammatory properties, and may be capable of diminishing the post-fasciotomy
tissue injury. While the exact mechanisms of its protective action remain to be
determined, CORM-3 may have an enormous potential as a pharmacological
adjunct to fasciotomy, and might, at least, be capable of prolongation of surgical
window and improvement of muscle salvage after fasciotomy.
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APPENDIX I:

SURGICAL APPROACHES TO LIMB COMPARTMENT
SYNDROME

There is only one gold standard surgical option for the treatment of
compartment syndrome: fasciotomy. The ultimate goal of the procedure is
salvage of a functional extremity; this must be kept in mind by the surgeon when
deciding on the fasciotomy technique to be employed.
The surgical techniques for complete limb fascial release have been well
studied in both the leg and the forearm. In the leg, three techniques are most
commonly

described:

two-incision

fasciotomy,

single

incision

perifibular

fasciotomy, and fibulectomy. In the forearm, two techniques are most commonly
described: dorsal approach and volar approach.

I.1

FASCIOTOMY IN THE LEG
Most surgeons prefer the double incision technique, which allows for

adequate visualization of all compartments, assessment of muscle viability, and
sufficient surgical control to avoid neurovascular structures. The single incision
four-compartment fasciotomy without fibulectomy is safe and can be useful in
cases where soft tissue trauma or contamination is of concern, including
situations in which only a single vessel perfuses the leg, or when flap coverage
may be necessary.
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Kelly and Whitesides (1967) described a four-compartment release with
fibulectomy performed through one lateral incision (Kelly and Whitesides 1967).
The technique takes advantage of the fascial anatomy, since all the fascial
membranes insert onto the fibula. However, this method is technically
challenging, may place the peroneal vessels at risk, and sacrifices the fibula
(which is usually unnecessary). Both the double and single incision techniques
are sufficiently effective at decreasing intracompartmental pressure (ICP)
(Mubarak and Owen 1977, Vitale, Richardson et al. 1988).
Subcutaneous fasciotomy is a technique in which the fascia is incised
blindly with dissecting scissors through a small skin incision (Hutchinson and
Ireland 1994). Advantages include technical ease and cosmesis; however,
access is limited to the deep posterior compartment and the neurovascular
bundle.

In addition, it is now recognized that intact skin may not allow for

complete release of ICP.
In acute compartment syndrome, the skin is an important boundary of all
compartments that must be released to achieve the greatest decrease in ICP.
While small incision fasciotomy and endoscopically-assisted fasciotomy may
have a role in chronic exertional compartment syndrome, these techniques
should not be used in acute compartment syndrome: the recurrence of limbthreatening ischemia may occur despite fascial release when the skin is left intact
(Illig, Ouriel et al. 1998, Leversedge, Casey et al. 2002, Hutchinson, Bederka et
al. 2003, Apaydin, Basarir et al. 2008).
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I.1.1 Surgical Technique: Single-Incision Fasciotomy
Single-incision fasciotomy was described in detail by Davey et al (Davey,
Rorabeck et al. 1984). The operative technique starts with the patient positioned
supine with a bump under the hip, tourniquet applied but not insufflated. The limb
is prepped and draped free. The surgery begins with a single longitudinal, lateral
incision in line with the fibula (Figure I.1). The incision extends from the fibular
head to 3-4 cm proximal to the lateral malleolus, taking care to minimize the risk
of injuring the superficial peroneal nerve toward the distal aspect of the incision.
Skin flaps are developed anterior, and a longitudinal fasciotomy of the anterior
and lateral compartments is performed with dissecting scissors.
Next, a posterior flap is developed and a fasciotomy of the superficial
posterior compartment is performed. The surgeon should identify the interval
between and superficial and lateral compartments distally, and develop this
interval proximally by detaching the soleus from the fibula. Flexor hallucis longus
should be dissected subperiosteally from the fibula; the muscle and the peroneal
vessels are retracted posteriorly. At this point, all four compartments would have
been decompressed. However, on occasion tibialis posterior exists within a selfcontained fascial envelope and, therefore, it is beneficial to continue the deep
dissection until tibialis posterior is decompressed. The muscle and the peroneal
vessels should be retracted posteriorly; the fascial attachment of the tibialis
posterior muscle to the fibula should be identified and this fascia then incised
longitudinally. At the conclusion of the surgery, wounds are packed open, or the
skin may be loosely closed over suction drains.

215

Figure I.1.

Single-incision fasciotomy. (A) Lateral aspect and (B) medial
aspect of the leg. The incision extends from the fibular head to 3
cm proximal to the lateral malleolus. Skin flaps are developed
anterior, and a longitudinal fasciotomy of the anterior and lateral
compartments is performed with dissecting scissors. Posterior flap
is developed and a fasciotomy of the superficial posterior
compartment is performed. Wounds are packed open or the skin
may be loosely closed over suction drains.
Reproduced with permission from Lawendy and Sanders (2010).
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I.1.2. Surgical Technique: Two-Incision Fasciotomy
Two-incision fasciotomy was described in detail by Mubarak and Hargens
(Mubarak and Hargens 1981). Patient is positioned supine, tourniquet applied
and not insufflated. The limb is prepped and draped free. The procedure begins
with a 20-25cm incision in the anterior compartment, centered halfway between
the fibular shaft and the crest of the tibia (Figure I.2), utilizing subcutaneous
dissection for wide exposure of the fascial compartment. Transverse incision is
made to expose the lateral intermuscular septum, and the superficial peroneal
nerve lying posterior to the septum is identified. Using dissecting scissors, the
anterior compartment is released proximally and distally in line with the tibialis
anterior. The lateral compartment is accessed, and a fasciotomy of the lateral
compartment is performed proximally and distally, in line with the fibular shaft.
A second longitudinal incision 2 cm posterior to the posterior margin of the
tibia is made, using wide subcutaneous dissection to allow identification of the
fascial planes. Skin flaps are elevated and the saphenous vein and nerve are
identified and protected. The septum between the deep and superficial posterior
compartments is then identified, and the fascia over the gastrocnemius-soleus
complex is released over its entire length. Another fascial incision is made over
the flexor digitorum longus muscle and the entire deep posterior compartment is
released. As the dissection is carried proximally, if the soleus bridge extends
more than halfway down the tibia, this extended origin must also be released.
After release of the posterior compartment, the tibialis posterior muscle
compartment is identified and released over the extent of the muscle belly if
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Figure I.2.

Two-incision fasciotomy. An incision in the anterior compartment
is centered halfway between the fibular shaft and the crest of the
tibia. Lateral intermuscular septum is exposed. The anterior
compartment is released proximally and distally in line with the
tibialis anterior. Fasciotomy of the lateral compartment proximally
and distally in line with the fibular shaft is performed. A second
longitudinal incision 2cm posterior to the posterior margin of the
tibia is made; fascia over the gastroc-soleus complex is released
over its entire length. Then, the deep posterior compartment is
released via fascial incision over the flexor digitorum longus.
Reproduced with permission from Lawendy and Sanders (2010).
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increased tension is evident in this compartment. The wound is packed open and
a posterior plaster splint is applied, with the foot plantigrade

I.2

FASCIOTOMY IN THE FOREARM
Decompression fasciotomy of the forearm is performed through a volar

approach, a dorsal approach, or both. Unlike the fascial compartments of the leg,
the volar compartment, dorsal compartment, and mobile wad compartment
(containing the brachioradialis and radial wrist extensors) are interconnected;
thus, fasciotomies of all 3 compartments may be unnecessary.
Superficial fasciotomy is usually adequate to decompress the entire
forearm (Lawendy and Sanders 2010). The flexor digitorum profundus and flexor
pollicis longus muscles (deep volar compartment) are among the most severely
affected muscles, due to their deep location adjacent to the radius and ulna. Prefasciotomy and post-fasciotomy pressures often are obtained from all
compartments of the volar forearm, and if deep compartment pressures remain
high after superficial fasciotomy, an additional release is indicated.
Forearm fasciotomy requires decompression from the wrist to mid arm,
including the lacertus fibrosus fascia, the fascial compartments over the flexor
carpi ulnaris, and the edge of the flexor superficialis muscles. With median nerve
involvement, in addition to carpal tunnel release, the surgeon must explore the
nerve in the proximal forearm.
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The median nerve is decompressed throughout its course, including highrisk areas that are deep to the bicipital aponeurosis (lacertus fibrosus), between
the humeral and ulnar heads of the pronator teres, the proximal arch, and deep
fascial surface of the flexor digitorum superficialis, and the carpal tunnel.
Preoperative prophylactic antibiotics against Staphylococcus aureus are
generally recommended.

I.2.1

Surgical Technique: Volar Approach
Volar approach to the superficial and deep flexors of the forearm was first

described in detail by Henry (Henry 1927). Standard surgical preparation and
draping are performed, but no tourniquet should be used. A volar curvilinear
incision medial to the biceps tendon, crossing the elbow flexion crease at an
angle is first made (Figure I.3). The incision is carried distally into the palm to
allow for a carpal tunnel release (similar to the McConnell’s combined exposure
of the median and ulnar nerves), avoiding crossing the wrist flexion crease at a
right angle.
Lacertus fibrosus is divided proximally, evacuating any hematoma. The
brachial artery is exposed to determine whether there is a normal blood flow. In
case of the unsatisfactory flow, the adventitia is removed to expose any
underlying clot, spasm or intimal tear, resecting the adventitia if necessary, and
anastomosing or grafting the artery. The superficial volar compartment is then
released throughout its length with open scissors under direct vision, freeing the
fascia over the superficial compartment muscles. The flexor carpi ulnaris is
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identified and retracted with its underlying ulnar neurovascular bundle medially.
The flexor digitorum superificalis and median nerve are retracted laterally to
expose the flexor digitorum profundus in the deep compartment. If its overlying
fascia is tight, it is incised longitudinally.
The dissection is continued distally, by incising the transverse carpal
ligament along the ulnar border of the palmaris longus tendon and median nerve.
The median nerve is then inspected and examined, to ensure that it is not injured
or entrapped between the ulnar and humeral head of the pronator teres (if it is, a
partial pronator tenotomy will be necessary). In the distal forearm, if the median
nerve is exposed, the distal radial-based forearm skin flap is loosely sutured over
the nerve, leaving the rest of the incision open. In case that an associated
fracture is present, the fracture is reduced and stabilized to obtain hemostasis.
At this point, the dorsal compartments are checked clinically, or repeated
pressure measurements are made. Usually, the volar fasciotomy decompresses
the dorsal musculature sufficiently; however, if the involvement of the dorsal
compartments is still suspected, they are also released. A sterile moist dressing
and a long arm splint are applied, taking care not to leave the elbow flexed
beyond 90°.
The volar ulnar approach (similar to the Henry approach) is used to
release the flexor carpi ulnaris and flexor digitorum superficialis. The proximal
edge of the flexor digitorum superficialis is carefully identified, and the ulnar
nerve at the wrist is decompressed.
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A
Flexor
Flexor
Flexor digitorum carpi
carpi ulnaris sublimis radialis

Brachioradialis

Extensor carpi
radialis brevis

B
Figure I.3.

Volar ulnar approach

Volar radial approach

Fasciotomy of the forearm. A volar curvilinear incision is made,
releasing superficial volar compartment. The flexor digitorum
superificalis and median nerve are retracted to expose the flexor
digitorum profundus in the deep compartment, incising the fascia
longitudinally. The dissection is continued by incising the transverse
carpal ligament along the ulnar border of the palmaris longus
tendon. The volar ulnar approach is used to release the flexor carpi
ulnaris and flexor digitorum superficialis, decompressing the ulnar
nerve at the wrist.
Reproduced with permission from Lawendy and Sanders (2010).
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I.2.2

Surgical Technique: Dorsal Approach
The technique for the dorsal approach has been described by Thompson

(Thompson 1918). The arm is pronated, and the incision distal to the lateral
epicondyle is made between the extensor digitorum communis and extensor
carpi radialis brevis, extending approximately 10 cm distally toward the midline of
the wrist. The subcutaneous tissue is gently undermined, and the fascia overlying
the mobile wad of Henry and the extensor retinaculum is released.
The skin is not closed at this time, anticipating secondary closure later. A
sterile moist dressing and a long arm splint are applied, taking care not to leave
the elbow flexed beyond 90°.
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